Growth in infants with bronchopulmonary dysplasia, endocrine and pulmonary aspects : clinical and follow-up studies by Huijsman, W.A. (Marianne)


Growth in infants with 
Bronchopulmonary Dysplasia,
endocrine and pulmonary aspects
clinical and follow-up studies
Cover: Wouter and Nicoline den Hollander
ISBN 90-6734-296-3
Copyright © 2003 W.A. Huijsman
All rights reserved. No part of this publication may be reproduced or transmitted in any form, by 
any means, electronic or mechanical, without the prior written permission of the author, or where 
appropriate, of the publisher of the articles.
The printing of this thesis was financially supported by:
Abbott BV, Friso Kindervoeding, Novo Nordisk A/S Denmark, Nutricia Nederland BV, Tyco Healthcare 
Nederland BV. 
Printed by Optima Grafische Communicatie, Rotterdam
Growth in infants with 
Bronchopulmonary Dysplasia,
endocrine and pulmonary aspects
clinical and follow-up studies
Groei bij zuigelingen met bronchopulmonale dysplasie, 
hormonale en pulmonale aspecten
klinische en follow-up studies
PROEFSCHRIFT
ter verkrijging van de graad van doctor aan
de Erasmus Universiteit Rotterdam
op gezag van de Rector Magnificus
Prof.dr.ir.  J.H.  van Bemmel
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op woensdag 18 juni 2003 om 9.45 uur
door
Wouterina Annemarie Huijsman
geboren te Benthuizen
Promotiecommissie
Promotoren: Prof.dr. P.J.J. Sauer
 Prof.dr. H.A. Büller
Overige leden: Prof.dr. J.C. de Jongste
 Prof.dr. S.W.J. Lamberts
 Prof.dr. H.N. Lafeber
Copromotor: Dr. A.C.S. Hokken-Koelega
Aan mijn ouders 
Contents
 
Chapter 1 Introduction 9
 General Introduction
 Definition / Epidemiology BPD
 Pathophysiology of BPD
 – Classic BPD
 – New BPD
 Glucocorticoids
 – Antenatal glucocorticoids 
 – Postnatal glucocorticoids
 Adrenal gland
 – Fetus
 – Neonate
 Growth
 – Fetal growth 
 – Postnatal growth in BPD
 Long-term lung function in BPD
 Aim of the studies
  
Chapter 2 Adrenal function in sick very preterm infants.  39
Chapter 3 Growth hormone profiles and growth factors in ventilated very  53
 preterm infants at risk for bronchopulmonary dysplasia (BPD).
Chapter 4 Effect of dexamethasone treatment on serum GH, IGF-I and the  69
 binding-proteins IGFBP-1 and-3 in ventilated very preterm infants. 
Chapter 5 Randomised placebo-controlled GH trial in very preterm infants  85
 at risk for bronchopulmonary dysplasia (BPD): rhGH treatment 
 does not prevent growth failure caused by dexamethasone.
Chapter 6 Growth and body composition in preterm infants with  105
 bronchopulmonary dysplasia.
Chapter 7 Worsening of V’
max FRC
 in infants with bronchopulmonary dysplasia  121
 in the first year of life: A more favourable outcome after 
 high-frequency oscillation ventilation.
Chapter 8  General discussion and future perspectives  133
Chapter 9  Summary 141
 Samenvatting 147
Dankwoord  155
Curriculum vitae 158
List of abbreviations 159

1
Introduction

Introduction 11
General introduction
In the last decades important advances in neonatal intensive care have been made leading 
to an increased survival of especially very preterm infants.1 Major changes in survival rate 
have been attributed to the use of antenatal steroids and surfactant in the prevention and 
treatment of respiratory distress. In the United States survival rates of very low birth weight 
infants have increased between 1991 and 1996. The overall survival in VLBW infants 
increased slightly from 79.8% to 83% but major increases in survival have been reported 
in the lower weight groups of 501 to 750 g and 751 to 1000 g, respectively. Birth weight 
specific survival rates of infants born in 1991 and 1995/1996 have been published. Survival 
to discharge from the neonatal intensive care unit (NICU) increased from 42% and 81% for 
infants with a birth weight of 501-700 g and 751-1000 g in 1991, to 52% and 82% in 1996, 
respectively.2 
Associated with the decline in mortality there was an increase in major morbidity over the 
6-year interval partly due to an increase in chronic lung disease (CLD) defined as oxygen 
need at 36 weeks postmenstrual age. CLD increased from 19% to 23 % between 1991 and 
1996 for the entire cohort of VLBW survivors. The largest increase in CLD from 41% to 56% 
occurred in infants born with a weight between 501-750 g. 
Survival rates vary across countries as consequence of differences in obstetric and 
neonatal management leading to differences in major morbidity.3 Therefore the data from 
the United States cannot be applied directly to the Netherlands, although a similar trend is 
observed. 
In the Netherlands an increase in the incidence of VLBW infants between 1983 and 1993 
from 8.4/1000 to 9.6/1000 live born infants has been documented, while simultaneously a 
decrease in mortality was observed.4 Mortality for infants born in 1983 with gestational ages 
of 25, 26, 27 and 28 weeks, respectively, was 65, 62, 46 and 32%, respectively, and decreased 
to 49, 40, 23 and 21%, respectively for infants born in 1993. Both these trends, the increase 
in number of VLBW and the decrease in mortality are leading to more VLBW survivors and 
more infants with morbidities such as chronic lung disease/ bronchopulmonary dysplasia 
(BPD) or neurologic impairment. The incidence for infants surviving with BPD in the 
Netherlands can only be calculated from extrapolation from the incidence in the South-West 
region of the Netherlands. These calculations show a mean rate of surviving infants with 
BPD around 170/100.000 births/year.5
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Definition/ Epidemiology BPD
Bronchopulmonary Dysplasia was first described by Northway et al in 1967 in a retrospective 
study as chronic lung injury developing after initial severe respiratory distress syndrome 
(RDS) in infants receiving artificial ventilation and 80-100% oxygen.6 The clinical picture 
of 32 infants initially treated because of RDS was described together with the pathology of 
the non-surviving infants. Nine out of thirteen infants who were treated with high oxygen 
(80-100%) in excess of a 150 hours, survived beyond 4 weeks of age and all demonstrated 
chronic pulmonary disease. They had a gestational age between 30 and 39 weeks (mean 34 
weeks) and a birth weight of 1474-3205 g (mean 2234 g). The clinical picture included the 
development of cyanosis without the use of supplemental oxygen, subcostal retractions, 
diffuse rales over the lungs and on X-ray examination rounded lucent areas in the lungs 
alternating with irregular dense strands.
This definition was changed in 1979 to the need for supplemental oxygen at 28 days 
after birth accompanied with radiological changes in infants who were ventilated in the 
first week of life for at least 3 days.7 In 1988, as younger infants were surviving and the 
radiological abnormalities were not comparable with the description of Northway anymore, 
a new definition of BPD was proposed by Shennan stating that oxygen requirement at 36 
weeks postmenstrual age, in infants with a birth weight of less than 1500 g was a better 
predictor of long-term respiratory outcome.8
The term chronic lung disease (CLD) was introduced by Koumbourlis in the 1990’s 
to describe clinical, radiological and lung function abnormalities evolving during and 
persisting beyond the neonatal period in prematurely born infants.9 
As practice on the NICU’s has changed by the use of antenatal steroids, surfactant 
treatment and use of gentler ventilation strategies, preterm infants with a higher birth 
weight nowadays seldom develop BPD. (BPD: 5.6% when birth weight 1250 -1500 g, 12.2% 
when birth weight 1001-1250 g).2 Presently, BPD occurs primarily in infants with a birth 
weight below 1000 g, in some of them even without preceding RDS.10
In 2001, a workshop on bronchopulmonary dysplasia initiated by the NICHD/NHLBI/
ORD reviewed the data on BPD and the epidemiological changes since the first description 
of BPD by Northway.11 The consensus was to retain the name BPD instead of CLD because 
it is clearly distinct from the multiple chronic lung diseases of later life and a definition with 
classification of the severity of BPD was proposed. The BPD classification for infants born 
with gestational ages less than 32 weeks was defined preliminary on information from the 
NICHD Neonatal Network and on the data of Palta.12 See for details Table 1.
By this definition the infants have BPD when they received oxygen treatment for at least 
28 days after birth, when needed because of persistence of clinical features of respiratory 
failure such as tachypnea, retractions and rales. For instance, in infants born after a 
gestational age of less than 32 weeks needing supplemental oxygen for at least 28 days, 
the severity of the BPD is assessed at 36 weeks postmenstrual age or at discharge to home, 
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whichever comes first. When, at that time point, the infants are breathing room air they 
have mild BPD, when they need oxygen treatment with a concentration less than 30% they 
have moderate BPD, and when they receive oxygen treatment of more than 30% or are 
ventilated they are classified to have severe BPD.
Although the terms BPD and CLD are both used in the literature describing persisting 
lung disease in preterm infants, within the framework of this thesis the term BPD is used 
according to the classification of the NICHD/NHLBI/ORD.11 
Pathophysiology of BPD
Classic BPD
The classic BPD as defined by Northway, Rosan and Porter is characterized by airway injury, 
inflammation, fibrosis and smooth muscle hypertrophy in the airways as result of mechanical 
ventilation and high oxygen treatment.6,13 Four stages were initially described. Stage 1, the 
acute phase lasting 2-3 days is indistinguishable from RDS with hyaline membranes, peri-
Table 1 Definition and classification of the severity of BPD. 
Gestational age < 32 weeks > 32 weeks
Requirement O2 treatment > 21% for at least 28 days
Time point of assessment 36 wk PMA or discharge to home, 
whichever comes first
> 28 d but < 56 d postnatal age 
or discharge to home, whichever 
comes first
Mild BPD Breathing room air at 36 wk PMA 
or discharge, whichever comes first
Breathing room air by 56 d 
postnatal age or discharge, 
whichever comes first
Moderate BPD Need for O2 treatment < 30% at 36 
wk PMA or discharge, whichever 
comes first
Need for O2 treatment < 30%  at 
56 d postnatal age or discharge 
whichever comes first
Severe BPD Need for O2 treatment > 30% 
and/or positive pressure (PPV or 
NCPAP) at 36 wk PMA or discharge 
whichever comes first 
Need for O2 treatment > 30% 
and/or positive pressure (PPV or 
NCPAP) at 56 d postnatal age or 
discharge, whichever comes first
BPD: bronchopulmonary dysplasia, O2: oxygen, PMA: postmenstrual age, PPV: positive pressure ventilation, NCPAP: nasal continuous positive airway 
pressure.
By definition the infants have BPD when they received oxygen treatment for at least 28 days after birth and have persistence of clinical features of 
respiratory failure such as tachypnea, retractions and rales. Infants treated with oxygen > 21% and/or positive pressure for nonrespiratory disease 
do not have BPD unless they also develop parenchymal lung disease and exhibit clinical features of respiratory distress. 
A day of treatment with oxygen > 21% means that the infant received oxygen > 21% for more than 12 hours on that day. Treatment with oxygen > 
21% and/or positive pressure at 36 weeks PMA, or at 56 days postnatal age or discharge, should not reflect an “acute’’ event, but should rather reflect 
the infant’s usual daily therapy for several days preceding and following these time points.
Adapted from NICHD/NHLB/ORD Workshop Summary 2001 Am J Respir Crit Care Med 163:1723-1729.11 
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vascular and alveolar-septal edema. Stage 2 shows inflammation, eosinophilic exsudate 
in the airways, patchy squamous metaplasia of the epithelium of the large and segmental 
bronchi. Stage 3 is characterised by necrosis of bronchial and bronchiolar epithelium with 
inflammation, large amounts of debris within the bronchial and bronchiolar lumina, marked 
squamous metaplasia and hypertrophy of bronchial and bronchiolar smooth muscle, 
interstitial fibrosis, necrosis alveolar cells and early vascular changes. Stage 4, the most 
severe stage is characterised by peribronchial and peribronchiolar fibrosis, widespread 
squamous metaplasia, marked hypertrophy of bronchial and bronchiolar smooth muscle, 
large areas with atelectasis alternating with bullous emphysema, severe vascular changes 
with adventitial fibrosis and narrowing of arterial and arteriolar lumina.14
The spectrum of infants with BPD has changed in the era of surfactant treatment and 
after the introduction of antenatal steroids. Before the era of surfactant treatment airway 
injury, inflammation and parenchymal fibrosis were the prominent findings in BPD. Lungs 
of infants nowadays dying of BPD show less fibrosis and a more uniform inflation.11
New BPD
The lungs of infants nowadays dying of BPD usually only show minimal diffuse alveolar 
septal fibrosis and fewer, larger alveoli in both surfactant-treated and non-surfactant treated 
infants. There seems to be an arrest in acinar development.15 Jobe published reviews about 
the new BPD describing the multifactorial pathogenesis.16,17 Although BPD can also develop 
in term infants after severe ventilation because of persistent pulmonary hypertension of the 
newborn or meconium aspiration syndrome, most infants nowadays developing BPD are 
born after a gestational age of 26-28 weeks and have very immature lungs.
The human lung undergoes a transition from the canalicular stage to the saccular stage 
at about 22 weeks gestational age and the alveolar stage begins around 30-32 weeks (See 
Figure 1). Intrauterine as well as early postnatal factors have the potential of influencing 
lung development and lung function. Animal models of BPD show that oxygen treatment 
alone, but also mechanical ventilation after surfactant treatment without high oxygen 
treatment leads to a reduction in the number of alveoli in baboons.18-20 A non-uniform 
inflation occurs with areas of atelectasis and hyperextension, inflammation and edema. In 
the overdistended regions the distal airspaces are dilated and appear as saccules. The walls 
of the terminal respiratory units are flat and straight because the units are not partitioned 
by alveolar secondary crests.
The baboon model demonstrates large simplified saccules with variable degrees of fibrosis 
and a decrease in alveolarization and vascular hypoplasia. This latter might reflect an arrest 
in vasculogenesis that is ongoing during the canalicular stage of lung development during 
which capillaries are formed in the mesenchyme and fuse with previously formed and 
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developing pulmonary arteries and veins.19 Thus, there is a large decrease in surface area 
which is associated with a decrease in pulmonary microvasculature.
In infants dying of BPD the amount of lung elastic tissue and the diameters of saccular 
and ducts are increased reflecting similar pathology as demonstrated in the baboon 
model.21
The signals essential for normal regulation of alveolarization are not known. Alveolar 
development can be delayed by hypoxia, hyperoxia, glucocorticoids and poor nutrition 
and stimulated by thyroxin and retinoic acid.22,23 Over-expression of cytokines such 
as tumour- necrosis-factor-α in the pulmonary epithelium results in fewer alveoli and 
inflammation.24 In transgenic mice over-expression of transforming-growth-factor- α (TGF-
α) results in fewer, larger alveoli and fibrosis, whereas over-expression of interleukin-11 
(Il-11) in utero and in the early postnatal period results in fewer and larger alveoli. Over-
expression of interleukin-6 (IL-6) induces a lymphocytic infiltrate in the lungs and fewer 
and larger alveoli.25-27
In humans elevated levels of proinflammatory cytokines like TNF-α, IL-1β, IL-6 and IL-8 
in amniotic fluid within 5 days of preterm delivery are associated with an increased risk 
of BPD as is colonization at birth with Ureaplasma urealyticum.28-30 Many very preterm 
deliveries are associated with a low-grade infection or inflammation of fetal membranes 
and amniotic fluid.31 Histologic chorioamnionitis is associated with an early elevation of 
IL-1β in lung lavage fluid, a decrease in the incidence of respiratory distress syndrome but 
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surprisingly, many of these fetuses may have been
exposed to low-grade inflammation for prolonged periods,
possibly beginning with colonization of the uterine tissue
prior to conception. For reasons that are presently
unknown, these pregnancies do not present with preterm
labor before 20 weeks gestation, even if the amniotic fluid
was positive for pro-inflammatory cytokines or organisms
prior to the preterm labor.
These very preterm deliveries are the major contributors to
postnatal morbidities and mortality, with the most common
acute morbidities being brain injury nd lung injury. The
infants seldom have positive blood cultures after delivery,
implying that infections had been isolated to the uterus,
placenta, and/or fetal membranes. However, more recent
information indicates that exposure to intrauterine infec-
tion/inflammation results in mor  s rious injury than the
preterm delivery alone. Altho gh not the topic of this
review, the major concern is that indicators of intrauterine
inflammation may be associated with periventricular leuko-
malacia and subsequently cerebral palsy. Chorioamnionitis
correlates with subsequent brain injury, and the presence
of the pro-inflammatory cytokines interleukin-6 (IL-6), i ter-
leukin-1β (IL-1β), or tumor necrosis factor α (TNF-α) in
amniotic fluid before preterm delivery predicts subsequent
brain injury [3,4]. The fetus may respond to intra-amniotic
infection with a systemic inflammatory response (defined
as elevated IL-6 in plasma) and preterm infants with such
a response are at increased risk of subsequent brain injury
[5,6]. Therefore, factors associated with antenatal infec-
tion/injury increase the risk of brain injury after preterm
birth, and this association may also explain much of the
cerebral palsy that occurs after term birth [7].
Antenatal infection/inflammation and lung
injury
The fetal lung is also a target for factors released by ante-
natal infection/inflammation. Most infants born after
amnionitis do not have either positive tracheal cultures or
a clear pneumonic process. However, as with the brain,
lung injury progressing to bronchopulmonary dysplasia
(BPD) can occur after exposur  to either elevated pro-
inflammatory cytokines in amniotic fluid or a systemic
inflammatory response [5,8••]. Yoon et al correlated ele-
vated levels of IL-6 in cord plasma with the subsequent
development of BPD after preterm birth [9]. Elevated
levels of IL-6, IL-1β, IL-8, and TNF-α in amniotic fluid within
5 days of preterm birth also predicted the subsequent
development of BPD [8••]. The most common commensal
organism associated with histologic chorioamnionitis after
very preterm birth is Ureaplasma urealyticum [2], which
induces a robust pro-inflammatory response characterized
by el vations of the previou ly listed cytokines in the amni-
otic fluid [10]. Infants colonized with Ureaplasma at birth
subsequently had a 43% incidence of BPD, in contrast to
a comparison group with an incidence of 19% [11]. In
another report, histologic chorioamnionitis was associated
with an increased incidence of BPD, while the infants that
developed it had elevated cytokine levels in tracheal aspi-
rates on the first day after birth.
Figure 1
Lung development must continue for survival of the very low birth weight infant after preterm delivery at 26 weeks. Antenatal infection/inflammation
associated with chorioamnionitis can modulate lung development, as can postnatal causes of inflammation such as mechanical ventilation,
supplemental oxygen, or infection. The stages of lung development are modified from Burri [1].
Figure 1 Stages of lung development.
Antenatal infection/ inflammation associated with chorioamnionitis can modulate lung development, as can postnatal causes of inflammation such 
as echa ical ventilation, supplemental oxygen or infectio .
Adapted from Jobe AH and Ikegami M 2001 Resp R s 2:27-32.17
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with an increase in the incidence of BPD.32 These clinical studies are consistent with the 
described interference of lung development by cytokines in transgenic mice.
Ventilation strategies also influence lung injury. Ventilation strategies with volumes 
approaching or exceeding total lung capacity, but also with volumes below a normal 
functional residual capacity result in edema and proinflammatory cytokines release in adult 
animals.33 Prior exposure to endotoxin amplifies the ventilation-mediated injury.34,35 Both 
conventional ventilation and high frequency oscillatory (HFO) ventilation interfere with 
septation. Although HFO results in somewhat better gas exchange, lung mechanics and 
lower pro-inflammatory cytokine levels, enhanced alveolarization is not observed.36
Glucocorticoids
Antenatal glucocorticoids
Animal studies
In the late 1960’s Liggins was the first to suggest a positive effect of glucocorticoids on fetal 
lung maturation by enhancement of surfactant production in preterm lambs.37,38 The effects 
of glucocorticoids on lung development have been reviewed by Bolt.39 Glucocorticoids 
have effects on structural lung growth and development, on antioxidant enzymes, lung 
tissue growth factors, inflammatory mediators and the regulation of pulmonary fluid 
absorption. In mice glucocorticoid deficiency during pregnancy resulted in a delayed 
anatomic maturation of the lung parenchyma, which proceeded normally when the fetuses 
received supplemental glucocorticoids in utero.40 The glucocorticoid deficiency resulted 
in overall hypercellularity and increased cell proliferation in the proximal and distal 
pulmonary epithelium and proximal mesenchyme.41
The effects of glucocorticoids on lung development seem to be time and dose 
dependent.42 In monkeys, interstitial and epithelial lung maturation accelerated irrespective 
in which phase of lung development triamcinolone (weaker glucocorticoid) was 
administered, but alveolarization accelerated only when triamcinolone was given during 
the canalicular phase. Reduction in body weight and growth of the lung septa occurred 
when triamcinolone was administered early in gestation.
Thus, glucocorticoids have a beneficial effect on the surfactant system and on the 
maturation of the lung by thinning the mesenchyme, however, at the same time they can 
interfere with normal alveolarization.22,43,44 The effects of glucocorticoids on the lungs and 
other organs seem to be gestational age and dose dependent.
Although several benefits of the use of antenatal steroids have been reported, adverse 
effects have been described such as diminished somatic, brain and lung growth and poorer 
brain function.45 In sheep maternal betamethasone administration induces lung maturation 
but at the same moment growth retardation in the fetus. When, however, betamethasone 
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was administered directly to the fetus no growth retardation and less lung maturation 
occurred, despite higher plasma betamethasone levels in the fetus than after maternal 
treatment.46 In monkeys, high doses of maternal betamethasone resulted in reduced length, 
body weight and reduced weight of brain, cerebellum, liver, pancreas, heart, adrenals, 
thymus, spleen, kidneys and lungs. When expressed in relative weight, the lungs, adrenals 
and spleen were even more reduced.43 Apparently high doses glucocorticoids administered 
antenatally are capable of inducing growth disturbance in all organs, but especially in the 
lungs, adrenals and spleen. 
Human studies
In 1972, Liggins and Howie suggested a positive effect of antenatal betamethasone on 
lung maturation by enhanced production or release of surfactant in preterm infants.47 
Ballard showed beneficial effects on the incidence of respiratory distress (RDS) and 
mortality when infants were delivered 2 to 10 days after antenatal glucocorticoid therapy 
and had a birth weight greater than 750 g.48 In a review of all randomized trials on the use 
of antenatal glucocorticoids conducted between 1972 -1994 it was concluded that antenatal 
corticosteroids given between 48 hr and 7 days before preterm delivery, decreased the 
incidence of RDS by 40-50 % as well as intraventricular hemorrhage (IVH) and mortality.49 
However, in these trials very few pregnancies with a gestation less than 28 weeks were 
included. In 1995 the National Institute of Child Health and Human Development published 
a consensus stating that the benefits of antenatal administration of corticosteroids to fetuses 
between 24 and 34 weeks of gestation at risk for preterm delivery vastly outweighs the 
potential risks.50 No evidence was found to prefer the use of either betamethasone or 
dexamethasone.51 
In preterm infants an increase in surfactant phosphatidylcholine synthesis is observed 
after administration of glucocorticoids antenatally.52 Antenatal glucocorticoids improve 
surfactant function in preterm infants by decreasing protein leakage in epithelial lining 
fluid, increasing secretion and rate of surfactant production at birth and by improving intra-
alveolar metabolism of exogenous surfactant.53-55 
The latest Cochrane review about the use of antenatal glucocorticoids included 18 trials 
with over 3700 infants. In these trials either 24 mg betamethasone, or 24 mg dexamethasone 
or 2 g hydrocortisone was administered to women expected to give preterm birth. Antenatal 
glucocorticoids (betamethasone or dexamethasone) decreased the incidence of RDS when 
infants were delivered between 48 hours and 7 days after administration, reduced the 
incidence of IVH and mortality, but did not have any effect on the incidence of BPD at 36 
weeks or necrotising enterocolitis (NEC). No evidence was found to support or condemn 
the use of repeated doses of corticosteroids.56
Follow-up studies included in this Cochrane review, although reporting on infants born 
after a gestational age of 31-35 weeks, did not show any adverse effect on physical growth 
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or lung growth. However, hospitalization because of infectious disease in the first years 
was increased.57-60 
As the use of antenatal steroids has increased to above 80-90% in mothers at risk for 
preterm delivery, new follow-up studies evaluating the long term effects of antenatal 
glucocorticoids in very preterm infants born after a gestational age of less then 28 weeks 
will be difficult due to the lack of a control group.
So far, in human studies the use of antenatal glucocorticoids is not associated with serious 
adverse outcome although the follow-up studies were performed on infants born after 
higher gestational ages than the infants nowadays treated at the NICU.
Postnatal glucocorticoids
Animal studies
Nowadays, most animal studies are focussed on the adverse effects of glucocorticoids. 
Numerous adverse effects of glucocorticoid treatment are presently known. Kamphuis 
reviewed the adverse effect of glucocorticoids on the cerebrum, hypothalamic-pituitary-
adrenal (HPA)- axis and behaviour in the neonatal rat.61 A permanent decrease in brain 
weight and DNA content in adulthood, a temporary inhibition of cell proliferation in 
cerebellum and dentate gyrus of the hippocampus, an effect on gliogenesis and myelination, 
and a delay in development of dendritic spines in the visual cortex was described in rats 
treated with glucocorticoids.62-65 
The effect of glucocorticoids on the HPA -axis in rats, included a delay in maturation 
of the HPA-axis response to stress during development and at 20-25 days of age, thereby 
suggesting a long-lasting effect on the HPA-axis responsivity to stress.66,67 
Glucocorticoids effect neurobehavioural development leading to permanent deficits in 
cognitive abilities, motor co-ordination, social behaviour, learning and memory processes 
later in life.61
In rats, neonatally treated with glucocorticoids a shorter lifespan was observed and this 
was most likely caused by end stage cardiac and renal failure as shown by histopathological 
examination.68 
Human studies
Most human studies were focussed especially in the years after introduction of 
dexamethasone on the beneficial effects of glucocorticoids. Postnatal glucocorticoids 
are effective in weaning infants at risk for BPD from the ventilator. In infants developing 
BPD dexamethasone treatment decreases the high levels of cytokines in the broncho 
alveolar fluid, increases surfactant proteins and decreases albumin levels in tracheal fluid 
by decreasing the pulmonary microvascular permeability.69-75 Thereby dexamethasone 
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improves respiratory compliance, reduces the need for oxygen supplementation and 
duration of mechanical ventilation.76-79 
The effects of early (< 96 hours after birth), moderate early (7-14 days) and late (> 3 
weeks) treatment with glucocorticoids in ventilated infants at risk for developing BPD have 
been reviewed by Halliday, Ehrenkranz and Doyle.80-82 
Early glucocorticoid treatment (< 96 hours after birth) facilitates weaning from the 
ventilator, decreases the incidence of BPD at 28 days and 36 weeks as well as patency of 
ductus arteriosis and severe retinopathy of prematurity (ROP). It also reduces the combined 
outcome death or BPD at 28 days and 36 weeks and the need for later steroid treatment. 
No effect is observed on mortality, the incidence of air leaks, severe IVH, pulmonary 
hemorrhage, periventricular leucomalacia, infection, NEC, and the need for home oxygen 
therapy. However an increased risk is documented of gastrointestinal bleeding, intestinal 
perforation, hyperglycemia, hypertension, hypertrophic cardiomyopathy and growth failure. 
Long-term complications like an increased risk for abnormal neurological examination (RR 
1.8, CI 1.33-2.47), developmental delay in one study (RR 1.68, CI1.08-2.61) and cerebral 
palsy (RR 1.69, CI 1.20-2.38) are observed, but no effect on the incidence of blindness, 
deafness or behaviour problems.83-88
Thus, early postnatal glucocorticoids result in short-term benefits such as earlier 
extubation and reduction of the incidence of BPD without an effect on mortality but with 
serious short tem adverse effects. The data on follow-up are limited with follow-up studies 
performed before school age and usually within the first 2 years of life. Regarding the 
serious short-term and long-term complications the benefits of early postnatal corticosteroid 
treatment may not outweigh the potential adverse effects. None of the reviewed studies had 
sufficient power to detect adverse long term neurosensory outcomes or looked for other 
somatic outcomes.
Moderate early dexamethasone treatment (7-14 days after birth) facilitates weaning from 
the ventilator, reduces mortality, decreases the incidence of BPD at 28 days and at 36 weeks 
as well as the combined outcome death or BPD and the need for late steroid treatment. No 
effect on the incidence of pneumothorax, severe IVH, NEC or severe ROP is demonstrated, 
but an increased risk was found for hyperglycemia, hypertension, gastrointestinal bleeding, 
infection, hypertrophic cardiomyopathy and infection. Four studies presented follow-up 
data, two by personal communication and one as article.89 The incidence of cerebral palsy, 
major neurosensory disability, blindness, deafness was not increased. 
Thus, the use of moderate early postnatal glucocorticoids reduces neonatal mortality and 
the incidence of BPD but has significant short-term adverse effects. The long-term follow-
up data are very limited and so far do not show adverse effects.
Delayed dexamethasone treatment (> 3 weeks after birth) has a borderline effect on 
the incidence of BPD at 36 weeks, facilitates weaning from the ventilator and reduces 
the need for late steroid treatment and for home oxygen therapy. No effect on mortality, 
20
Ch
ap
te
r 1
gastrointestinal perforation or bleeding, NEC and infection, but an increased risk was found 
for glycosuria, hypertension and severe ROP.
The incidence of long-term complications as abnormal neurological examination in the 
total group (RR1.90, CI 1.08-3.33) and in survivors (RR1.73, CI 1.01-2.97) was increased. The 
importance of this finding is unclear as the incidence of cerebral palsy, blindness, deafness, 
major neurosensory disability and moderate to severe neurological impairment was not 
increased.78,90-93 However, one study reported an increase in cerebral palsy at 1 year.93 
Thus, delayed administration of glucocorticoids had a borderline effect on the incidence 
of BPD, facilitates extubation, but has no effect on mortality. Serious short-term adverse 
effects are found and serious long-term adverse effects are described in one follow-up 
study so far. Again, the long-term follow-up data are of limited quantity and quality.
Apart from the Cochrane reviews, several non-randomised studies have been published 
about adverse effects of glucocorticoid treatment in preterm infants. Adverse effects such 
as hypertension, hyperglycemia, cardiac hypertrophy, gastroduodenal perforation and 
catabolic effects such as increase in plasma amino acids and increased protein breakdown 
are reported.76,77,94-99 Impairment of growth of length, weight but also of head-circumference 
has been associated with the use of glucocorticoids.100-102 Infants treated with dexamethasone 
more often show nephrocalcinosis and abnormal general movements.103,104
In conclusion, the data of the Cochrane reviews show that glucocorticoids facilitate 
extubation and depending on the time of administration after birth have a beneficial effect 
on mortality and the incidence of BPD. Long-term follow-up data included in these reviews 
are very limited and mainly about neurological outcome. The non-randomised studies 
suggest numerous adverse effects of glucocorticoids, not evaluated in long-term follow-up 
studies, so far.
Adrenal gland
Fetus
During fetal life the adrenal glands grow rapidly and by term they reach an adult size 
weighing about 4 grams, each. Glucocorticoids are involved in fetal development and 
maturation and prepare various organs such as the lungs, liver and the immune system for 
the metabolic adaptations that are necessary for extrauterine life.48 The fetal adrenal cortex 
develops into two zones, a large fetal zone compromising 80-90% of the volume and a 
smaller definitive zone. The cells of the fetal zone are in contrast to the definitive zone well 
differentiated for active steroidogenesis.
Adrenocortical cells produce cortisol, aldosterone, dehydroepiandrosterone (DHEA) 
and androstenedione. In these cells two branchpoints for steroidogenesis exists (See 
Figure 2).The first branch point is at the level of pregnenolone where the enzyme 3β-HSD 
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converts pregnenolone to 17- desoxysteroids such as progesterone and aldosterone, while 
P450
c17
 converts pregnenolone to 17OH-pregnenolone. The second branchpoint is at the 
level of 17OH-pregnenolone that can be converted to either cortisol or DHEA. The relative 
activities of these two enzymes determine whether 17OH-pregnenolone is converted to 
cortisol or to DHEA.105
The active fetal zone expresses abundant amounts of P
450SCC
 and P
450C17 , 
but no 
3β-HSD mRNA or protein. Thus the major secretion product of the fetal zone is 
dehydroepiandrosterone-sulphate (DHEAS). The outer definitive zone expresses small 
amounts of P
450SCC
 and produces little steroid in early pregnancy. Later in pregnancy some 
expression of P
450SCC 
and 3β-HSD occurs.
The major products of the fetal zone are several free Δ5-3β-hydroxysteroids such as 
pregnenolone, 17OH - pregnenolone, DHEA and their sulfates. Lesser amounts of active Δ4-
3-ketosteroids such as cortisol are produced. The definitive zone, provides only a fraction 
of the total adrenal output but produces relatively more cortisol per cell.
Cord serum cortisol levels obtained at caesarian section without prior labor increase from 
20 nmol/l at 13 weeks gestation to 150 nmol/l at term.106
Figure 2 Pathways of steroid biosynthesis in the adrenocortical cell. 
Steroidogenic enzymes: P450SCC : cholesterol side-chain cleavage, P450C17 :17-hydroxylase and 17,20 desmolase, P450C21 :21-hydroxylase, P450C11 :
11β-hydroxylase, P450aldo : 18-hydroxylase and aldosterone synthetase,  3β-HSD.
Adapted from Winter JSD 1998.105
Figure 2 
Is gescand uit een boek 
Figure 2 
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Cord serum cortisol levels are influenced by input from fetal and maternal sources and 
by clearance through fetal and placental metabolism. About 60 - 75% of the cortisol in the 
fetal compartment originates directly from adrenal secretion, while the remainder derives 
from placental transfer of maternal cortisol or from conversion of cortisone.107 Clearance 
from the fetal unit is extremely rapid with 80% being oxidized in fetal tissues and placenta 
to cortisone and its metabolites. About 60% of the cortisone in the fetal compartment is 
transferred to the mother either as cortisol or cortisone. 
The fetus is relatively protected against maternal glucocorticoids by the placental enzyme 
11β-HSD type 2, which rapidly converts active cortisol to inactive cortisone.108 Placental 
11β-HSD type 2 activity is regulated by several factors such as thyroid hormones and 
related with birth weight and severe fetal distress.109 The function of 11β-HSD type 1 is to 
convert cortisone back into cortisol.110 The level of expression and activity of 11β-HSD is 
determined by a delicate balance between stimulatory (such as estrogens) and inhibitory 
(progesterone and nitric oxide) influences.111 
In contrast to cortisol, maternal dexamethasone and betamethasone pass the placenta 
without being inactivated by 11β-HSD type 2. Dexamethasone binds to the glucocorticoid 
receptor and suppresses the secretion of ACTH and indirectly cortisol but not the secretion 
of DHEAS.112
ACTH in the fetus derives from the fetal pituitary as maternal ACTH cannot cross the 
placenta. Fetal immunoreactive ACTH can be detected in the pituitary by 5 to 8 weeks 
gestation and responds to corticotrophine releasing hormone (CRH) and arginine-
vasopressine as early as 14 weeks gestation. ACTH is secreted by the anterior pituitary 
gland and its secretion is regulated by CRH which is synthesized in the paraventricular 
nucleus and released from the median eminence of the hypothalamus. Cortisol has a direct 
negative feedback effect on CRH and ACTH release.113
Neonate
After delivery the influence of the placenta on cortisol metabolism has ceased and due to 
the considerable excess of the adrenal secretory capacity and the stress of delivery, free 
cortisol levels increase on the day of birth. As a consequence plasma ACTH levels decline 
and the neonatal adrenal cortex rapidly involutes. In the first 4 days of life the adrenals lose 
25% of their mass and by 1 month they have decreased to 50% of their fetal size.
The Δ5- 3β- hydroxyl steroids such as DHEA, pregnenolone and 16α OH-DHEA almost 
disappear from the circulation. Serum cortisol levels are high at birth around 500 nmol/l, 
decline immediately on day 1 to 100 nmol/l, tend to increase slightly at day 4 and 5 and 
thereafter decrease further to 90 nmol/l at the end of the first week.105,114,115 Serum 17-
hydroxyprogesterone (17OHP) levels, one of the precursors of cortisol are also high on 
the first day of life, decline immediately after birth and remain stable from day 2 until day 
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7.114-117 Cortisone levels are in the same range as cortisol levels and decline immediately in 
the first 2 hours after birth and very gradually thereafter in the first week.
The circadian rhythm of cortisol secretion, also in very low birth weight infants, develops 
after 3 months and is present at 6 months of age.118,119
Nowadays, very preterm infants admitted to the NICU show signs of systemic hypotension 
accompanied by oliguria and edema, hyponatremia and hyperkalemia in the first postnatal 
days. This hypotension is resistant to volume expansion and cardiotonic drugs, but reacts 
to the administration of glucocorticoids.120 
Serum cortisol levels in sick preterm infants and in non-ventilated infants show no 
correlation with the degree of illness.119,121-124 Most of these infants were treated with 
antenatal glucocorticoids. In the past, short and long courses of maternal glucocorticoid 
treatment did not result in adrenal insufficiency.125,126 However, in those days infants were 
tested with high doses of ACTH and were born after a higher gestational age than the 
preterm infants currently admitted to the NICU.
In conclusion, in the adrenals major changes occur during the adaptation from fetal 
to extrauterine life. Clinical symptoms suggestive for adrenal insufficiency have been 
described, however these were not supported by biochemical evidence by means of ACTH 
testing. 
Growth
Fetal growth
Fetal growth has been stated to be influenced by insulin, insulin-like growth factor-I (IGF-I) 
and IGF-II, placental lactogen and to a limited extent by growth hormone (GH). Studies in 
IGF-I and IGF-II knockout mouse demonstrated growth-retarded embryos.127 The reduction 
of birth length in GH-deficient infants suggests that GH does have some effect on fetal 
growth.128 The exact role of various hormones and factors such as insulin, IGF-I and IGF-II, 
GH and leptin in promoting growth in utero and in early postnatal life, is still unknown.129-
131
In the fetal circulation, pituitary GH can be determined from the 12th week of gestation. 
Levels increase until mid-gestation when the highest levels of GH are reached (119 ± 20 
ng/ml), thereafter GH levels decrease to 33 ± 4 ng/ml measured in umbilical cord blood 
at term age.132 Preterm infants have elevated levels of serum GH which decrease with 
advancing gestational and postnatal age.133-137 At term, GH levels are still elevated compared 
to childhood but there is a rapid decline of GH pulse frequency, GH amplitude and nadir 
GH levels within the first postnatal days.134,135,138 The typical childhood circadian pattern of 
GH secretion develops after 3 months and is present at 6 months of age.139 
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GH receptors mRNA and protein are present by the 15th week of gestation in 
fetal chondrocytes, osteoblasts, epidermis and fibroblasts, and GH receptors can be 
demonstrated in fetal liver, pancreas and brain in second trimester and in the placenta 
throughout gestation.140,141 However, during gestation the fetus is relatively GH insensitive 
due to a reduced GH receptor expression. Postnatally, GH receptor expression is gradually 
upregulated.142
IGF-I is detectable in several tissues starting at 9 weeks gestation. By mid-pregnancy IGFs 
are abundant in many tissues as lung, intestine, kidney, muscle and skin, with the highest 
levels in the lung.143,144 Around mid-pregnancy receptors for IGF-I and-II are present in 
nearly all fetal tissues.145 
Infants born small for gestational age (SGA) have elevated GH levels and lower IGF-
I levels in cord blood compared to appropriate for gestational age infants.146-148 It has 
been reported that SGA infants and animals have smaller kidneys compared to their size 
than appropriate for gestational age infants, which is supposed to increase the risk for 
hypertension in later life.149
Postnatal growth in BPD
In preterm infants, especially in those with major morbidities such as BPD, early postnatal 
growth retardation is reported.101,150,151 As growth retardation in general might also reflect 
disturbances in growth of organs such as lungs, kidneys and the brain, the implications of 
such a persistent growth disturbance might have long-term effects on the development, 
functioning and survival of many organs. One might hypothesize that very preterm infants 
developing early postnatal growth retardation might suffer from comparable reduction in 
organ development as intra uterine growth retarded fetuses.
Especially in the 1980’s and beginning of the 1990’s much attention has been given to 
the growth of infants with BPD. These early studies report an established growth failure 
in infants with BPD at term age.150,151 Follow-up studies regarding growth in preterm 
infants with BPD show impaired growth of weight and length throughout infancy and 
childhood.101,150-154 Vrlenich and Suave reported more often stunting of growth at 8 and 10 
years when compared with either preterm or term controls.154,155 Permanent growth failure 
has been reported in one long-term follow-up study.156 However, these adolescents were 
born and treated in the 1980’s, without the use of surfactant and postnatal glucocorticoids 
and with ventilation strategies different from those currently used. 
Many studies have focussed on etiological factors causing the retardation of growth 
in infants with BPD. Several factors have been proposed such as increased energy 
consumption for breathing, high metabolic rate, early use of glucocorticoids, undetected 
hypoxia during night and after feeding, and difficulty to achieve recommended feeding 
intake due to gastro-oesofageal reflux, fluid restriction or respiratory infection.153,157-159 
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Nowadays, glucocorticoids are frequently administered to ventilated preterm infants 
to facilitate weaning from the ventilator. Adverse effects of DEXA on growth in preterm 
infants are reported. However, most studies are limited to the short-term adverse effects of 
dexamethasone (DEXA) and describe an inhibiting effect on weight gain, linear growth and 
head circumference.100,101,160 
Very limited data are available documenting the pattern of growth and body composition 
in infants with BPD after discharge from the NICU.
Long-term lung function in BPD
During the 1970’s introduction of continuous positive airway pressure (CPAP) and positive 
end expiratory pressure (PEEP) resulted in a decrease in mortality rates from RDS. The first 
studies reporting on lung function in children with BPD are confined to the pre surfactant 
era without use of antenatal steroids.
These studies reported expiratory flow limitation in infants with BPD persisting during 
their second year of life.161 Gerhardt showed a gradual improvement in lung function 
parameters as functional residual capacity (FRC
p
), compliance and conductance towards 
the normal range during the first 3 years of life.162
The first follow-up study on adult BPD survivors from the 1960s and early 1970’s 
performed by Northway reported pulmonary dysfunction and complaints in most 
adolescents and young adults (76%). In these adult BPD survivors lung function tests 
showed airway obstruction (68%), airway hyperreactivity (51%) and hyperinflation.156 
These BPD survivors were born after a gestational age of 33 weeks and with a mean birth 
weight of 1899 g. Therefore, the stage of lung development at birth in those infants is not 
comparable with the more immature lungs of the infants nowadays admitted to the NICU 
and developing BPD.
In the 1980’s conventional ventilation was used without surfactant. Follow up studies on 
lung function on infants from this period are now available. Gross reported on preterm 
infants with and without BPD (oxygen need at 36 weeks) at 7 years of age. Preterm children 
with BPD demonstrated airway obstruction worsening with exercise, while the preterm 
infants without BPD had a pulmonary function similar to that of healthy control infants.163 
Half of the children with and 25% of the preterm children without BPD had asthma defined 
as bronchodilator responsiveness at age 7 years. Kitchen and Doyle demonstrated an 
association between BPD (28 days oxygen) and subsequent airway obstruction with lower 
FVC, FEV1 and higher residual volume even after adjustment for birth weight.164,165 Several 
studies reported obstructive lung disease, air trapping and bronchial hyperreactivity at 
school age in preterm infants with BPD born at the end of the 1970’s to mid 1980’s.166-169 
Other studies reported air flow obstruction in preterm infants with and without BPD.170,171
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In the late 1980’s and beginning of the 1990’s surfactant treatment has been introduced. 
The influence of this treatment on the population of surviving infants and the long-term 
prognosis for BPD-infants, have not been studied, yet.172 The effect of high frequency 
oscillation described by one study, the HiFi Study showed no improvement in pulmonary 
mechanics at 9 months of age compared to conventional ventilation.173
Aim of the studies
As a result of advanced care such as surfactant treatment and the use of antenatal steroids 
increasing numbers of very preterm infants survive. However, despite these advances in 
perinatal care bronchopulmonary dysplasia (BPD) still develops, nowadays mainly in 
younger and smaller infants. Infants with BPD have a higher neonatal and infant mortality 
rate and in survivors morbidity is increased especially in relation to growth, pulmonary 
and neurological function. As most ventilated infants who develop BPD are treated with 
dexamethasone and serious concerns have been raised about possible side effects of this 
drug also on the long-term, we performed several studies in these infants.
The following questions were raised:
1. In very preterm infants two clinical features attract attention. First, the development of 
BPD is associated with an ongoing inflammation in the lungs and secondly very preterm 
infants are increasingly treated with glucocorticoids because of circulatory problems. 
Both symptoms can be related to the adrenal function. Therefore the following questions 
were raised:
a. Is there biochemical evidence suggestive for adrenal insufficiency in very preterm 
infants?
b. Is there a relation between adrenal function in the first days after birth and the 
development of BPD?
To answer these questions cortisol and 17-OH-progesterone (17OHP) levels were measured 
at baseline and after ACTH stimulation in very preterm ventilated and non-ventilated 
infants 3 days after birth. Secondly, the data were correlated with severity of illness and the 
outcome of BPD. 
2. Diminished growth is a well-known problem in infants at risk for BPD during their stay 
on the neonatal intensive care unit. It is unknown if this retardation of growth is related 
to changes in hormonal factors. Therefore we evaluated the GH-IGF-I axis in ventilated 
preterm infants developing BPD and raised the following questions: 
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a. Are disturbances in the GH-IGF-I axis responsible for the observed growth failure?
b. Is there a relation between serum GH levels and severity of illness and nutritional 
intake?
c. What is the effect of dexamethasone on the GH-IGF-I axis? 
The study performed to answer questions 2a and 2b was conducted in ventilated preterm 
infants who could not be weaned from the ventilator and were developing clinical signs of 
BPD. A 6-hour growth hormone (GH) profile and serum IGF-I, IGFBP-1 and-3 levels were 
assessed and correlated with severity of respiratory failure and nutritional intake. 
The study performed to answer question 2c was conducted in 10 infants who could not 
be weaned from the ventilator and in whom dexamethasone treatment was started in order 
to wean them from the ventilator. The GH-IGF-I axis was investigated immediately before 
start of dexamethasone and at day 2 of the initial high doses of dexamethasone treatment.
3. As dexamethasone was demonstrated to have a significant inhibiting influence on the 
GH-IGF-I axis and induces growth retardation in ventilated very preterm infants, we 
raised the following question: 
Is it possible to overcome the adverse effect of dexamethasone on growth by 
simultaneous administration of recombinant human growth hormone (rhGH)? 
To answer this question a randomized placebo-controlled trial with recombinant human 
growth hormone in ventilated very preterm infants receiving dexamethasone in order to 
wean them from the ventilator was performed.
4. Diminished growth in infants at risk for BPD is a well-known problem. However, it is 
unknown to what extent growth retardation persists during the first year of life in infants 
nowadays treated on the neonatal intensive care, and what pattern of growth occurs.
Therefore the following questions were raised:
a. To what extent does growth retardation persist in infants who developed BPD?
b. Does growth during the first year of life in infants with BPD, result in a body 
composition comparable to healthy infants of the same age?
The study performed to answer this question was started in 1996/1997 and included 
patients who had developed BPD. Patients were included during the following 2 years and 
prospectively followed on the neonatal follow-up clinic.
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5. In infants with BPD born in the 1980’s pulmonary function tests show obstructive airways 
and airtrapping. However, these children were born in a period without the use of 
antenatal steroids and without surfactant treatment. Nowadays, treatment on the neonatal 
intensive care has changed and smaller preterm infants survive and develop BPD.
Therefore the following questions were raised:
a. What is the development of the pulmonary function in infants who developed BPD, 
nowadays, during their first year of life?
b. Is the pulmonary function and growth of the airways of the infants with BPD 
comparable to healthy infants, during the first year of life?
The study performed to answer these questions was in collaboration with the department of 
paediatric pulmonology. Patients with BPD were included during 2 years and prospectively 
followed on the neonatal follow-up clinic.
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Abstract
Some very preterm neonates admitted to the neonatal intensive care unit show circulatory 
and respiratory problems that improve after administration of steroids. It is unclear whether 
these symptoms could be caused by adrenal insufficiency. 
The objective of our study was to investigate the cortisol levels and the cortisol release 
from the adrenals after ACTH in very preterm infants with and without severe illness and 
to find whether a relation exists between adrenal function and outcome. An ACTH test (0.5 
µg) was performed on d 4 in 21 very preterm infants (gestational age, 25.6 –29.6 wk; birth 
weight, 485–1265 g). Baseline cortisol and 17-hydroxyprogesterone (17OHP) levels and the 
cortisol levels 30, 60, and 120 min after ACTH administration were measured. The Score for 
Neonatal Acute Physiology was used to measure illness severity.
All infants showed an increase in cortisol levels after ACTH, but the cortisol levels 
were significantly lower in the ventilated more severely ill infants. After adjusting for 
birth weight and gestational age, the mean baseline cortisol levels and cortisol/17OHP 
ratios were significantly lower and the 17OHP levels significantly higher in the ventilated 
infants compared with the nonventilated infants. Patients with an adverse outcome had 
significantly lower baseline cortisol/ 17OHP ratios and 60-min cortisol levels during ACTH 
testing (p = 0.002 and p = 0.03, respectively). 
Conclusion: These data suggest an insufficient adrenal response to stress in sick 
ventilated very preterm infants with gestational ages younger than 30 wk compared with 
nonventilated less sick preterm infants. Further studies are required to investigate whether 
supplementation with physiologic doses of hydrocortisone may benefit the outcome.
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Introduction
With increasing neonatal and obstetric treatment modalities, younger and smaller neonates 
are admitted to neonatal intensive care units (NICU). Some of these infants show not only 
respiratory but also circulatory problems such as systemic hypotension resistant to volume 
expansion and cardiotonic drugs but reactive to the administration of corticosteroids.1 
Declining cortisol levels in the first week of life in patients with ongoing respiratory 
problems are reported, and a higher incidence of bronchopulmonary dysplasia (BPD) in 
patients with an insufficient cortisol response to ACTH has been found.2,3
In the 1970’s, the adrenal function of preterm neonates was investigated after administration 
of a short course of corticosteroids during gestation, and no signs of adrenal insufficiency 
were found.4 These preterm neonates, however, were born after a greater gestational age, 
had a higher birth weight than the infants presently seen in the NICU, and were tested with 
a relatively high dose of ACTH (15 µg/kg) on the first day of life. In infants exposed to long 
courses of corticosteroids during gestation, no evidence of adrenal insufficiency was found 
when tested with a higher dose of ACTH (36 µg/kg).5 These infants, however, were of 
greater gestational age compared with the very preterm infants now treated at the NICU.
Insufficient cortisol production may not only lead to disturbed vital signs such as low 
blood pressure and poor glycemic control but also may influence illness severity and 
outcome.
According to previous studies, cortisol and 17OHP levels are high on the first day of life. 
Thereafter, cortisol levels decrease immediately and tend to increase at d 4 and 5, whereas 
17OHP levels decline immediately after birth but remain stable from d 2 until 7.6–9 Recent 
studies show low cortisol levels in ill very preterm infants, whereas others find low cortisol 
levels that may be explained as physiologic as these infants no longer required mechanical 
ventilation.10-14 Cortisone levels decline immediately in the first 2 h and very gradually 
thereafter in the first week of life. The levels between term and preterm infants are not 
significantly different. Corticosterone levels are much lower than cortisol levels, increase 
in the first 2 h, decrease until 6 h, and decrease again to 24 h, after which a slight increase 
is seen.
The aim of the present study was to investigate the release of cortisol and the precursor 
17OHP from the adrenals of very preterm infants under conditions of stress compared with 
the nonstressed situation and to evaluate whether a relation exists between the cortisol 
release on d 4 of life and the development of BPD, severe cerebral complications, and 
mortality.
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Methods
Patients
Twenty-one patients admitted to the NICU of the Sophia Children’s Hospital were 
included in the present study. The inclusion criteria were immediate admission at the 
intensive care unit after birth, gestational age younger than 30 wk, and indwelling arterial 
line. Exclusion criteria were a maternal history of endocrine disorders such as diabetes, 
thyroid or adrenal problems, or congenital malformations. The present study was approved 
by the local Medical Ethics Committee, and informed consent was obtained from the 
parents of each child.
Methods
Infants were studied on d 4 of life. Most of the infants were tested at 0800 h, but some were 
tested in the afternoon. A standard dose of 0.5 µg of ACTH was given. ACTH was diluted 
with saline to a concentration of 1 µg/mL in a plastic syringe and immediately given i.v. by 
a short venous cannula and a connection close to the patient.
Baseline blood samples for cortisol, 17OHP, and C/17OHP were taken. Cortisol was also 
measured 30, 60, and 120 min after administration of ACTH. All blood samples were taken 
from an indwelling arterial line. Oxygen saturation was measured continuously by pulse 
oxymetry (Nellcor 3000), ventilation settings were recorded every 30 min during testing, 
and arterial blood pressure was measured continuously. 
Illness severity was measured by the SNAP score.15 We performed this score on d 4 to 
determine whether other pathophysiologic parameters such as blood pressure, frequency 
of bradycardia, disturbances in glucose, in serum electrolytes, and liver or kidney function, 
often seen in more severely ill patients and not always accompanied by higher ventilation 
settings, were related to the adrenal function. Although the SNAP score is designed to 
reflect the severity of illness on d 1, we believe that the score on d 4 also reflects the 
severity of illness on d 4.
BPD was defined as persisting respiratory problems with a need for oxygen at d 28 and 
an abnormal chest x-ray.16 Adverse outcome was defined as mortality or severe morbidity 
defined by severe cerebral problems (intracranial hemorrhage grade 3 or more and severe 
cystic leukomalacia) and/or BPD.
Hormone Assays
Serum cortisol was determined by using a commercial chemiluminescent labeled antibody 
assay (Nichols Institute Diagnostics Cortisol Kit, San Juan Capistrano, CA, U.S.A.). The 
intraassay coefficients of variation were 3.1–4.8%, and the interassay coefficients of 
variation were 6.2–10.2%. Cross-reactivity with cortisone is unknown within physiologic 
ranges. Hyperbilirubinemia did not influence the assay. 
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The precursor 17OHP was determined by RIA (Coat-A-Count, Diagnostic Products Corp., 
Los Angeles, CA, U.S.A.) (Laboratory Internal Medicine, Academic Hospital Rotterdam, The 
Netherlands; Head, Prof.Dr. F. de Jong). The interassay coefficient of variation was 10% for 
17OHP. The main cross-reactivity in the 17OHP assay occurred with progesterone 5%.17
Statistical Analyses
Statistical analyses were made by SPSS package, version 8.0 Windows, released in 1997. 
Results are expressed as mean (SD) unless indicated otherwise. Linear regression analysis 
was used to examine the relations between determinants such as birth weight, gestational 
age, birth weight SD-score (SDS), illness severity, and ventilation and continuous outcome 
variables such as cortisol, 17OHP, and C/17OHP. The relation with ventilation, BPD, and 
adverse outcome was adjusted for gestational age and birth weight. The baseline 17OHP 
data showed a skewed distribution and were log transformed for statistical analyses. A 
p value < 0.05 was considered significant.
Results
Twenty-one patients were enrolled in the study (14 male, seven female); the patients had a 
mean gestational age of 27.7 (interquartile (i.q.) range, 26.4 –28.9 wk), a mean birth weight 
of 887 g (i.q. range, 708–1005 g), a mean SD-score for birth weight of -1.43 (i.q. range, -2.82 
to -0.30), and a mean weight at day of testing of 845 g (i.q. range, 738–933 g).
Sixteen patients received antenatal betamethasone, and 10 patients were artificially 
ventilated during ACTH testing. The ventilated and nonventilated group were not 
significantly different except for gestational age, birth weight, and SNAP score p = 0.03, p = 
0.03, and p = 0.003, respectively). The ACTH dose expressed in µg/kg was not significantly 
different between the groups. Five patients died in the neonatal period.
Baseline Cortisol Levels
The mean (SD) baseline cortisol level for the total group was 277 (144) nmol/L. The 
baseline cortisol levels were not influenced by the mode of delivery or the presence of 
preeclampsia of the mother and did not correlate with gestational age, birth weight, and 
birth weight SD-score.
In boys, the mean baseline cortisol level was 116 nmol/L lower than in girls (p = 0.21). 
In the patients treated with antenatal steroids, the mean baseline cortisol level was not 
significantly lower compared with the group without use of antenatal steroids.
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Cortisol Response after ACTH
The mean (SD) cortisol levels 30 and 60 min after ACTH administration were 558 (180) and 
753 (250) nmol/L, respectively. Some infants continued to have high cortisol levels at 120 
min, but others already showed a decline. The mean (SD) cortisol level at 120 min was 694 
(251) nmol/L.
The cortisol levels at 30 and 60 min were positively correlated with gestational age (r = 
0.57, p = 0.008 and r = 0.59, p = 0.006, respectively). The 60-min cortisol levels showed a 
positive correlation with birth weight (r = 0.49, p = 0.029). The cortisol levels at 30 and 60 
min were not correlated with the ACTH dose per kilogram of body weight (r = -0.26, p = 
0.26 and r = -0.43, p = 0.06, respectively) or with birth weight SD-score (r = -0.23, p = 0.92 
and r = 0.82, p = 0.73).
Baseline 17OHP Levels
The baseline levels of 17OHP showed a skewed distribution and were log transformed 
for statistical analyses. The baseline 17OHP levels showed a negative correlation with 
gestational age (r = -0.53, p = 0.020) but did not correlate with birth weight or birth weight 
SD-score. The baseline 17OHP levels were not related with the baseline cortisol levels but 
were negatively correlated with the cortisol levels at 30 and 60 min (r = -0.52, p = 0.025 and 
r = -0.51, p = 0.032, respectively).
Cortisol and 17OHP Levels in Relation to Ventilation
The mean baseline cortisol level was not significantly lower, but the cortisol levels at 30 
and 60 min after administration of ACTH were significantly lower in the ventilated infants 
compared with the nonventilated infants (p < 0.001 and p < 0.01, respectively) (Fig. 1). 
The mean baseline 17OHP level in the ventilated infants was 45.6 (34.3) nmol/L and 
significantly higher compared with the nonventilated infants 8.5 (6.4) nmol/L (p = 0.014). 
The mean baseline C/17OHP was significantly lower in the ventilated compared with the 
nonventilated infants (p = 0.004). After adjusting for gestational age and birth weight, the 
mean baseline cortisol, the cortisol level at 30 min, and the C/17OHP were significantly 
lower in the ventilated group (p = 0.046, p = 0.013, and p = 0.015, respectively).
Cortisol and 17OHP Levels in Relation to Illness Severity
The baseline cortisol levels were not related to SNAP scores, but the 30- and 60-min cortisol 
levels were negatively correlated with higher SNAP scores, indicating lower cortisol levels 
at higher SNAP scores (r = -0.62, p = 0.005 and r = -0.61, p = 0.006, respectively) (Fig. 2, A– 
C). For every increment of 10 points in the SNAP score, the 30-min cortisol level decreased 
with 215 nmol/L, and the 60-min cortisol level decreased with 272 nmol/L.
The baseline 17OHP level was positively correlated with higher illness severity as 
measured by SNAP (r = 0.49, p = 0.039).
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Cortisol and 17OHP Levels in Relation to Outcome
BPD. Patients who developed BPD were not significantly different with respect to 
gestational age, birth weight, and birth weight SD-score compared with patients who did 
not develop BPD.
Patients who developed BPD showed a significantly lower mean cortisol level at 60 min 
(p = 0.029) than patients who did not develop BPD. In addition, the mean baseline value 
for 17OHP was significantly higher and mean C/17OHP was significantly lower in infants 
who developed BPD (p = 0.009 and p = 0.008, respectively).
Adverse outcome. Gestational age, birth weight, and birth weight SD-score were not 
significantly different in patients with a poor outcome compared with patients with a good 
outcome.
Patients with a poor outcome showed a significantly lower mean 60-min cortisol level (p 
= 0.025), a significantly higher mean baseline 17OHP level (p = 0.006), and a significantly 
lower mean baseline C/17OHP (p = 0.002) compared with infants with a better outcome.
Cortisol Response after ACTH
The mean (SD) cortisol levels 30 and 60 min after ACTH
administration were 558 (180) and 753 (250) nmol/L, respec-
tively. Some infants continued to have high cortisol levels at
120 min, but others already showed a decline. The mean (SD)
cortisol level at 120 min was 694 (251) nmol/L.
The cortisol levels at 30 and 60 min were positively corre-
lated with gestational age (r � 0.57, p � 0.008 and r � 0.59,
p � 0.006, respectively). The 60-min cortisol levels showed a
positive correlation with birth weight (r � 0.49, p � 0.029).
The cortisol levels at 30 and 60 min were not correlated with
the ACTH dose per kilogram of body weight (r � �0.26, p �
0.26 and r � �0.43, p � 0.06, respectively) or with birth
weight SDS (r � �0.23, p � 0.92 and r � 0.82, p � 0.73).
Baseline 17OHP Levels
The baseline levels of 17OHP showed a skewed distribution
and were log transformed for statistical analyses. The baseline
17OHP levels showed a negative correlation with gestational
age (r � �0.53, p � 0.020) but did not correlate with birth
weight or birth weight SDS. The baseline 17OHP levels were
not related with the baseline cortisol levels but were negatively
correlated with the cortisol levels at 30 and 60 min (r��0.52,
p � 0.025 and r � �0.51, p � 0.032, respectively).
Cortisol and 17OHP Levels in Relation to Ventilation
The mean baseline cortisol level was not significantly lower,
but the cortisol levels at 30 and 60 min after administration of
ACTH were significantly lower in the ventilated infants com-
pared with the nonventilated infants (p � 0.001 and p � 0.01,
respectively) (Fig. 1). The mean baseline 17OHP level in the
ventilated infants was 45.6 (34.3) nmol/L and significantly
higher compared with the nonventilated infants 8.5 (6.4)
nmol/L (p � 0.014). The mean baseline C/17OHP was signif-
icantly lower in the ventilated compared with the nonventilated
infants (p � 0.004). After adjusting for gestational age and
birth weight, the mean baseline cortisol, the cortisol level at 30
min, and the C/17OHP were significantly lower in the venti-
lated group (p � 0.046, p � 0.013, and p � 0.015, respective-
ly).
Cortisol and 17OHP Levels in Relation to Illness Severity
The baseline cortisol levels were not related to SNAP scores,
but the 30- and 60-min cortisol levels were negatively corre-
lated with higher SNAP scores, indicating lower cortisol levels
at higher SNAP scores (r � �0.62, p � 0.005 and r � �0.61,
p� 0.006, respectively) (Fig. 2, A– C). For every increment of
10 points in the SNAP score, the 30-min cortisol level de-
creased with 215 nmol/L and the 60-min cortisol level de-
creased with 272 nmol/L.
The baseline 17OHP level was positively correlated with
higher illness severity as measured by SNAP (r � 0.49, p �
0.039).
Cortisol and 17OHP Levels in Relation to Outcome
BPD. Patients who developed BPD were not significantly
different with respect to gestational age, birth weight, and birth
weight SDS compared with patients who did not develop BPD.
Patients who developed BPD showed a significantly lower
mean cortisol level at 60 min (p� 0.029) than patients who did
not develop BPD. In addition, the mean baseline value for
17OHP was significantly higher and mean C/17OHP was
significantly lower in infants who developed BPD (p � 0.009
and p � 0.008, respectively).
Adverse outcome. Gestational age, birth weight, and birth
weight SDS were not significantly different in patients with a
poor outcome compared with patients with a good outcome.
Patients with a poor outcome showed a significantly lower
mean 60-min cortisol level (p � 0.025), a significantly higher
mean baseline 17OHP level (p � 0.006), and a significantly
lower mean baseline C/17OHP (p � 0.002) compared with
infants with a better outcome.
DISCUSSION
We performed this study to evaluate the capacity of the
adrenals of very preterm infants in the first week of life to
produce cortisol under normal conditions and under conditions
of stress.
Our study suggests that sick very preterm infants do not
release more cortisol than less severely ill very preterm infants.
Our data show significantly lower baseline cortisol levels and
a diminished cortisol response after ACTH in ventilated com-
pared with nonventilated infants and a significantly lower
C/17OHP in ventilated infants. A normal reaction to stress
would show a higher cortisol level with increasing illness as is
seen in critically ill adults (18). Our study, however, was not
designed to answer whether these infants became ill because of
a low cortisol production or showed adrenal insufficiency as a
result of their severe illness. The results, however, do support
the idea of considering supplementation of cortisol in severely
Figure 1. Cortisol levels before and after ACTH (0.5 �g) in ventilated and
nonventilated infants. Results are expressed as mean cortisol levels with 95%
confidence intervals. � � nonventilated infants, � � ventilated infants. �p �
0.001 vs nonventilated group, ��p � 0.01 vs nonventilated group.
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Figure 1 Cortisol levels before and after ACTH (0.5 µg) in ventilated and nonventilated infants. Results are given as mean cortisol levels with 
95% confidence intervals. 
● =  nonventilated infants, ■ = ventilated infants. 
*p < 0.001 and **p < 0.01 vs nonventilated group.
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Figure 2 
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Figure 2 Cortisol levels in relation to illness severity (SNAP score).
A Baseline cortisol levels 
B Thirty-minute cortisol levels after ACTH administration;  regression line: C30 =  797 - 22 SNAP. 
C Sixty-minute cortisol levels after ACTH administration;  regression line: C60 = 1041 - 27 SNAP.
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Discussion
We performed this study to evaluate the capacity of the adrenals of very preterm infants 
in the first week of life to produce cortisol under normal conditions and under conditions 
of stress.
Our study suggests that sick very preterm infants do not release more cortisol than less 
severely ill very preterm infants. Our data show significantly lower baseline cortisol levels 
and diminished cortisol response after ACTH in ventilated compared with nonventilated 
infants and a significantly lower C/17OHP in ventilated infants. A normal reaction to stress 
would show a higher cortisol level with increasing illness as is seen in critically ill adults.18 
Our study, however, was not designed to answer whether these infants became ill because 
of low cortisol production or showed adrenal insufficiency as a result of their severe illness. 
The results, however, do support the idea of considering supplementation of cortisol in 
severely ill very preterm infants with ongoing blood pressure problems and persisting 
hypoglycemia. 
Scott and Watterberg have demonstrated that very sick infants with gestational ages 
younger than 28 wk have lower morning cortisol levels than less severely ill infants of 
the same gestational age.19 This negative correlation between illness and morning cortisol 
levels, however, seems diminished in patients of greater gestational age. Other markers 
of illness such as ventilatory support pattern or use of surfactant were also negatively 
correlated with cortisol levels.
Our findings are in contrast with Hingre et al. who found in sick preterm and healthy full-
term infants comparable baseline cortisol levels and with Thomas et al. who even showed 
higher baseline cortisol levels in sick compared with healthy preterm infants.11,20,21 The 
difference with our data may be due to the fact that the patients in the Thomas study had 
a gestational age greater than 30 wk, whereas our patients were all younger than 30 wk. 
In agreement with Lee et al. and in contrast with other studies, we did not find a relation 
between baseline cortisol level and gestational age.10,19,22 It could be that our population 
was too homogeneous in gestational age to detect a relationship.
Although we are not informed about the amount of cross-reactivity between baseline 
cortisol and cortisone, we know from other studies that the levels of cortisone can be in the 
same range as the cortisol levels.8,23,24 This may have contributed to the measured baseline 
cortisol levels, especially when the baseline cortisol levels are low. We did find a difference 
in baseline cortisol levels between ventilated and nonventilated infants. As it is unlikely 
the levels of cortisone were higher in ventilated compared with nonventilated infants, the 
conclusion remains true.
The interpretation of ACTH test results is complicated by the fact that no agreement exists 
about the correct dose of ACTH, and different criteria for diagnosing adrenal insufficiency 
are used in the literature. We tested with a fixed dose of 0.5 µg, corresponding with an 
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ACTH dose of 0.5–1 µg/kg or 10–15 µg/1.73 m2 and found differences between ventilated 
and nonventilated infants.
The baseline cortisol levels in ventilated infants are remarkably low considering the 
degree of illness. Ventilated infants do have significantly lower 30- and 60-min cortisol 
levels after ACTH compared with nonventilated infants, which can only be caused by 
a lower adrenal cortisol release in response to ACTH administration. It is known from 
the literature that increases in cortisol are much higher than increases in cortisone after 
ACTH.23,25 It is only when the increase in cortisol after ACTH is very low that cortisone can 
still contribute to the measured cortisol level. In fact, we may have underestimated the 
differences in cortisol response between ventilated and nonventilated infants.
Thus, in contrast with earlier studies, we found evidence for adrenal insufficiency in 
very preterm ventilated infants when tested with a low-dose ACTH.4,26,27 It seems that 
the adrenals in these ventilated sick infants are less capable of releasing cortisol after 
an additional ACTH stimulus compared with nonventilated infants. Possible explanations 
may be that the adrenals in these infants were already down-regulated by high circulating 
interleukin levels and no longer reactive to high serum ACTH levels or that the adrenals in 
the ventilated infants were not capable enough of recognizing higher serum ACTH levels. 
The ventilated infants, however, showed higher levels of the cortisol precursor 17OHP and 
a lower C/17OHP compared with nonventilated infants. This indicates that the adrenals 
are responsive to ACTH and produce precursors but, at the same time, may not be able 
to convert the precursor to cortisol. Hanna et al. reported a normal ACTH and cortisol 
response to ovine corticotropin releasing hormone (CRH) and a normal cortisol response 
to exogenous ACTH in extremely low birth weight infants, thereby suggesting that the low 
baseline cortisol levels were partly due to an inability of the brain to recognize the stress 
of illness or an inability of the hypothalamus to secrete CRH.27 They, however, used a high 
dose of ACTH (62.5 µg) and 1 d after CRH testing, which by itself induces an increase in 
baseline cortisol levels. Ng et al. showed a higher ACTH response after CRH administration 
in ventilated infants without an increase in cortisol levels, suggesting that the pituitary is 
more matured than the adrenals in preterm infants.28
Our study showed significantly higher 17OHP levels and lower C/17OHP in ventilated 
infants compared with nonventilated infants adjusted for gestational age and birth weight, 
as well as, in more severely ill infants. Both suggest a reaction of the adrenals to stress by 
increasing a cortisol precursor but showing a lower capacity, especially in the severe ill and 
ventilated infants, to convert this precursor 17OHP to cortisol. The high levels of 17OHP 
in relation to cortisol can be caused by a decreased activity of the enzyme CYP21A2 or 
due to a lower conversion of 11-deoxycortisol to cortisol by CYP11B, which seems to be a 
greater problem in the sick very preterm infant. Higher 17OHP levels in sick preterm infants 
compared with term infants have been described earlier.10,29,30 High baseline levels of 17OH-
pregnenolone, 17OHP, and 11- desoxycortisol in sick infants with gestational ages younger 
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than 30 wk compared with term infants have been reported and are also consistent with a 
decreased CYP11B activity.11
In summary, our data demonstrate lower baseline cortisol levels, a lower cortisol response 
to ACTH, higher 17OHP levels, and lower C/17OHP in ventilated very preterm infants 
compared with nonventilated preterm infants and those who did not have an adverse 
outcome. The data suggest an insufficient adrenal response to stress in sick ventilated very 
preterm infants with gestational ages younger than 30 wk. Further studies are required to 
investigate whether supplementation with physiologic doses of hydrocortisone may benefit 
the outcome.
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Abstract
Very preterm infants ventilated for a prolonged period of time and at risk for BPD frequently 
show an impaired growth. The potential role of GH, IGF-I and the binding proteins in the 
growth retardation of these infants in the neonatal period is unknown and before GH 
therapy is considered, it is necessary to be informed about the GH-IGF-I axis.
In twenty-four very preterm ventilated infants (mean birth weight 953 (± 330) g, mean 
gestational age 27.5 (± 1.7), mean postnatal age 2.8 (± 1.4) weeks) a 6- h GH profile was 
performed and serum levels of IGF-I, IGFBP-1 and -3, nutritional intake and severity of 
respiratory failure were determined. GH profiles were analysed by Pulsar.
A wide variation in serum GH levels (6.0 - 55.8 µg/l, median 19.9 µg/l) and a correlation 
between serum GH and IGF-I (r = 0.42; p < 0.05) was observed. Serum GH levels did 
not correlate with gestational age, birth weight, postnatal age, weight gain or severity of 
respiratory failure. IGFBP-1 correlated with IGF-I and GH levels (r = 0.55; p < 0.01 and r = 
0.48; p < 0.05, respectively) and with daily caloric, fat and protein intake (r = 0.54, p < 0.01, 
r = 0.53; p < 0.01 and r = 0.43; p < 0.05).
Serum GH and IGF-I levels in ventilated preterm infants at risk for BPD were comparable 
to those found in non-ventilated preterm infants of similar postconceptional age and thus 
not correlated with severity of respiratory failure. Serum GH levels were related with IGF-I 
suggesting that GH exerts some effect through IGF-I. These findings together suggest that 
these infants do not have GH deficiency.
Conclusion: Our data show that poor growth in ventilated very preterm infants at risk for 
BPD is not the result of either low GH or IGF-I levels. For that reason our study does not 
provide arguments to consider GH therapy for growth-retarded ventilated preterm infants.
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Introduction
Preterm infants developing a chronic lung disease in the neonatal period frequently showed 
an impaired growth. Their growth will further decline when steroids are started to facilitate 
weaning from the ventilator. The impaired growth might persist into infancy.1-4 There 
are a number of definitions describing chronic lung disease in preterm infants. The term 
‘bronchopulmonary dysplasia’ (BPD) was introduced by Northway in 1967.5 Thereafter an 
increasing number of authors have used the term chronic lung disease instead of BPD.6 
Nowadays, BPD in most studies is defined as a persistent need for supplemental oxygen 
for at least 28 days.7 
Due to improvement in neonatal intensive care treatment, not only the survival rate of 
very preterm infants, but also the incidence of surviving preterm infants with BPD has 
increased. The incidence of BPD in infants surviving the neonatal period increases from 
12% in infants born after a gestational age of 30 weeks to 30% when born after a gestational 
age of 25 weeks.8
The early postnatal insufficient growth is a general pattern in infants at risk for 
developing BPD. Several factors have been considered to cause growth retardation in 
preterm infants with respiratory problems. Some studies showed an elevated metabolic rate 
in these infants, however these results have been challenged.9,10 Caloric intake is often less 
than recommended due to fluid restriction whereas the absorption in the gastrointestinal 
tract might also be impaired. Infections, even low-grade lung infections can have a negative 
influence on growth. Hormonal abnormalities, particularly reduced levels of growth 
hormone (GH) and growth factors or the opposite, an increased GH insensitivity might 
play a role.
The exact role of various hormones and factors such as GH, insulin-like growth factor 
(IGF-I and IGF-II), leptin and insulin in promoting growth in utero and in early postnatal 
life, is still unknown.11-13 Although it is widely assumed that the GH-IGF-I axis is not the 
major system determining foetal and early postnatal growth, the reduction of birth length 
in GH- deficient infants suggests that GH does have some effect on foetal growth.14 Most 
studies reported a decline in serum GH levels with advancing gestational and increasing 
postnatal age.15-23 The decline in GH levels has been attributed to a decrease in GH pulse 
frequency, GH secretory bursts amplitudes and in nadir GH levels.16,17,24 However, no data 
exist about GH profiles in ventilated very preterm infants at risk for BPD. 
The potential contribution of GH, IGF-I and the IGFBP’s to the growth retardation of 
preterm infants with respiratory failure who are at risk to develop BPD in the neonatal 
period is unknown. Before GH therapy in these infants is considered it is necessary to be 
informed about the GH-IGF-I axis.
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We therefore assessed serum levels of GH, IGF-I, and their binding proteins in preterm 
infants with respiratory failure at risk to develop BPD. In addition, we analysed if these 
levels were related to nutrition, medication and illness severity.
Methods
Patients
Twenty-four preterm infants, born after a gestational age of less than 33 weeks and with 
a persistent need for artificial ventilation (after an initial phase of respiratory distress 
syndrome) were studied. All patients received treatment consisting of diuretics, fluid 
restriction and inhalation therapy. Exclusion criteria were: steroid treatment, persistent 
ductus arteriosus, pulmonary infection, ongoing sepsis, grade 3 or 4 intraventricular 
haemorrhage, chromosomal defects or major congenital anomalies. None of the infants 
received blood transfusions within 2 days before the study. If the mother was being treated 
for an endocrine disorder with GH, hydrocortisone, thyroxin, or thyrostatic drugs, the infant 
was not included. All patients were admitted to the NICU of the Sophia Children’s Hospital 
in Rotterdam, the Netherlands.
The Medical Ethics Committee of the Erasmus University Medical Center approved the 
study protocol and written informed consent was obtained from the parents of each child.
Methods
All patients had an indwelling arterial line. A plasma sample was taken, every 30 minutes, 
during a 6-hours period. A longer sampling period and more frequent blood sampling was 
considered unethical in this group of very small, sick, preterm infants. Studies in these 
preterm infants are restricted due to the small size of the infants and their severe illness. 
The total blood volume of these infants is 50 - 80 ml. It was considered unacceptable to 
withdraw more than 5% of the total blood volume for study purposes. For the present study 
the maximal volume was 2.5 - 4 ml, which made it impossible to sample for a longer period 
than 6 hours or more frequently. As these infants do not yet have a diurnal GH secretion 
and are being nursed under conditions that do not change significantly throughout day and 
night, a 6-h GH profile was considered to be sufficient. 
All blood samples were stored directly on ice for no longer than 3 hours. After 
centrifugation, plasma samples were frozen (- 20 ‘C) until assayed. Serum GH was 
measured in all samples and serum IGF-I, IGFBP-1, and IGFBP-3 levels were determined 
in the first sample.
The attending neonatologist provided routine care and feeding decisions. According to 
the policy of the NICU, infants were started on parenteral nutrition (PN) on the second day 
of life and enteral feedings were initiated on day 7. Preterm infant formulas were used with 
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a caloric density of 80-88 kcal/100 ml and a protein content of 2.4-2.6 g/100 ml. The daily 
protein, caloric and fat intake was calculated from the total enteral and parenteral intake 
during the 48 hours period prior to the study and during the day of study.
Weight gain in the week of study was measured by performing daily weight measurements 
and expressed in g/kg/wk. Illness severity was assessed by calculating the oxygenation 
index (mean airway pressure times inspired fraction of oxygen / PaO2) and by calculating 
the ventilation score (mean airway pressure times inspired fraction of oxygen). Use of 
cardiotonic drugs because of hypotension was also recorded.
Hormone assays
All GH determinations were performed in the Endocrine Laboratory of the University 
Hospital Rotterdam, the Netherlands.
GH determinations in plasma were measured using a two-site immunoradiometric assay 
(ELSA-HGH, CIS bio international, ORIS Group, France). The assay measured the 22 kD GH 
and showed no cross reactivity with 20 kD GH. All samples were analysed in duplicate in 
the same assay. The WHO First International Reference Preparation WHO 80/505 was used 
as a standard. The intra-assay coefficients of variation were 2.4%, 2.8%, 2.8% and 2.3% at 
GH concentrations of 3.46, 7.3 17.0 and 47.4 µg/l, respectively. The inter-assay coefficients 
of variation were 4.2%, 3.2%, 4.4% and 4.0% at GH concentrations of 3.32, 7.10, 16.4, and 
45.4 µg/l. The detection limit of the assay was 0.04 µg/l. 
IGF-I was determined by RIA (SM-C-RIA-CT, Biosource Europe SA) and after acid-ethanol 
extraction.25 The sensitivity was 0.25 ± 0.10 ng/ml, the intra-assay coefficients of variation 
were 6.1%, 4.1%, 4.7% at IGF-1 levels of 54.2, 194 and 491 ng/ml. The inter-assay precision 
was 9.9%, 9.6%, 9.3% at levels of 121, 251 and 494 ng/ml. Cross-reactivity with IGF-II was 
0.2%, with insulin < 0.001% and with GH < 0.01%.
IGFBP-1 was determined using a two-site immunoradiometric assay principle (Total 
IGFBPI IRMA DSL-7800, Diagnostic Systems Laboratories, Webster, Texas, USA). The 
sensitivity of the assay was 0.33 ng/ml and the intra-assay coefficients of variation were 
between 5.2%, 4.6% and 2.7% with IGFBP-1 levels of 5.23, 50.23 and 144.60 ng/ml. The 
inter-assay coefficients of variation were 3.5%, 6.0% and 3.6% at IGFBP-1 levels of 5.15, 
47.08 and 142.03 ng/ml. No cross-reactivity was seen with the IGFBP-2, -3, -4, -5, and -6. 
IGFBP-3 was determined using a two-site immunoradiometric assay (IGF-BP3 IRMA, 
DSL-6600, Diagnostic Systems Laboratories Webster, Texas, USA). The sensitivity of the 
assay was 0.5 ng/ml, with intra-assay coefficients of variation of 1.8%, 3.2%, and 3.9% at 
IGFBP-3 levels of 82.72, 27.53 and 7.35 ng/ml. The inter-assay coefficients of variation were 
1.9%, 0.5% and 0.6% at IGFBP-3 levels of 76.90, 21.51 and 8.03 ng/ml, respectively.
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Analysis of the 6-h GH profiles
The 6-h GH profiles were analysed with the Pulsar program from Merriam and Wachter26 
and adapted for Quick Basic by Rosberg and Albertsson-Wikland (PC-Pulsar, 1987). From 
the Pulsar analysis, the following values were extracted: the overall mean, the baseline, the 
maximal GH value, and the number of GH peaks in 6 hours. 
Statistical analysis
Statistical analysis was performed using SPSS 9.0 for Windows 95, SPSS software (Chicago, 
IL, U.S.A.). All hormone values were log transformed before analysing to obtain approximate 
normal distributions. Differences between two groups were tested with the Mann-Whitney 
test in case of deviation from a normal distribution. Correlations were evaluated with the 
non-parametric Spearman’s rank correlation. Multiple regression analysis was used to 
evaluate various parameters simultaneously with regard to their relation with IGFBP-1. 
Results are expressed as the mean (SD), unless indicated otherwise. Two tailed p-values ≤ 
0.05 were considered significant.
Results
Clinical characteristics
Twenty-four ventilated very preterm infants, 13 boys and 11 girls, with a mean gestational 
age of 27.5 (± 1.7) weeks, a mean birth weight of 935 (± 330) g and a mean postnatal age 
of 2.8 (1.4) weeks were included in the study. 
The clinical data of the infants at day of study are shown in Table 1. The mean weight 
gain was 59.3 (30.1) g/kg/wk and 20 patients showed a weight gain less than 12 g/kg/day. 
GH profiles 
The 6-h GH profiles of the individual patients are shown in Figure 1. Serum mean GH 
levels varied between 6.0 and 55.8 µg/l with a median of 19.9 µ/l. The number of GH peaks 
within the 6-h period ranged from 0 to 4. Different types of growth hormone profile were 
seen. Some patients (numbers 4, 8, 14, 18, 21, 23 and 24) had serum mean GH levels below 
15 µg/l without any obvious GH peaks. The other patients had serum mean GH levels 
above 15 µg/l with one or more GH peaks (numbers 1 - 3, 5, 7, 9 -13, 15, 17, 19, 20 and 
22). Two patients had quite different GH profiles: patient 6 had relatively low GH levels, 
with several GH peaks and patient 16 had high serum GH levels above 50 µg/l with only 
slight variation. The clinical condition of these patients was not different with respect to 
birth weight, postnatal age, respiratory failure or need for dopamine or morphine.
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Figure 1 6-hours GH profiles in preterm infants on prolonged ventilation.
Serum GH levels expressed in µg/l, time in hours.
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Univariate analysis showed no correlation between mean, baseline or maximal GH levels 
and gestational age, birth weight, birth weight SD-score, weight during study, weight gain, 
postconceptional age or postnatal age, except for a positive correlation between gestational 
age and the number of GH peaks (r = 0.44, p = 0.03). 
Table 1 Clinical data at day of study.
N = 24 Mean SD
Weight (g) 1163 372
Postnatal age (wk) 2.8 1.4
Postconceptional age (wk) 30.2 2.4
Oxygenation Index 76 53
Ventilation score 524 273
Weight gain (g/kg/wk) 59.3 30.1
Energy intake (kcal/kg/day) 99.2 26.9
Protein intake (g/kg/day) 2.9 0.6
Fat intake (g/kg/day) 5.0 2.1
Use of PN (n) 8
Use of PN and dopamine (n) 6
Use of morphine (n) 6
Use of PN, dopamine and morphine (n) 3
No use of PN, dopamine or morphine (n) 3
Results are given as mean SD or number of infants.
Table 2 Characteristics of 6-h GH profile and serum levels of IGF-I and IGF-binding proteins in very preterm ventilated infants.
Median Range
GH levels
  Mean
  Baseline
  Maximal
  Peaks (n /6 hr)
19.9
18.1
33.4
2
6.0 - 55.8
5.7 - 55.7
8.7 - 66.2
0 - 4
IGF-I 38.6 20.7 - 117.8
IGFBP-1 108.0 7.9 - 717.4
IGFBP-3 600 200 - 3700
Serum GH levels expressed in µg/l, serum IGF-I in ng/ml, serum IGFBP-1 in ng/ml and serum IGFBP-3 in ng/ml. 
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Serum IGF-I, IGFBP-1 and IGFBP-3 levels
Serum IGF-I levels ranged from 20.7 to 117.8 ng/ml with a median of 38.6 ng/ml (Table 
2). Serum IGFBP -1 levels varied between 7.9 to 717.4 ng/ml, and serum IGFBP-3 levels 
from 200 to 3700 ng/ml. IGF-1 and IGFBP-1 levels did not correlate with gestational age, 
birth weight, birth weight SD-score, postnatal age, postconceptional age and weight during 
study. IGFBP-3 levels were only positively correlated with gestational age and birth weight 
(r = 0.43, p = 0.04; r = 0.49, p = 0.02, respectively). Only the IGFBP-1 levels and not IGF-I 
and IGFBP-3 levels were positively associated with indicators of nutritional intake (Table 3). 
Weight gain (g/kg/wk) was not correlated with serum IGF-I and IGFBP-1 and –3 levels.
Associations between GH, IGF-I and the binding proteins 
Mean GH levels were positively correlated to baseline and maximal GH levels and 
negatively to the number of peaks (Table 4). IGF-I levels correlated with the mean GH 
levels, whereas IGFBP-1 levels correlated with mean, baseline and maximal GH levels, and 
IGF-I levels. No correlation was seen between IGFBP-3 and any of the other growth factors 
and binding proteins.
Severity of illness
The ventilation score was not correlated with serum GH, IGF-I and IGFBP levels. Infants 
treated with dopamine, morphine or PN during the study had a significantly higher 
ventilation score and oxygenation index compared to infants without such treatment (p < 
0.01, p < 0.05, p < 0.01, respectively), indicating more severe ventilation and higher severity 
of illness in these infants. 
The various characteristics of the GH profile were not significantly different between 
infants with and without use of dopamine, morphine, or PN. Infants with dopamine treatment 
had significantly lower serum IGF-I and IGFBP-1 levels than infants without dopamine (p 
< 0.05 and p = 0.05, respectively). Infants on PN had a significantly lower energy, protein- 
and fat intake (all p< 0.01) and significantly lower levels of serum IGF-I and IGFBP-1 (p < 
0.05 and p < 0.01, respectively) than infants on complete enteral nutrition. However, as all 
patients treated with dopamine also received PN, it was impossible to distinguish between 
effects of dopamine and PN. Similarly, it was not possible to distinguish between the effects 
of PN and caloric intake, as these two factors were strongly related.
Morphine treatment was not associated with a lower nutritional intake and did not result 
in significantly different serum levels of IGF-I, IGFBP-1 and –3 compared to no morphine 
treatment. Birth weight SD-score did not have any effect in these models.
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Table 3 Correlation between nutritional intake, weight gain and serum levels of GH, IGF-I and IGF-binding proteins in very preterm ventilated 
infants.
Mean GH IGF-I IGFBP-1 IGFBP-3
Caloric intake 
   48 hr before study (kcal/kg/d) 0.23 0.27  0.52** 0.03
   During study (kcal/kg/d) 0.21 0.23 0.54* 0.23
Fat intake
   48 hr before study (g/kg/d) 0.26 0.20  0.51** 0.27
   During study (g/kg/d) 0.32 0.23 0.53 * 0.21
Protein intake
   48 hr before study (g/kg/d) 0.23 0.19 0.37 0.07
   During study (g/kg/d) 0.31 0.18   0.43 ** -0.02
Weight gain (g/kg/wk) 0.01 0.21 -0.03 -0.33
* p < 0.01, ** p < 0.05
Table 4 Correlation between various characteristics of 6-h GH profile and levels of IGF-I and IGF-binding proteins in very preterm ventilated 
infants.
Baseline GH Maximal GH N of peaks IGF-I IGFBP-1 IGFBP-3
Mean GH 0.99 * 0.97 * -0.75 *   0.42*** 0.48 *** -0.28
Baseline GH 0.95 * -0.79 * 0.34 0.45 *** -0.26
Max GH -0.71 * 0.40   0.45 *** -0.25
N of peaks -0.21 -0.29   0.27
IGF-I 0.55** -0.41
IGFBP-1 0.04
* p < 0.001, ** p < 0.01, *** p < 0.05
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Discussion
This study is the first one describing 6-hours GH profiles in combination with serum IGF-I, 
IGFBP-1 and-3 levels in very preterm ventilated infants at risk for BPD. We found a wide 
range of mean GH levels comparable to GH levels previously described in non-ventilated 
preterm infants, thereby not providing arguments for GH deficiency in most infants. We 
have found a relation between GH and IGF-I suggesting that GH exerts some effect through 
IGF-I, even in these very preterm infants. There was no correlation between severity of 
disease and weight gain, and serum GH, IGF-I, and IGFBP levels, but daily nutritional 
intake was significantly correlated with IGFBP-1 levels. 
Mean serum GH levels measured by performing 6-h GH profiles in our ventilated very 
preterm infants were comparable with GH levels previously reported in other groups of 
non-ventilated preterm infants.16,22 However, like Ogilvy-Stuart et al. we observed a wide 
individual variance of GH levels for which no clinical explanation as nutritional factors, 
severity of illness, parenteral nutrition and use of cardiotonic drugs could be found.
Miller et al. (1992) found mean GH levels of 37.1 µg/l and 35.8 µg/l in healthy preterm 
boys and girls born after a gestational age of 32-33 weeks at only 40 hours of age. Ogilvy-
Stuart et al. reported serum baseline, mean and maximal GH levels of 17.1 µg/l, 22.5 µg/l 
and 30.7 µg/l, respectively in preterm infants at a postnatal age of 4.4 days. These data are 
comparable with the GH levels we have found at a postnatal age of 2.8 weeks, suggesting 
that the GH levels in our ventilated preterm infants may still be in the normal range, 
especially when considering their younger gestational and higher postnatal age compared 
to those of Ogilvy-Stuart. Serum IGF-I levels were also within the normal range when 
compared with those reported in non-ventilated preterm infants of similar postconceptional 
age.27 
In spite of these findings, however, our ventilated very preterm infants had a poor growth 
in terms of weight gain when compared with the described intrauterine growth rate of 14-
15 g/kg/day.28 This suggests that their poor growth is not attributable to GH deficiency but 
to other factors. 
Serum IGFBP-1 levels were comparable with those in non-ventilated preterm infants 
and positively correlated with daily nutritional intake.22 We had expected to find lower 
IGFBP-1 levels since our patients were continuously and adequately fed and had no 
signs of hypoglycaemia. It has been reported that serum IGFBP-1 levels are inversely 
correlated with serum insulin levels indicating that low serum insulin levels will increase 
serum IGFBP-1 levels.29,30 Also undernutrition is known to up-regulate hepatic production 
of IGFBP-1 suggesting that elevated serum IGFBP-1 might act as glucose counterregulator 
and protect against hypoglycaemia during conditions of undernutrition.31,32 We have no 
explanation for the positive correlation between nutritional intake and IGFBP-1 levels in 
our ventilated preterm infants. Further studies should measure serum insulin, glucose and 
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free fatty acids in various groups of preterm infants, in combination with determinations of 
IGFBP-1 and free IGF-I levels.
We had expected to find an association between severity of illness and serum GH and 
IGF-I levels. To our surprise, we did not find such a relation between severity of respiratory 
failure and serum GH, IGF-I, IGFBP-1 and -3 levels thereby indicating that more severely ill 
preterm infants do not have lower or higher levels of GH and growth factors. 
Infants receiving dopamine treatment had significantly lower serum IGF-I levels but no 
difference in GH levels. De Zegher et al. reported lower GH levels in infants treated with 
dopamine.33 Some of our dopamine-treated infants also received morphine, known for its 
stimulatory effect on GH release.34,35 However, no effect of concomitant morphine treatment 
on serum GH, IGF-I and IGFBP-3 levels was observed. Patients with dopamine treatment 
had the worst clinical condition and significantly lower IGFBP-1 levels than those without. 
This is in contrast to studies in children and adults where IGFBP-1 levels were positively 
correlated with disease severity and mortality risk.36-38
Infants receiving PN had significantly lower serum IGF-I levels as well as lower total 
nutritional intake than infants on total enteral feeding. The lower IGF-I levels might thus be 
explained by their lower nutritional intake.39 
In conclusion, we showed that ventilated very preterm infants have poor weight gain and 
serum GH levels comparable to GH levels in healthy preterm infants, albeit with a wide 
variation. Serum IGF-I levels were also comparable with levels found in non-ventilated 
preterm infants of similar postconceptional age. Severity of illness was not correlated 
with serum GH, IGF-I, IGFBP-1 and -3 levels. Serum GH levels were related with IGF-I, 
suggesting that GH exerts some effect through IGF-I. 
Our findings show that poor growth in most preterm infants with respiratory failure at 
risk for BPD is not the result of either low GH or IGF-I levels. For that reason our study 
does not provide arguments to consider GH therapy for growth-retarded ventilated infants 
at risk for developing BPD. 
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Abstract
Very preterm infants developing bronchopulmonary dysplasia frequently show a 
compromised growth in the neonatal period especially when steroids are given to facilitate 
weaning from the ventilator.
The aim of this study was to evaluate the short-term effect of dexamethasone (DEXA) 
on the GH-IGF axis in ventilated very preterm infants developing bronchopulmonary 
dysplasia. 
We studied 10 very preterm artificially ventilated infants with bronchopulmonary 
dysplasia [median (range) gestational age 27.5 wk (25.9 –32.0 wk), median (range) birth 
weight 970 g 610–2150 g)] immediately before and 2 days after the start of DEXA treatment. 
On both days of study, serum GH profiles were obtained, and serum IGF-I and IGF binding 
protein (IGFBP) -1 and -3 levels were measured. The ventilation score and the nutritional 
intake were calculated.
Before the start of DEXA treatment, the median serum mean GH level was 12.0 µg/L (6 
–28.4 µg/L), whereas 2 days after the start of DEXA treatment the median serum mean GH 
level declined significantly to a value of 4.4 µg/L (1.7–11.9 µg/L). During DEXA treatment, 
mean, baseline, and maximal GH levels (Pulsar analysis) were significantly lower compared 
with pre-treatment levels (p < 0.01, p < 0.01, and p < 0.05, respectively). Serum IGF-I and 
IGFBP-3 levels did not decline during DEXA. Serum IGFBP-1 levels were significantly lower 
compared with pre-treatment levels (p < 0.01). Serum GH levels during DEXA treatment, 
were correlated with neither the time interval between the administration of DEXA and 
the second GH profile nor the cumulative DEXA dose administered. Ventilation score and 
nutritional intake did not significantly correlate with serum GH, IGF-I, or IGFBP-1 or -3 
levels, either before or after the start of DEXA. 
Conclusions: Two days of DEXA treatment in very preterm ventilated infants has a 
suppressive effect on serum GH levels, without an acute decline in serum IGF-I levels. A 
concomitant decrease in serum IGFBP-I levels was found.
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Introduction
Very preterm infants developing BPD, with a persistent need for artificial ventilation 
and oxygenation, frequently show a very compromised growth in the neonatal period.1,2 
Their growth will be further attenuated when DEXA treatment is given after conservative 
treatment, including increased ventilation settings and fluid restriction, has failed to wean 
them from the ventilator.3–5 The hormonal mechanisms underlying this early postnatal 
growth retardation and the role of glucocorticosteroids have not been elucidated. DEXA 
has a catabolic effect by increasing protein breakdown and alters skeletal metabolism 
by inhibition of intestinal calcium absorption, stimulation of renal calcium excretion, and 
suppression of collagen turnover in preterm infants.6–8 
Glucocorticosteroids have been suggested to have a suppressive effect on the pituitary GH 
secretion with attenuation of the spontaneous GH secretion and decreased GH responses 
to various stimuli.9–11 A direct antagonizing effect of DEXA on the epiphyseal cartilage to the 
action of GH has been reported, probably by inhibition of the local secretion and paracrine 
action of IGF-I and the inhibition of the expression of the GH and IGF-I receptor.12
The clinical significance of GH in the perinatal period is not well understood, although 
GH-deficient infants show a reduction in birth length, suggesting some role for GH in 
regulation of fetal growth.13 In the postnatal period in particular, insulin and IGF-I are 
important regulators of physical growth, and in mice disruption of genes for IGF-I, IGF-II, 
or their receptors results in intrauterine growth retardation.14 –16
So far, no studies have evaluated the short-term effect of DEXA treatment on serum GH 
levels and growth factors in ventilated very preterm infants. To understand the effect of 
DEXA on spontaneous GH secretion and the GH-IGF axis, we performed a 6-h GH profile 
and measured serum IGF-I and IGFBPs, before and 2 days after the start of DEXA treatment 
in very preterm infants developing BPD.
Methods
Patients
Preterm infants born with a gestational age of ≤ 32 weeks, developing BPD, were included 
in the study if the attending neonatologist decided to start DEXA treatment to wean the 
infant from the ventilator. The indication to start DEXA treatment was a persistent need for 
artificial ventilation and oxygen dependency after 1 wk of age when conservative treatment 
such as increased ventilation settings, fluid restriction, diuretics, antibiotics, and inhalation 
therapy had failed to wean the infant from the ventilator. DEXA treatment was started with 
a dosage of 0.5 mg/kg per day, in two doses per day, during 3 days. Thereafter the dosage 
was tapered to 0.3 mg/kg per day for 3 days, and gradually tapered every 3 days to 0.1 
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mg/kg per day every other day during a 3-wk period. Infants were excluded if they had 
a persistent ductus arteriosus, pulmonary infection, sepsis, grade 3 or 4 intraventricular 
hemorrhage, chromosomal defects, or major congenital anomalies or when the mother was 
being treated for an endocrine disorder with GH, thyroxin, or thyreostatic drugs during 
pregnancy. All patients were admitted to the neonatal intensive care unit of the Sophia 
Children’s Hospital in Rotterdam, The Netherlands.
The Medical Ethics Committee of the Erasmus University Medical Center approved the 
protocol, and written informed consent was obtained from the parents of each child.
Methods
All patients had an indwelling arterial catheter and were studied twice. Immediately before 
the start of DEXA treatment and 2 days thereafter plasma samples were taken every 30 min 
during a 6-h period for determination of serum GH levels and once to determine serum 
IGF-I, IGFBP-1, and IGFBP-3 levels. Sampling of blood in these very preterm infants was 
restricted because of the small size of the infants and their severe illness. The total blood 
volume of these infants is 50–80 mL, and it was unacceptable to withdraw more than 5% of 
the total blood volume for study purposes. A longer period or more frequent sampling was 
therefore impossible. All blood samples were stored directly on ice for no longer than 3 h. 
After centrifugation, plasma samples were frozen (-20°C) until assayed. 
Birth weight was expressed in SD-scores according to Usher and McLean.17 Daily weights 
were obtained by the nursing staff using an electronic weight scale (Digital Baby Scale, 
model DS-30 A; Kubota, Ltd, Japan). 
The attending neonatologist provided routine care and feeding decisions. According to 
the policy of the neonatal intensive care unit, infants were started on parenteral nutrition 
on the second day of life, and enteral feedings were initiated on day 7. All infants were 
continuously fed, and blood glucose levels were determined every day. Preterm infant 
formulas were used with a caloric density of 80–88 kcal/100 mL and a protein content 
of 2.4 –2.6 g/100 mL. On both days of study, the protein, energy, and fat intakes were 
calculated. 
The severity of respiratory failure was assessed by calculating the ventilation score (mean 
airway pressure times inspired fraction of oxygen).
Hormone assays
All hormonal determinations were performed in the Endocrine Laboratory of the University 
Hospital Rotterdam, The Netherlands.
GH levels in plasma were measured using a two-site immunoradiometric assay (ELSA-
HGH; CIS bio international, ORIS Group, France). The assay measured the 22-kD GH and 
showed no cross-reactivity with 20-kD GH. All samples were analyzed in duplicate in the 
same assay. The WHO First International Reference Preparation WHO 80/505 was used as 
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a standard. The intraassay and interassay coefficients of variation were < 2.8% and 4.4%, 
respectively. The detection limit of the assay was 0.04 µg/L.
Serum IGF-I levels were determined by RIA (SM-C-RIACT, Biosource Europe SA), 
after acid-ethanol extraction.18 The sensitivity was 0.25 ± 0.10 ng/mL, the intraassay and 
interassay coefficients of variation were < 6.1% and 9.9%, respectively. Cross-reactivity with 
IGF-II was 0.2%, with insulin < 0.001%, and with GH < 0.01%. 
Serum IGFBP-1 levels were determined using a two-site immunoradiometric assay 
(Total IGFBP-1 IRMA DSL-7800; Diagnostic Systems Laboratories, Webster, TX, U.S.A.). 
The sensitivity of the assay was 0.33 ng/mL, and the intraassay and interassay coefficients 
of variation were < 5.2% and 6.0%, respectively. No cross-reactivity was seen with serum 
IGFBP-2, -3, -4, -5, and -6.
Serum IGFBP-3 levels were determined using a two-site immunoradiometric assay (IGF-
BP3 IRMA, DSL-6600; Diagnostic Systems Laboratories). The sensitivity of the assay was 
0.5 ng/mL, with intraassay and interassay coefficients of variation of < 3.9% and 1.9%, 
respectively.
Analysis of GH profiles 
The GH profiles were analyzed with the Pulsar program developed by Merriam and 
Wachter and adapted for Quick Basic by Rosberg and Albertsson-Wikland (PC-Pulsar, 
1987).19 From the Pulsar analysis the following values were extracted: the overall mean, 
baseline, and maximal GH levels.
Statistical analysis 
Statistical analysis was performed using SPSS 9.0 for Windows 95, SPSS software (Chicago, 
IL, U.S.A.). All hormone levels were logarithmically transformed in the analyses. Differences 
between paired samples were tested with the Wilcoxon signed ranks test. Correlations were 
evaluated with the nonparametric Spearman’s rank correlation. Results are expressed as 
median (range), unless indicated otherwise. Two tailed p values ≤ 0.05 were considered 
significant. 
Results
Clinical characteristics
Ten very preterm infants, seven boys and three girls, with a median (range) gestational age 
of 27.5 wk (25.9–32.0 wk) and a median (range) birth weight of 970 g (610–2150 g), were 
included in the study. Six infants were treated with antenatal steroids.
The clinical characteristics of the infants on both days of study, before and 2 days 
after start of DEXA treatment, are shown in Table 1. The infants were studied when they 
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had received at least three doses of DEXA. The nutritional intake was not significantly 
different between both days of study. Three infants were receiving parenteral nutrition. 
The ventilation score, however, had decreased significantly on the second day of study 
compared with the day before the start of DEXA (p < 0.05).
GH profiles 
The GH profiles of the individual patients before and during DEXA treatment are shown 
in Figure 1. Mean pre-treatment serum GH levels varied between 6 and 28.4 µg/L with a 
median of 12.0 µg/L, whereas 2 days after the start of DEXA treatment the mean GH level 
had declined to a median of 4.4 µg/L.
Two days after start of DEXA treatment the overall mean, baseline, and maximal serum 
GH levels were significantly lower compared with pre-treatment levels (p < 0.01, p < 0.01, 
and p < 0.05, respectively; Table 2). In all patients, except one, the GH levels declined 
during DEXA treatment. The percentage decline in serum mean GH levels was on average 
54%, in serum baseline GH levels 56%, and in serum maximal GH levels 35%, and these 
levels were not correlated with gestational or postnatal age. Serum GH levels were not 
significantly different between patients receiving parenteral or enteral nutrition.
The time interval between the administration of DEXA and the start of the second GH 
profile varied. In the first five patients DEXA was administered between 6 and 0 h before 
the start of the second profile, whereas in the other five patients DEXA was also given 
during the sampling period. No significant correlation was found between the time interval 
between administration of DEXA and the serum GH levels during the second profile.
The cumulative dose of DEXA (in mg/kg of body weight) administered before the second 
GH profile did not correlate with mean, baseline, and maximal GH levels, nor with the 
Table 1 Clinical data before and during DEXA treatment in 10 very preterm infants developing BPD.
Pre-treatment During dexamethasone 
Median Range Median Range
Weight (g) 1092 750 - 2265 1125 695 - 2195
Postconceptional age (wk) 29.6 27.6 - 34.6 30.5 2.1
Postnatal age (wk) 2.1 1.0 - 3.6 2.4 1.4 - 4.0
Doses of dexamethasone (n)  - 5 3 - 7
Cum. dexamethasone dose (mg/kg)  - 1.23 0.76 - 1.7
Ventilation score 454* 240 - 1700 210 105 - 1024
Energy intake (kcal/kg/d) 97.3 64.2 - 144.3 118.7 43.6 - 144
Protein intake (kcal/kg/d) 2.6 1.9 - 3.9 2.7 1.9 - 3.9
Fat intake (g/kg/d) 4.9 1.4 - 8.6 5.2 0.6 - 9.6
Results are given as median and range.
*  p<0.05
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Figure 1 6-hours GH profiles in ventilated preterm infants before (●—●) and during (■---■) DEXA treatment. 
GH levels are expressed in µg/l on a logarithmic scale against time in hours. 
In patients 1–5, time t = 0 corresponds to 6, 5, 2.5, 0.5, and 0 h after DEXA administration, respectively. In patients 6–10, ↑ corresponds with 
time of DEXA administration.
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percentage decline in serum GH levels. The same applied for the number of DEXA doses 
given before the second profile.
Serum IGF-I and IGFBP-1 and -3 levels
During DEXA treatment, serum IGFBP-1 levels significantly declined from a median of 69.9 
to 13.5 ng/mL (p < 0.01), whereas serum IGF-I and IGFBP-3 levels did not change (Fig. 2). 
The number of doses of DEXA administered before the start of the second profile did not 
significantly correlate with serum levels of IGF-I, IGFBP-1, and IGFBP-3. The cumulative 
dosage of DEXA (in mg/kg of body weight) given before the start of the second profile 
showed a trend toward lower IGF-I levels, although this did not reach significance (r = 
Figure 2 Effect of DEXA treatment on serum IGF-I, IGFBP-3, and IGFBP-1 levels in ventilated preterm infants. 
Serum IGF-I is expressed in ng/ml, serum IGFBP-3 in mg/ml, and serum IGFBP-1 in ng/ml.
Table 2  Characteristics of 6-h GH profile, IGF-I and binding proteins before and during DEXA in 10 very preterm infants with BPD.
Pre-treatment During treatment 
Median Range Median Range
GH profile
 Baseline GH 11.3 5.7 - 28.6 3.8* 1.7 - 11.8
 Mean GH 12.0 6.0 - 28.4 4.4* 1.7 - 11.9
 Max GH 17.3 8.7 - 48.9 8.9** 2.7 - 18.8
IGF-I 32.9 22.2 - 89.5 36.3 19.9 - 65.8
IGFBP-1 69.6 23.2 - 341.4 13.5* 8.2 - 62.6
IGFBP-3 0.6 0.4 - 1.2 0.6 0.4 - 1.0
Results are given as median and range.
Serum GH levels calculated by Pulsar analysis and expressed in µg/l, serum IGF-I and IGFBP-1 in ng/ml and serum IGFBP-3 in mg/l. 
* p < 0.01 compared to levels before DEXA.
** p < 0.05 compared to levels before DEXA.
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-0.6; p = 0.08). Serum IFG-I, IGFBP-1, and IGFBP-3 levels were not significantly different 
between patients receiving parenteral or enteral nutrition. 
Correlations between serum GH and IGF-I, IGFBP-1, and IGFBP-3 levels 
Before the start of DEXA, no correlation was found between gestational age, birth weight, 
birth weight SD-score, and serum levels of IGF-I, IGFBP-1, and IGFBP-3. Mean, baseline, 
and maximal serum GH levels also did not correlate with serum IGF-I, IGFBP-1, and 
IGFBP-3 levels. No correlation was found between serum levels of IGF-I and IGFBP-1 or 
IGFBP-3 levels.
During DEXA treatment, however, serum IGFBP-1 levels were significantly correlated 
with mean and baseline GH levels (r = 0.71, p = 0.03 and r = 0.70, p = 0.04, respectively), 
but not with serum IGF-I levels. Ventilation score and nutritional intake did not significantly 
correlate with serum GH, IGF-I, IGFBP-1, and IGFBP-3 levels, neither before nor after the 
start of DEXA treatment.
Discussion
In this study we demonstrate a significant decline in serum baseline, mean, and maximal 
GH levels and serum IGFBP-1 levels in ventilated very preterm infants 2 days after the start 
of DEXA treatment. Two days of DEXA treatment had no significant acute effect on serum 
IGF-I and IGFBP-3 levels. So far, no studies have described the effect of 2 days of high-dose 
DEXA administration on GH secretion, serum IGF-I levels, and serum IGFBPs in ventilated 
very preterm infants.
It has been reported that DEXA treatment in preterm infants results in reductions in weight 
gain, growth in occipitofrontal head circumference, linear growth, and lower leg growth; 
has a catabolic effect by increased protein breakdown; and alters skeletal metabolism.3–
8,20–22 Despite substantial concerns questioning the benefits of the use of postnatal steroids 
and concerns about long-term neurologic outcome raised by the American Academy of 
Pediatrics and Canadian Paediatric Society, DEXA is still administered to preterm infants 
to wean them from the ventilator when clinical and radiologic signs of BPD develop and 
conservative treatment, such as increased ventilation settings, fluid restriction, diuretics, 
antibiotics, and inhalation therapy, has failed.23 The starting dose of DEXA usually given 
to very preterm infants in most neonatal intensive care units is 0.5 mg/kg per day for 
3 days, which is equivalent to 13.3 mg/kg per day of hydrocortisone or 3.3 mg/kg per 
day of prednisone. Thus, compared with other corticosteroid treatments, the DEXA dose 
used in preterm infants is 11- to 22-fold higher than in children with kidney transplants 
(prednisone, 0.15 – 0.25 mg/kg per day) or in physiologic replacement in relative adrenal 
insufficiency in very preterm infants (1.2 mg of hydrocortisone in a 1000-g infant).
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Besides, the biologic half-time of DEXA is much longer than that of prednisone (36–72 
h compared with 8–12 h).24 
Inasmuch as we present the first data of an acute DEXA effect on serum GH levels in 
preterm infants, we cannot compare our results with other studies in preterm infants. In 
older individuals the effects of glucocorticoids on spontaneous and stimulated GH secretion 
appear contradictory.25–27 Chronic hypercortisolism inhibits spontaneous and stimulated GH 
secretion in children and adults.9–11,28 Hokken-Koelega et al. demonstrated a significant 
decrease in mean GH levels during chronic prednisone administration in pediatric growth-
retarded renal allograft recipients.29 In contrast, acute administration of DEXA increases 
spontaneous GH secretion in children and adults.30–33 In rats, spontaneous GH levels were 
significantly decreased and the GH-releasing hormone–induced GH response was blunted 
after 4 days of DEXA treatment. Subsequent immunologic neutralization of somatostatin, 
however, resulted in a significantly enhanced GH response, suggesting that steroids inhibit 
the GH response to GH releasing hormone by increasing the hypothalamic somatostatin 
secretion.27 Miell et al., however, found in healthy volunteers a persistent but attenuating 
rise in serum GH levels after 4 days of DEXA treatment.34 This different effect of DEXA 
administration compared with our data might be caused by the 10-fold lower dosage of 
DEXA (0.05 mg/kg per day) used by Miell et al. than the dosage used in our preterm 
infants.34 Thus, the potentiating or blocking effect of DEXA on GH secretion seems to be 
dependent on the duration and dose of administration of DEXA. 
We could not demonstrate a relationship between the serum GH levels and the cumulative 
dose or the number of doses of DEXA given before the second profile. This might be 
because of the small variation in the cumulative dose in our patients. The suppressive 
effect of DEXA on serum GH levels in most infants was still present 12 h after the last dose, 
suggesting a GH-suppressive effect of at least 12 h in most infants. In children undergoing 
renal transplantations, the suppressive effect of prednisone on GH secretion was similar 
whether given as daily or alternate day prednisone therapy, suggesting a prolonged effect 
of prednisone administration. As the biologic half-life of DEXA is much longer and the 
dose of DEXA given to our patients much higher compared with the prednisone dose in 
the renal allograft patients, we speculate that the suppressive effect on serum GH levels 
might be at least 24 h. 
After 2 days of high-dose DEXA treatment, we could not demonstrate a decline in serum 
immunoreactive IGF-I and IGFBP-3 levels whereas serum GH levels significantly declined. 
We had expected to find the decline in serum GH levels being accompanied by a decline 
in serum IGF-I levels. However, it might be that 2 days of DEXA treatment was too short to 
observe an acute decline in serum IGF-I or IGFBP-3 levels. It was not possible to perform 
the second GH profile at a later moment during DEXA treatment as most infants did not 
retain their arterial catheter once they were extubated. Pre-treatment IGF-I levels were low 
already, with high serum GH levels, suggesting a relatively GH-resistant state; this might 
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also explain the apparent lack of effect of DEXA on circulating IGF-I. Serum IGF-I levels 
might also be more influenced by nutritional intake.35 Data on the effect of DEXA on 
serum IGF-I and IGFBP-3 levels in preterm infants are limited. Serum IGF-I and IGFBP-3 
levels have been reported to rise in preterm infants after cessation of DEXA treatment.5,20 
Bloomfield et al. showed increasingly higher levels of IGF-I and IGFBP-3 with reducing 
dosages of DEXA, suggesting a dose-dependent effect of DEXA on IGF-I and IGFBP-3 
levels.22 However, in these studies, at all time points during and after DEXA treatment, 
serum IGF-I and IGFBP-3 levels were higher than before the start of DEXA and therefore 
not lower than baseline values. Our study showed that there was no decline in serum IGF-I 
and IGFBP-3 levels at least after 2 days of DEXA treatment. Because none of the studies had 
an untreated control group, no data are available about the IGF-I and IGFBP-3 levels from 
patients with similar respiratory problems when no DEXA has been started. The higher 
levels of IGF-I and IGFBP-3 observed after stopping DEXA might not be merely caused by 
cessation of steroids but also by other factors such as improvement in the clinical condition 
and nutritional intake of the infants.35 
In this study we did not observe a relationship between serum IGF-I and IGFBP-3, in 
contrast to other studies in older children. Whether this is related to the developmental 
range of the infants or other factors needs further study.
The high pre-treatment IGFBP-1 levels observed in our patients might be related to 
their severe illness as has been described in older children.36 High IGFBP-1 levels are also 
found in conditions such as prolonged fasting, anorexia nervosa, and fetal hypoxemia.37,38 
The high IGFBP-1 levels in our study were not caused by fasting as all our preterm infants 
were continuously fed and never showed low glucose levels. We cannot rule out a possible 
additional effect of short-term hypoxemia on serum IGFBP-1 levels immediately before 
starting DEXA treatment. The observed decline in serum IGFBP-1 levels during DEXA 
treatment in our patients agrees with Miell et al., who described an increase in serum insulin 
levels accompanied by a decrease in serum IGFBP-1 after short-term DEXA treatment in 
adults.39 As it has been demonstrated that insulin and not glucose levels are regulating 
serum IGFBP-1 levels in vivo, we speculate that high insulin levels during DEXA might have 
resulted in a decline in serum IGFBP-1 as observed in our patients.40,41 However, as some of 
our patients were extubated after 2 days of DEXA, thereby showing clinical improvement, 
this might also have contributed to the decrease in serum IGFBP-1 levels.
The GH-IGF axis in childhood is important for growth, but the precise role of GH and 
IGF-I in preterm infants is as yet unknown. DEXA treatment is known to reduce physical 
growth and to induce catabolism. Although our study showed a significant decline in serum 
GH levels after 2 days of DEXA, no acute decline in serum immunoreactive IGF-I levels was 
seen. This is in agreement with other studies.5,20,22 It therefore remains a question whether 
the low GH levels observed after the start of DEXA are responsible for the decline in growth 
rate in these preterm infants. It might well be that the decline in growth is rather the result 
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of a direct effect of DEXA on the epiphyseal cartilage by inhibition of the local secretion 
and paracrine action of IGF-I.12 Prednisone causes in vitro a 46% fall in IGF bioactivity 
and has a suppressive effect on IGF-I mRNA in the tibia, liver, lung, and kidney in the 
rat, without causing significant changes in serum IGF-I levels.42,43 Thus, DEXA-induced 
inhibition of local IGF-I gene expression might be one of the mechanisms of growth 
retardation as well. In addition the low serum GH levels might result in a diminished direct 
effect on the epiphyseal plate as well.12
In conclusion, our data show a suppressive effect of 2 days of DEXA treatment on serum 
GH levels, without an acute decline in serum IGF-I levels. A concomitant decline in serum 
IGFBP- 1 levels was found.
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Abstract
Preterm infants developing bronchopulmonary dysplasia (BPD) are frequently treated 
with dexamethasone (DEXA) to facilitate weaning from the ventilator. DEXA has a 
growth suppressive effect which might have long-term consequences on growth and 
development.
The aim of this study was to evaluate if treatment with recombinant human growth 
hormone (rhGH) is able to overcome the growth inhibiting effect of DEXA treatment in 
preterm infants.
Thirty preterm artificially ventilated infants median (range) gestational age 27.0 (24.6-
30.6) wks, birth weight 852 (501-1335 g) were randomly assigned to receive either DEXA 
and placebo (n = 15) or DEXA and GH (n = 15) treatment. DEXA was given during a 
24-day period, starting with a dose of 0.5 mg/kg/day and tapering off every third day. 
Simultaneously rhGH (0.3 mg/kg/day) or placebo was administered during 6 weeks. 
Weight, length (CHL), knee-heel length (KHL) and head-circumference (OFC) were 
measured, as well as, serum GH, IGF-I and IGFBP-1 and -3 levels. Adverse effects were 
recorded and echocardiography was performed.
In the first week of DEXA treatment (dose 0.5-0.3 mg/kg/day) no gain in weight, CHL, 
KHL and OFC occurred in both groups. In week 2 and 3 on DEXA, as well as in the 3-week 
period after discontinuation of DEXA, growth was not significantly different between the 
GH and the placebo group. Growth during week 2 and 3 on DEXA was not different from 
growth after discontinuation of DEXA. 
Serum IGF-I levels did not increase during the 6-week period, while serum IGFBP-3 
levels increased significantly (p < 0.02) during DEXA, in both groups. In the placebo group 
two patients died. The frequency and severity of hyperglycemia, hypertension, retinopathy 
and cardiac hypertrophy was not different between the groups.
Conclusion: Two major conclusions arise from this study. First rhGH treatment has no 
effect in preventing impairment of growth in DEXA-treated preterm infants when a rhGH 
dose of 0.3 mg/kg/day is given for a 6 - week period. Secondly, the impairment of growth 
is particularly associated with high-dose DEXA treatment during the first week. Follow-
up studies are needed to evaluate possible effects of rhGH on growth, lung function and 
neurodevelopment on the longterm.
We suggest that future research could be directed at the use of lower doses of 
glucocorticoids, aiming at both, maintenance of the beneficial effect of DEXA of weaning 
from the ventilator, and prevention of adverse effects.
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Introduction
In very preterm infants the development of bronchopulmonary dysplasia (BPD) is a 
major problem. According to the latest consensus BPD is defined as a persistent need 
for supplemental oxygen for at least 28 days and respiratory features such as retractions, 
tachypnea and rales.1 The incidence of BPD increases from 12% in infants with a gestational 
age of 30 weeks to 30 - 40% in those born after a gestational age of 25-26 weeks.2,3 
In the neonatal period systemic corticosteroids are frequently given to reduce the duration 
of artificial ventilation, although they do not always effect mortality.4,5,6 Most infants at risk 
for development of BPD will be treated with dexamethasone (DEXA) to facilitate weaning 
from the ventilator. DEXA treatment in preterm infants is known for its inhibiting effect on 
weight gain as well as linear growth and head circumference.7-11 Some follow-up studies 
suggest impairment in brain growth and persisting growth retardation into childhood.12-15 
In addition, DEXA has a catabolic effect by increasing protein breakdown whereas skeletal 
metabolism is altered by inhibition of intestinal calcium absorption, stimulation of renal 
calcium excretion and suppression of collagen turnover in preterm infants.16-18
Corticosteroids have a suppressive effect on pituitary GH secretion in children.19 In a 
previous study we evaluated the effect of high dose DEXA (0.5 mg/kg/day) on serum 
GH levels in ventilated preterm infants and found a significant DEXA-induced decline in 
serum GH levels.20 Klaus et al suggested that the growth - inhibiting effect of DEXA might 
be overcome by high dose GH treatment.21 Several studies have demonstrated a beneficial 
effect of GH treatment on linear growth and on neurodevelopment in steroid - treated older 
children.22 
As the growth suppressive effects of DEXA in preterm infants might have long-term 
consequences on longitudinal growth and development, we performed a randomised 
double-blind GH-controlled trial in ventilated preterm infants treated with DEXA in order 
to evaluate if recombinant human GH (rhGH) overcomes the growth inhibiting effects of 
DEXA treatment.
Methods
Patients
Thirty ventilated preterm infants born after a gestational age ≤ 32 weeks at risk for 
developing BPD were included in the study at the moment DEXA treatment was initiated 
in order to wean them from the ventilator. The indication to start DEXA treatment was 
made by the attending neonatologist and based on a persistent need for artificial ventilation 
and oxygen dependency accompanied by an abnormal chest X-ray. Patients were 
excluded when they had a persistent ductus arteriosus, pulmonary infection or sepsis at 
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randomisation or when they had a grade 3 or 4 intraventricular hemorrhage, chromosomal 
defect or major congenital anomalies. Patients were also excluded when the mother was 
treated for an endocrine disorder with rhGH, thyroxin or thyreostatic drugs. All patients 
were admitted to the Neonatal Intensive Care Unit (NICU) of the Sophia Children’s Hospital 
in Rotterdam, The Netherlands.
The Medical Ethics Committee of the Erasmus University Medical Center approved the 
study protocol and written informed consent was obtained from the parents of each child.
Methods
Directly after inclusion all patients started with DEXA treatment and were randomly and 
blindly assigned to receive recombinant human GH (rhGH) 0.3 mg/kg/day (Norditropin R, 
Novo Nordisk A/S) or placebo treatment (Novo Nordisk A/S) administered once daily by 
subcutaneous injection for a period of 6 weeks. GH or placebo treatment was started within 
4- 6 hours after start of DEXA. DEXA treatment was started with a dosage of 0.5 mg/kg/day, 
in two doses per day, during 3 days. Thereafter the dosage was tapered to 0.3 mg/kg/day 
for three days and gradually tapered every three days to 0.1 mg/kg/day every other day 
over a 24 - day period. When extubation did not succeed a second course or prolonged 
course of DEXA was given, while GH or placebo treatment was continued. The day and 
time of starting DEXA treatment was t = 0 and the number of days in study were calculated 
from the start of DEXA. 
All patients underwent a physical examination before start of DEXA. Attending 
neonatologists, investigators and parents were unaware of the treatment allocation due to 
the double-blind-design.
The attending neonatologist provided routine care and feeding decisions. According to 
the policy of the NICU, infants were started on parenteral nutrition on the second day of 
life and enteral feedings were initiated on day 7. Premature infant formulas were used with 
a caloric density of 80-88 kcal/100 ml and a protein content of 2.4-2.6 g/100 ml. 
Serum GH levels were measured weekly and in infants with an arterial line a 6-hours GH 
profile was performed. Serum IGF-I and IGF- binding protein -3 (IGFBP- 3) and -1 (IGFBP-
1) levels were measured before as well as 3 and 6 weeks after start of DEXA.
Severity of respiratory failure at start of DEXA was assessed by calculating the ventilation 
score (mean airway pressure times inspired fraction of oxygen). Possible neonatal side 
effects of DEXA and of GH treatment such as hypertension requiring treatment with 
antihypertensive drugs, hyperglycaemia treated with insulin therapy, cardiac hypertrophy, 
and incidence and severity of retinopathy of prematurity (ROP) were recorded.
Nutritional intake was calculated from the daily nutritional intake during the 6 week 
study period.
Cardiologic evaluation occurred in all patients before, during and after stopping DEXA 
treatment by the same investigator. M-Mode echocardiography was used to measure the 
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dimensions of the left ventricular wall and internal dimensions at systole and diastole 
according to the recommendations of the American Society of Echocardiography.23 The 
occurrence of left ventricular hypertrophy was assessed by calculating the relative wall 
thickness of the left ventricle. Relative wall thickness (RWTh) was calculated by dividing 
the posterior wall thickness of the left ventricle by the left ventricle internal dimension 
measured at end- diastole. Left ventricular hypertrophy was defined as a RWTh > 0.2.
Anthropometric measurements 
Anthropometric measurements as weight, recumbent crown-heel length (CHL), knee-heel 
length (KHL) and occipito-frontal circumference (OFC) were performed. All anthropometric 
measurements were done by two experienced observers. Baseline measurements were 
performed before starting DEXA. Weight was measured daily, OFC and CHL weekly. KHL 
was measured twice a week. The time of measurements was recorded and calculated as 
hours from the start of DEXA administration.
CHL was measured using a neonatometer in the incubator, with full extension of the hips 
and knees and with both heels pressing the end of the neonatometer. CHL was measured 
three times and recorded to the nearest millimeter and the mean was used for analysis. 
Weight was measured on an electronic baby scale (TEC, Tokyo Electronic Co) to the 
nearest gram, every day on the same time. OFC was measured three times using a standard 
plastic measuring tape (1 cm wide) and recorded to the nearest millimetre. The mean of 
three measurements was used for analysis. KHL was measured according to Gibson with 
a hand-held knemometer.7 Each measurement consisted of 8 readings; the mean of these 
measurements was used for analysis. The investigator performed the measurements and a 
second observer performed the readings. 
Birth weight was expressed as SD-scores for gestational age according to the standards 
of Usher and McLean.24 
Hormone assays
All hormone determinations were performed in the Endocrine Laboratory of the Erasmus 
University Hospital Rotterdam, the Netherlands.
Serum GH levels were measured using a two-site immunoradiometric assay (ELSA-HGH, 
CIS bio international, ORIS Group, France). The assay measured the 22 kD GH and showed 
no cross reactivity with 20 kD GH. All samples were analysed in duplicate in the same 
assay. The WHO First International Reference Preparation WHO 80/505 was used as a 
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standard. The intra-assay and inter-assay coefficients of variation were less then 2.8% and 
less then 4.4%, respectively. The detection limit of the assay was 0.04 µg/l. 
Serum IGF-I levels were determined by RIA (SM-C-RIA-CT, Biosource Europe SA) after 
acid- ethanol extraction. The sensitivity was 0.25 ± 0.10 ng/ml, the intra-assay coefficients of 
variation were less than 6.1%. The inter-assay precision was less than 9.9%. Cross-reactivity 
with IGF-II was 0.2%, with insulin < 0.001% and with GH < 0.01%.
Serum IGFBP-1 levels were determined using a two-site immunoradiometric assay 
principle (Total IGFBPI IRMA DSL-7800, Diagnostic Systems Laboratories, Webster, Texas, 
USA). The sensitivity of the assay was 0.33 ng/ml and the intra-assay coefficients of 
variation were less than 5.2%. The inter-assay coefficients of variation were less than 6.0%. 
No cross-reactivity was seen with the IGFBP-2, -3, -4, -5, and -6. 
Serum IGFBP-3 levels were determined using a two-site immunoradiometric assay (IGF-
BP3 IRMA, DSL-6600, Diagnostic Systems Laboratories Webster, Texas, USA). The sensitivity 
of the assay was 0.5 ng/ml, with intra-assay coefficients of variation of less than 3.9%.The 
inter- assay coefficients of variation were less than 1.9%.
Statistical analyses
Statistical analyses were performed using SPSS 9.0 for Windows 95, SPSS software, 
Chicago (IL) or SAS version 6.12 for Windows, SAS Institute Inc., Cary (NC), U.S.A. Power 
calculations had led to a required number of 2 x 25 patients. However, as recruitment was 
slower than expected, the inclusion period was stopped after 3 years when a total of 30 
patients was included. The decision to stop was made when the trial was still blind and 
without consideration of the accumulated data. 
Visual inspection of scatterplots of anthropometric data showed more or less stable values 
during the first week for all parameters, but an increase thereafter. Therefore these data 
were analysed using peacewise linear regression, also called the “broken-stick” method, 
with a breakpoint at day 7.25 In a secondary analysis, the effect of stopping DEXA was 
investigated using the same method. This was done by allowing for a second breakpoint 
at the day of stopping DEXA. These analyses were done using repeated measurements 
analysis of variance, and calculations for this particular analysis were done with SAS 
software (random coefficients model from SAS PROC MIXED). 
Weight and the hormone values were logarithmically transformed before analysis to 
obtain approximate normal distributions. Percentages were compared using Fisher’s exact 
test. Two-sided p-values ≤ 0.05 were considered significant. 
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Results
Clinical characteristics
Thirty patients were included in the study. Fifteen patients received DEXA and GH and 
15 patients were treated with DEXA and placebo. The clinical data of the patients before 
start of the study are shown in Table 1. The groups were comparable regarding all 
characteristics. 
The clinical data during the study are shown in Table 2. The baseline data at randomisation 
were comparable between groups. During the 6 - week study period no difference in daily 
nutritional intake, number of days on artificial ventilation, on supplemental oxygen and on 
DEXA treatment between the GH and the placebo group was observed.
Anthropometric measurements 
First, we analysed the data for the total study period of 6 weeks in both treatment groups. 
In the secondary analysis we evaluated within group differences comparing the period on 
DEXA treatment with the period after discontinuation of DEXA (Table 3).
Table 1  Perinatal data of the 30 study patients.
DEXA-GH
N = 15
DEXA-placebo
N = 15
Male / female (n) 7 / 8 11 / 4
Gestational age (wk) 27.2 (24.6 - 30.6) 27.3 (24.9 - 29.9)
Birth weight (g) 889 (580 - 1335) 847 (501 - 1335)
Antenatal steroids (n) 14 12
Premature rupture of the membranes (n) 2 4
Preeclampsia (n) 3 4 
Caesarian Section (n) 6 7
Twin pregnancy (n) 1 4 
Apgar 1 min 4.6 (2.2) 5.3 (2.4)
Apgar 5 min 7.3 (1.4) 8.0 (1.3)
Respiratory distress syndrome (n) 9 14
Surfactant use (n) 10 14
Patent ductus arteriosus (n) 9 14
Intraventricular haemorrhage grade 1-2 (n) 6 6
Intraventricular haemorrhage grade 3-4 (n) 0 0
Results are given as median (range) or number of infants.
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Weight. In the first week on DEXA no increase in weight was observed in both the GH 
and the placebo group. The mean change in weight in the first week was –2.7 and –3.1 g 
/kg /day in the GH and placebo group, respectively. In both treatment groups a significant 
increase in weight occurred (p < 0.001) during the 2 to 6 week period after start of DEXA. 
The mean increase in weight in the GH group was 15.8 g/kg/day versus 15.6 g/kg/day in 
the placebo group (Figure 1). 
Table 2 Clinical data of the study patients.
DEXA-GH
N = 15
DEXA-placebo
N = 15
At randomisation
Postnatal age (wk) 3.1 (1.1 - 4.6) 2.6 (1.0 - 5.4)
Postconceptional age (wk) 30.3 (27.6 - 35.1) 29.0 (27.4 - 33.9)
Ventilation score 429 (255 - 880) 450 (250 - 1800)
Weight (g) 1101 (750 - 1510) 1035 (720 - 1630)
Crown- heel length (cm) 36.5 (31.9 - 40.7) 36.1 (31.1 - 41.2)
Knee-heel length (mm) 87.7 (73.9 - 98.1) 87.6 (69.4 - 99.2)
Occipito-frontal headcircumference (cm) 26.5 (23.0 - 29.7) 26.3 (22.5 - 29.6)
During 6- weeks study period
Caloric intake (kcal/kg/day) 133.6 (17.1) 128.7 (21.1)
Protein intake (g/kg/day) 3.4 (0.2) 3.5 (0.3)
Number of days on DEXA (days) 24 (22 - 42) 24 (3 - 36)
Number of days on artificial ventilation (days) a 3 (1 - 31) 4 (1 - 30)
Number of days O2 (days) a 36 (2 - 42) 42 (4 - 42)
Use of antihypertensive drugs (Y/N) 0 / 15 1 / 14
Insulin treatment (Y/N) 3 / 12 2 / 13
LVH 3 wks after start DEXA (Y/N) b 12 / 14 13 / 14
Follow-up at 36 wk PCA (after study period)
Need for supplemental O2 at 36 wk PCA (Y/N) 11 / 4 9 / 4
ROP grade 3-4 (Y/N) 2 / 13 3 / 11
Cystic PVL (Y/N) 0 / 15 1 / 13
Death (Y/N) 0 / 15 2# / 15
Results are given as median (range) or number of infants.
PCA: post conceptional age (wks), O2: oxygen, LVH: left ventricular hypertrophy, ROP: retinopathy of prematurity, PVL: periventricular 
leucomalacia.
a after start of DEXA, 
b defined as Relative Wall Thickness of the left ventricle (posterior wall thickness left ventricle / left ventricle internal dimension) > 0.2
#2 patients died: one patient due to progressive respiratory insufficiency (study day 3) and one patient due to cystic PVL (study day 46) 
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Occipito Frontal Circumference (OFC). In the first week on DEXA treatment no growth 
in OFC was observed in both the GH and the placebo group. In both treatment groups OFC 
increased significantly during week 2 to 6 after start of DEXA (both groups, p < 0.001). The 
increase in OFC in the GH group was 1.0 cm/wk versus 0.9 cm/wk in the placebo group 
and not significantly different between the groups (p = 0.32).
Crown Heel Length (CHL). In the first week on DEXA no significant increase in mean 
CHL occurred in both the GH and the placebo group. The mean change in CHL was –0.5 
cm/wk in both groups. In both treatment groups a significant increase in CHL occurred (p 
< 0.0001) during week 2 to 6 after start of DEXA. In the GH as well as in the placebo group 
CHL increased with 1.0 cm/wk (Figure 2). 
Knee Heel Length (KHL). In the first week on DEXA treatment no increase in mean KHL 
was observed in both the GH and the placebo group. In both treatment groups an identical 
significant increase in KHL (p < 0.001) was observed during week 2 to 6 after start of DEXA. 
In both treatment groups the increase in KHL was 3.1 mm/wk.
Serum GH levels
Serum GH profiles were performed in 6/15 infants during treatment with rhGH (Figure 
3). Serum GH levels varied between 1.4 and 518 µg/l. In all patients high GH levels after 
administration of rhGH were followed by a rapid decline. In 3 patients serum GH half-life 
could be calculated and these were 1.9, 5.2 and 5.5 hours, respectively. Serum GH levels 
measured just before administration of the next dose GH were lower than 5 µg/l. 
Table 3  Anthropometric measurements during the 6 - week study period.
DEXA-GH DEXA-placebo
Week 1 Week 2 – 6 Week 1 Week 2 – 6
During 
DEXA1
After 
DEXA2 Total
during 
DEXA1
after 
DEXA2 Total
Weight
g/kg/day
-2.7
(-7.8; 2.4)
16.2
(14.6; 17.8)
15.8
(14.2; 17.4)
15.8
(12.5; 19.1)
-3.1
(-7.8; 1.6)
15.3
(13.5; 17.1)
16.0
(14.2; 17.8)
15.6
(12.3; 18.9)
CHL
cm/wk
-0.5
(-1.1; 0.2)
0.8
(0.5; 1.0)
1.2#
(1.0; 1.4)
1.0
(0.8; 1.1)
-0.5
(-0.9; 0.0) 
0.9
(0.7; 1.1 )
1.1
(0.9; 1.3)
1.0
(0.8; 1.1)
KHL
mm/wk
0.1
(-1.3; 1.5)
2.6
(2.1; 3.2)
3.7##
(3.2; 4.2)
3.1
(2.8; 3.5)
0.0
(-1.3; 1.3)
2.7
(2.2; 3.4)
3.5
(3.0; 3.9)
3.1
(2.7; 3.4)
OFC
cm/wk
-0.0
(-0.3; 0.2)
1.0
(0.9; 1.2)
1.0
(0.9; 1.1)
1.0
(0.9; 1.1)
-0.3
(-0.6; 0.1)
1.0
(0.8; 1.1)
0.9
(0.8; 1.0)
0.9
(0.8; 1.0)
Results are given as mean (95% CI) increase per day or week. 
CHL: crown-heel length, KHL: knee-heel length, OFC: occipito-frontal head circumference. 
1period from week 2 until stop DEXA, 2period after stop of DEXA.
# p=0.028, ## p=0.022, significant increase versus during DEXA.
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Serum IGF- I, IGFBP- 3 and –1 levels
Serum IGF-I levels did not increase during the 6- week study period in both the GH and 
placebo group (Table 4). Serum IGFBP-3 levels increased significantly during DEXA in both 
groups (p < 0.02), but the increase in IGFBP-3 was not significantly different between the 
groups (p = 0.15). 
Baseline serum IGFBP-3 levels were significantly higher in the GH than in the placebo 
group (p < 0.05). Serum IGFBP-1 levels at day 21 were significantly lower in the GH 
compared to the placebo group (p < 0.05) and to baseline levels (p < 0. 01). The change 
from baseline was not significantly different between the groups.
Adverse effects
One patient received antihypertensive treatment and 2 patients received insulin treatment 
in the placebo group, while 3 patients in the GH group received insulin treatment. 
Two patients in the placebo group died; one patient because of progressive respiratory 
insufficiency at study day 3 and one patient died because of severe cystic leucomalacia at 
study day 54 during the follow up period. None of the infants in the GH group died.
At follow-up until 36 weeks postconceptional age 11/15 infants in the GH group and 
9/13 in the placebo group had developed bronchopulmonary dysplasia (BPD). Severe 
retinopathy had developed in 2 patients in the GH group and 3 patients in the placebo 
group.
Left ventricular hypertrophy measured by RWTh of the left ventricle occurred in the 
majority of infants in both groups during DEXA treatment. The mean RWTh of the left 
ventricle 3 weeks after start DEXA was not significantly different between the groups.
Table 4 Serum IGF-I, IGFBP-3 and -1 levels in DEXA-GH and DEXA-placebo treated infants.
DEXA- GH DEXA – placebo
Baseline Day 21 Day 42 Baseline Day 21 Day 42
IGF-I 39.8
(20.7 - 96.7)
53.2
(9.9 - 95.6)
36.0
(9.9 - 222.6)
42.1
(7.7 - 234.8)
30.6
(6.1 - 65.8)
37.5
(17.6 - 73.4)
IGFBP-1 108.0
(7.9 - 485.0)
48.4*,# 
(5.9 - 138.0)
35.9
(6.4 - 183.0)
64.1
(32.4 - 421.0)
105.7
(16.2 - 385.0)
102.2
(14.4 - 997.0)
IGFBP-3 0.7#
(0.3 - 3.7)
1.3*
(0.7 - 2.2)
1.2**
(0.8 - 3.2)
0.5
(0.2 - 0.9)
1.1***
(0.4 - 1.6)
1.2***
(0.8 - 1.5)
Results are given as median (range). 
Serum levels of IGF-I expressed in ng/ml, IGFBP-1 in ng/ml and IGFBP-3 in mg/l. 
* p < 0.01, ** p < 0.02, *** p < 0.001, versus baseline. 
# p < 0.05 between both groups.
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Figure 1 Weight and occipito-frontal headcircumference in DEXA-GH and DEXA-placebo treated infants.
Weight on a logaritmic scale and expressed in grams. Head-circumference expressed in cm. DAYS meaning the number of days after starting of 
DEXA treatment, calculated from t = 0 (hour of first DEXA dose). 
Figure 2 Crown-heel length and Knee-heel length in DEXA-GH and DEXA-placebo treated infants.
Crown-heel length expressed in cm and knee-heel length in mm. DAYS meaning the number of days after starting of DEXA treatment, calculated 
from t = 0 (hour of first DEXA dose). 
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DEXA effects on growth and serum IGF-I, IGFBP-1 and -3 levels 
In both treatment groups the increase in weight, CHL, KHL and OFC was significantly 
lower during the first week than during the next weeks on DEXA (both groups, p < 0.001). 
Interestingly, the increase in weight and OFC during week 2 and 3 on DEXA, was not 
significantly different from the increase in weight and OFC after discontinuation of DEXA 
(Table 3). 
In the placebo group the increase in CHL and KHL after discontinuation of DEXA was not 
significantly different from the increase during week 2 and 3 on DEXA (p = 0.26 and p = 
0.059, respectively). In the GH group the increase in CHL and KHL after discontinuation of 
DEXA was significantly higher than during week 2 and 3 on DEXA (p = 0.028 and p = 0.022, 
respectively). This increase in CHL and KHL during GH treatment was not different from 
the corresponding increase in the placebo group (p = 0.37 and p = 0.55, respectively). 
In both treatment groups start and discontinuation of DEXA did not result in a change 
in serum IGF-I levels from baseline. Serum IGFBP-3 levels increased during DEXA, but 
discontinuation of DEXA did not result in a further increase in serum IGFB-3 levels in both 
groups (p = 0.46).
Discussion
In this double-blind GH-controlled trial we showed that 6 weeks of treatment with rhGH 
is not able to overcome the growth failure caused by DEXA in very preterm infants who 
are at risk for BPD. No gain in weight, CHL, KHL, and OFC was observed during the first 
week of DEXA treatment in both the GH and placebo group. In the second and third week 
on DEXA as well as during the 3 – week period after discontinuation of DEXA the gain in 
weight, CHL, KHL and OFC was not significantly different between the groups. 
Figure 3 
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Figure 3 Serum GH levels in 6 patients after administration of rhGH.
Serum GH levels expressed in µg/l versus time expressed in hours after administration of rhGH.
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Interestingly, in the placebo group, the growth during DEXA treatment with reduced 
doses of DEXA during the second and third week was not different from the growth 
observed after discontinuation of DEXA. In the GH group the growth in CHL and KHL was 
significantly higher after discontinuation of DEXA. This increase, however, was not different 
from the increase observed in the placebo group.
GH treatment did not result in an increase in serum IGF-I levels and higher serum IGFBP-
3 levels.
Nowadays, DEXA treatment in very preterm infants in order to facilitate extubation is 
an area of great concern especially when high doses of glucocorticoids are given. DEXA 
treatment in very preterm infants has been associated with reduced cerebral cortical gray 
matter, an arrest of alveolarisation of the lungs, catabolic effects, alteration of skeletal 
metabolism and cessation of growth.7-18 Despite these substantial concerns, DEXA is still 
administered to preterm infants in order to wean them from the ventilator when clinical and 
radiological signs of BPD develop and conservative treatment such as increased ventilation 
settings, fluid restriction, diuretics, antibiotics and inhalation therapy has failed.26 The starting 
dose of DEXA usually given to very preterm infants in most neonatal intensive care units 
is 0.5 mg/kg/day for 3 days, which is equivalent to 13.3 mg/kg/day hydrocortisone and to 
3.3 mg/kg/day prednisone, and thus much higher than the physiological hydrocortisone 
production of approximately 1 mg/kg/day.
This is the first GH - controlled study measuring the effect of rhGH versus placebo in 
combination with DEXA on growth in preterm infants. By accurately measuring weight, 
CHL, KHL and OFC we were able to minimize intra- and inter-observer variations and 
obtained narrow confidence intervals, allowing evaluation of growth on a weekly base. 
Two major conclusions arise from this study. First rhGH treatment has no effect in 
preventing impairment of growth in DEXA-treated preterm infants when a rhGH dose 
of 0.3 mg/kg/day is given for a 6 - week period. Secondly, the impairment of growth is 
particularly associated with high-dose DEXA treatment during the first week. 
During the first week, a high dose of DEXA 0.5 mg/kg for 3 days is given, followed by a 
dose of 0.3 mg/kg for 3 days and 0.25 mg/kg for 3 days, respectively. It is of importance, 
that when the daily DEXA dose was decreased to less than 0.25 or 0.20 mg/kg/day, which 
is equivalent to 5 mg/kg/day of hydrocortisone, the rate of growth in these preterm infants 
was similar to the growth rate during the first 3 weeks after discontinuation of DEXA. 
This applied to growth of weight, crown-heel length and knee-heel length as well as for 
occipito-frontal head-circumference. Apparently there is a dose- effect relationship as has 
also been described in older children. One study evaluating the catabolic effect of DEXA 
treatment showed a higher nitrogen excretion, leucine turnover and breakdown at day 
4 with a DEXA dose of 0.35 mg/kg/day, compared to day 19 when a dose of 0.10 mg/
kg/day was adminstered.17 In addition, increases in plasma amino acid levels have been 
reported during high doses of DEXA, whereas Crofton et al. reported a dose–dependent 
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decrease in collagen markers during DEXA and a significant increase after discontinuation 
of DEXA.18,27
Several other studies reported a decline in growth during DEXA treatment in preterm 
infants.7,9,28,29 Shrivasta et al. described in a small study a decline in growth of OFC, weight 
and KHL during the first week of DEXA, but thereafter growth was unclear. Gibson et al 
found a decline in KHL velocity during 10 days of DEXA treatment and an even higher KHL 
velocity after discontinuation of DEXA compared with pre-treatment velocity. No relation 
with dosage of DEXA was described. Skinner et al. reported in 10 infants a lower weight 
gain, smaller increase in OFC and lower increase in CHL during DEXA and lower weight 
gain during the first 2 weeks on DEXA compared with week 3 and 4. Although there was a 
great variation in duration of DEXA treatment (10 - 70 days) these data suggest that the dose 
of DEXA was negatively correlated with growth. In another study, comparing the effect of 
a long course of DEXA with a 3-day pulse of DEXA every 10 days, a lower KHL velocity 
was found during the first 2 weeks of DEXA in infants receiving the long course. Thus, all 
studies point to a possible dose- effect of DEXA on growth.
The mechanisms by which DEXA induces growth retardation in preterm infants are as 
yet poorly understood. In an earlier study we showed that two days of DEXA in a dose 
of 0.5 mg/kg/day induced a significant decrease of serum GH levels in ventilated preterm 
infants.20 Although preterm infants are known to be GH insensitive, the low GH levels 
we have found during DEXA might cause the growth retardation occurring in preterm 
infants during DEXA treatment. These findings formed the reason to initiate the present 
randomized double-blind GH-placebo controlled trial.
Very limited data are available about GH treatment in the neonatal period in either term 
or preterm infants. Only one study evaluated the effects of recombinant GH treatment in 
preterm infants born small for gestational age (SGA) showing that rhGH did not have any 
effect on growth and body composition during the neonatal period.30 It is known that the 
GH/ IGF-I ratio in SGA infants is higher than in AGA infants during the neonatal period, 
suggesting a higher GH insensitivity in SGA compared to AGA infants, at least directly after 
birth. Therefore the results of the GH study in SGA infants cannot be directly applied to 
other preterm infants. 
In our study, we showed that rhGH treatment versus placebo did not result in an 
improved growth in very preterm infants during DEXA treatment in the neonatal period. 
The effect on growth was not different between the GH and the placebo group during the 
whole period of DEXA treatment. Therefore, we conclude that rhGH treatment was not 
effective, neither during the high doses nor during the lower doses of DEXA to enhance 
growth in this period. This is in contrast to studies performed in newborn piglets where 
adjunctive treatment with either GH or GH plus IGF-I in DEXA-treated animals resulted in 
an improvement of growth.31 Treatment with GH plus IGF-I did enhance protein synthesis 
but did not result in a further improvement of growth compared to GH treatment alone.32 
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Possible explanations for this discrepancy in results between very preterm infants and 
animals might be a significantly higher dose of glucocorticoids and/ or GH insensitivity in 
very preterm infants. The dose of DEXA used in our preterm infants is much higher than 
the dosages used in older children in which GH treatment is effective. Improvements of 
weight and height velocity with GH treatment have been reported in children receiving 
glucocorticoids dosages equivalent to 0.5 mg/kg day of prednisone in chronic diseases as 
asthma, lupus, autoimmune colitis and to 0.1-0.2 mg/kg/day of prednisone in children after 
renal transplantation.33,34,22 The effect of GH treatment on linear growth has been suggested 
to be dependent on the dose of glucocorticoids used.35 Another explanation might be that 
very preterm infants still have a GH insensitivity as shown by the high serum GH and low 
serum IGF-I levels. Three weeks after start of DEXA no change from baseline levels of 
serum immunoreactive IGF-I was observed, neither in the placebo nor in the GH group. 
In our earlier study we did not find an effect on serum IGF-I levels two days after starting 
DEXA.20 Therefore it might well be that serum IGF-I levels do not decline during DEXA 
treatment and that the growth reducing effect of DEXA is not mediated by IGF-I, but due 
to a direct effect of DEXA on the epiphyseal cartilage by inhibition of the local secretion 
and paracrine action of IGF-I.36 Prednisone causes in vitro a 46% fall in IGF bioactivity and 
has a suppressive effect on IGF mRNA in the tibia, liver, lung and kidney in the rat, without 
causing significant changes in serum immunoreactive IGF-I levels.37,38 We and others did 
not observe a decline in serum IGF-I levels after administration of DEXA.29,39,40 Thus DEXA-
induced inhibition of local IGF-I gene expression might be one of the mechanisms of 
growth retardation as well. 
We carefully evaluated adverse effects such as cardiac hypertrophy, hyperglycemia, 
hypertension and retinopathy and mortality. We did not find any significant difference 
between the GH and the placebo group. Two patients in the placebo group died. Insulin 
requirement because of hyperglycemia occurred in both groups and was most likely 
caused by insulin resistance due to DEXA. GH treatment did not increase the need for 
insulin. Similarly, we could not detect an increase in cardiac hypertrophy in the GH group 
compared to the placebo group. In adults, an excess of GH is associated with cardiac 
hypertrophy and even a low dose of GH is capable of increasing left ventricular mass.41,42 In 
our GH- treated patients we did not find an increase in severe retinopathy (ROP), although 
recent studies suggest an association between the persistence of high GH levels in preterm 
infants and the development of severe retinopathy.43
Although treatment with rhGH did not result in a positive effect on growth on the short-
term, it might be that GH treatment is able to diminish the reported adverse effects of DEXA 
on neurodevelopment and lung function. For that reason, we will follow these patients on 
the long-term.
In conclusion, treatment with recombinant human GH during 6 weeks is not able to 
overcome the growth failure induced by DEXA when dosages of 0.5 to 0.3 mg/kg/day 
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are used in very preterm infants at risk for BPD. No gain in weight, CHL, KHL, and OFC 
was observed during the first week of high- dose DEXA treatment despite GH treatment. 
Therefore the use of rhGH in the neonatal period cannot be recommended to prevent 
growth failure when treating very preterm infants with DEXA. Secondly, the lower gain in 
weight, CHL, KHL and OFC was restricted to the first week of DEXA when a high dose of 
DEXA was used. Growth in week 2 and 3 was comparable to the growth in the first weeks 
after discontinuation of DEXA, indicating that the growth- limiting effect of DEXA might 
be dose-related. We, therefore suggest that future research should be directed at the use 
of lower doses of glucocorticoids, aiming at both, maintenance of the beneficial effect of 
DEXA of weaning from the ventilator, and prevention of adverse effects.
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Abstract
In this study we compared growth and body composition in preterm infants with 
bronchopulmonary dysplasia (BPD) with normal healthy term infants during the first year 
of life. 
Twenty nine preterm infants with BPD with a mean (SD) gestational age 27.1 (1.6) 
weeks and birth weight 852 (173) g) were followed prospectively. Anthropometry and 
body composition determined by total body electrical conductivity were measured and 
compared with those of healthy term infants at the same post-term age.
In infants with BPD, the mean weight standard deviation scores (SD-scores) at 6 weeks 
post-term age were significantly lower (-1.44 and -2.68, boys and girls respectively) than in 
healthy term infants of the same age and did not improve during the first year. The mean 
length SD-score in infants with BPD at 6 weeks post-term age was significantly lower than 
in healthy term infants of the same age, and, although it improved significantly during the 
first year, the mean length SD-score in girls with BPD remained significantly below zero at 
12 months post-term age. 
In infants with BPD, the mean free fat mass (FFM) SD-score and the mean total body fat 
(TBF) SD-score at 6 weeks post-term age were significantly below zero. The mean FFM 
SD-scores (-1.01 and -2.56, boys and girls respectively) and the mean TBF SD-scores (-1.14 
and -2.40, boys and girls respectively) at 12 months post-term age were significantly lower 
than in healthy term infants of the same age.
Conclusions: Preterm infants with BPD have impaired growth, with a deficit in TBF and 
FFM already at 6 weeks post-term age; FFM and TBF remain low compared with healthy 
term infants during the first year of life. Nutritional intervention studies in infants with BPD 
are needed to evaluate if nutrition is the major determinant of growth and body composition 
or that this observed pattern of growth is the result of disturbed endocrine control.
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Introduction
Preterm infants who develop bronchopulmonary dysplasia (BPD) show impaired growth 
during early infancy compared with term and preterm infants who do not.1,2,3 The impaired 
growth sometimes extends over the first few years of life.4 Different explanations for the slow 
growth in infants with BPD have been proposed, such as the increased work required to 
breathe, early use of glucocorticoids, intrauterine growth retardation, early postnatal growth 
retardation and feeding problems related to inadequate intake or high metabolic rate.5-7 
In rats, early postnatal starvation results in reduced growth in infancy.8 Barker et al. 
showed that intrauterine malnutrition is associated with adult morbidity, especially when 
the malnutrition is combined with accelerated catch up growth during childhood.9-11 
Therefore, both under-nutrition and over-nutrition during early postnatal life should be 
avoided. Nutritional intervention should aim to obtain not only an increase in weight and 
length, but also a body composition comparable to that of healthy term infants. 
Body composition can be measured by total body electric conductivity (TOBEC), which 
has emerged as an accurate, precise, and reproducible method for estimating fat free mass 
(FFM) and total body fat (TBF).12–14 Reference standards for healthy term Caucasian Dutch 
infants for TBF and FFM have been developed by De Bruin et al. as well as the normal 
pattern of TBF and FFM accretion in infants in the first year of life.15 
No data exist on the pattern of body composition in preterm infants with BPD during the 
first year of life, and without these data it is impossible to design an appropriate nutritional 
intervention for infants with BPD and to know whether to recommend supplemental 
energy or protein or both.
Therefore, the aim of our study was to collect data on growth and body composition 
in preterm infants with BPD, after discharge from the neonatal intensive care unit, and to 
compare them with reference data in healthy term infants. 
Methods
Patients
Patients were enrolled in the study between January 1997 and January 1999, had a 
gestational age < 30 weeks, and had developed BPD according to the criteria of Northway 
et al.16 All patients had been admitted to the neonatal intensive care unit of Sophia 
Children’s Hospital. The study was approved by the local Medical Ethics Committee, and 
informed consent was obtained from the parents of each child.
All patients were prospectively followed at the neonatal follow-up clinic at the post-term 
ages of 6 weeks, 3, 6, 9, and 12 months. During these follow-up visits, recumbent crown-
heel length, weight, and head circumference were measured. TOBEC measurements were 
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only performed if the infants weighed more than 3 kg, because such measurements are 
only validated for infants with a body weight of 3–10 kg.13 Neonatal risk factors such as 
intrauterine growth retardation, use of antenatal steroids, duration of ventilation, duration 
of supplemental oxygen, use of dexamethasone, sepsis, necrotising enterocolitis, and 
intraventricular haemorrhage were determined. None of the infants showed signs of fluid 
retention or was artificially ventilated during the period of study.
We calculated dietary intake by recording a 48 hour feeding history during each visit 
at the neonatal follow-up clinic. All infants received formula feeding according to the 
policy on the unit, and were exclusively formula fed until at least 3 months post-term 
age. Solid food was introduced at a time determined by the paediatrician (current Dutch 
recommendations for term infants are to introduce solids at 4 – 6 months of age).
Anthropometric measurements
Anthropometric measurements were carried out by one observer (WH) at each visit. 
Recumbent crown-heel length was measured to the nearest millimetre on a length board. 
Weight was measured on an electronic baby scale (TEC, Tokyo Electronic Co, Tokyo, 
Japan) to the nearest gram. Head circumference (fronto-occipital) was measured using a 
standard plastic measuring tape (1 cm wide) to the nearest millimetre. All anthropometric 
measurements were performed three times, and the mean was used for analysis. Birth 
weight was expressed as SD-scores for gestational age according to the standards of Usher 
and McLean.17 The anthropometric measurements after discharge were expressed as SD-
scores for post-term age, according to the Dutch reference.18
Measurement of body composition
The TOBEC measurements (Body Composition Analyser, model HP-2; EM-Scan Inc, 
Springfield, Illinois, USA) were performed by GH and MH. The principle underlying the 
TOBEC technique is that lean tissue or FFM is far more electrically conductive than fat, 
because of its greater content of electrolytes. When a conductive mass passes through 
the electromagnetic field, a small amount of energy is produced within the conductive 
mass. This energy is distracted from the magnetic field, detected as a phase change in coil 
impedance, and serves as an index of the amount of conductive mass—that is, the infant’s 
FFM. The amount of TBF is calculated by subtracting FFM from body weight. 
The TOBEC procedure was carried out as described by De Bruin et al.14 Before each 
measurement, background noise and a cylindrical reference phantom were measured. 
All measurements were performed in the peak mode. The infants were undressed and 
carefully swaddled in a fully extended position in a large blanket. Care was taken that the 
limbs did not touch each other or the trunk. The infants were not fed for two hours before 
the measurement and they did not have a fever. When the infant had urinated, it was 
swaddled again in a dry blanket and measured again. 
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One TOBEC reading took about 10 seconds, and a complete TOBEC measurement 
consisted of 8–10 of these readings. The mean of the readings was taken for further body 
composition calculations. FFM, TBF, and TBF as a percentage of weight (%TBF) were 
calculated. The SD-scores for FFM, TBF, and %TBF were expressed for post-term age using 
the reference centiles for body composition constructed by De Bruin et al.15 Hydration is 
known to influence the conductance of the FFM, and is a potential measurement error 
in non-stable infants. As all our infants were stable with supplemental oxygen without a 
need for additional diuretic treatment, we believe that the calculation of the FFM was not 
influenced by their hydration. 
Statistical analysis
Statistical analysis was performed using SPSS 9.0 for Windows 95 (SPSS Software, Chicago, 
Illinois, USA) and SAS version 8.0 for Windows (SAS Institute Inc, Cary, North Carolina, 
USA). Differences in baseline data between boys and girls were tested with Student’s t test. 
All statistical analysis requiring repeated measurement analyses were carried out using 
SAS Proc mixed. Repeated measurement analyses were performed because of incomplete 
data for some of the infants. We used a model for repeated measurements with a random 
intercept and a random slope (age) for the subjects. The models for anthropometric data 
included age and sex as fixed effects, and the interaction between age and sex if significant. 
The models for body composition data also included weight, to correct for the fact that 
infants weighing less than 3 kg could not be measured by TOBEC. Using these models, we 
tested the differences in absolute values between boys and girls with BPD, the differences 
between infants with BPD and the reference population by measuring the difference from 
zero for the mean SD-scores, and we measured the differences in mean SD-scores at 
different ages in the infants with BPD.
To compare data at different ages, the means given in the Results section were 
calculated (estimated) means from the repeated measurement models. A p value < 0.05 
was considered significant. Pearson correlation was used to evaluate the relation between 
nutritional intake and growth.
Results
Twenty nine patients with BPD (15 boys) were prospectively followed up. Table 1 shows 
the baseline characteristics and neonatal morbidity of these infants. The mean (SD) 
gestational age was 27.1 (1.6) weeks. Boys with BPD had a significantly higher mean birth 
weight 955 (165) g and mean birth weight SD-score -0.56 (1.0) than girls with BPD (743 
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(102) g and -1.69 (1.0) respectively; p < 0.001 and p < 0.01, respectively). Also the mean 
head circumference SD-score in boys was significantly higher than in girls (p < 0.01). 
The boys and girls with BPD were not significantly different with regard to their perinatal 
morbidity, particularly the number of days receiving dexamethasone, artificial ventilation, 
or supplemental oxygen. All infants developed BPD as defined by Northway et al. 16, and 21 
infants had a requirement for supplemental oxygen at 36 weeks postmenstrual age. Twenty 
six infants were treated with dexamethasone in order to be weaned from the ventilator.
Feeding history could be accurately collected until 6 months post-term age. Weaning was 
started at 3 months post-term age in some of the infants, but most were predominantly 
formula fed until 6 months post-term age. Table 2 shows the calculated energy, protein, and 
fat intake during the first half year after term.
Table 1 Neonatal data for 29 infants with bronchopulmonary dysplasia.
N = 29 Mean SD N
Gestational age (wk) 27.1 1.6 Antenatal steroids 25
Birth weight (g) 852 173 HELLP 12
Birth weight SD score -1.11 1.17 PROM 5
Head circumference -0.21 1.10 RDS treated with surfactant 23
Apgar 1 min 5.0 2.5 Ductus treated with indocid and/or ligation 22
Apgar 5 min 7.8 1.7 Sepsis 19
Dexamethasone treatment (days) 32.5 34.9 Intraventricular hemorrhage > grade 2    6
Ventilation (days) 29.1 15.8
Extra O2 need (days) 201 221
HELLP: haemolysis elevated liver enzymes low platelet syndrome, PROM: premature rupture of the membranes, RDS: respiratory distress syndrome
Table 2 Daily nutritional intake in preterm infants with BPD during the first half year of life.
6 weeks 3 months 6 months
Volume intake (ml/kg/day) 138 (28) 142 (30) 115 (17)
Energy intake (kcal/kg/day) 119 (32) 109 (26) 100 (21)
Protein intake (g/kg/day) 2.7 (0.7) 2.4 (0.5) 2.2 (0.4)
Fat intake (g/kg/day) 6.7 (2.5) 5.7 (1.5) 4.1 (1.0)
Results are given as mean (SD) at given post-term age.
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Anthropometric measurements
Table 3 gives the mean weight, length, and head circumference during the first year of life. 
As in healthy infants, a clear sex difference was seen. Boys with BPD had a significantly 
higher mean weight, length, and head circumference at all ages than girls with BPD (p < 
0.001). In boys and girls with BPD, a similar growth pattern for weight and length was 
observed. 
Infants with BPD had significantly lower mean weight SD-scores at 6 weeks post-term 
age than healthy term infants of the same age (-1.44 and -2.68, boys and girls respectively; 
p < 0.0001). The mean weight SD-score improved significantly from 6 weeks to 6 months 
post-term age (p < 0.0001), but worsened again from 6 to 12 months post-term age (p < 
0.0001). At 12 months post-term, the mean weight SD-score in infants with BPD was not 
improved compared with the mean weight SD-score at 6 weeks post-term and remained 
significantly lower than in healthy term infants of the same age ( p < 0.0001) (Fig. 1).
Infants with BPD had significantly lower mean length SD-scores at 6 weeks post-term 
age than healthy infants of the same age (-2.31 and -2.99, boys and girls respectively; p 
< 0.0001). The mean length SD-scores improved significantly from 6 weeks to 12 months 
post-term age (p < 0.0001). In girls with BPD, the mean length SD-score was significantly 
lower than in healthy term infants at 12 months post-term age (p < 0.001) (Fig. 2).
Measurements of body composition
Total FFM increased gradually during the first year of life in infants with BPD (Table 4). 
TBF increased during the first 9 months after term, but decreased between 9 and 12 months 
after term. FFM and TBF in the infants with BPD were compared with sex specific body 
composition data for healthy term Dutch infants of the same post-term age and expressed 
Table 3 Anthropometric measurements in preterm infants with BPD during the first year of life.
6 weeks 3 months 6 months 9 months 12 months 
Boys
Weight (kg) 3.863(0.128) 5.156(0.127) 7.038(0.178) 8.209(0.259) 8.670(0.364)
Length (cm) 51.4(0.6) 56.7(0.6) 64.8(0.6) 70.5(0.7) 73.9(0.9)
Headcircumference (cm) 37.9(0.3) 40.2(0.3) 43.5(0.3) 45.4(0.4) 46.0(0.4)
Girls
Weight (kg) 3.134(0.134) 4.276(0.132) 5.874(0.176) 6.761(0.246) 6.938(0.337)
Length (cm) 48.8(0.6) 54.1(0.6) 62.3(0.7) 67.9(0.7) 71.3(0.9)
Headcircumference (cm) 36.0(0.4) 38.3(0.4) 41.6(0.4) 43.5(0.4) 44.1(0.4)
Results are given as estimated mean (SE) at given post-term ages. At all ages, weight, length, and head circumference were significantly greater 
for boys than for girls with BPD (p < 0.001).
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in SD-scores (Fig. 3). Although variability is seen between patients, the pattern for each 
individual patient is quite constant. 
In infants with BPD, the mean FFM SD-scores were significantly below zero at 6 weeks 
post-term age (-2.39 and -3.11, boys and girls respectively; p < 0.0001). They increased 
slightly during the first year, but were significantly lower than in healthy infants at 12 
months post-term age (-1.01 and -2.56, boys and girls respectively; p < 0.001). 
The mean TBF SD-scores in infants with BPD were significantly below zero at 6 weeks 
post-term age (-0.91 and -0.73 for boys and girls respectively; p < 0.05). The mean TBF SD-
scores at 12 months post-term age were significantly lower than in healthy infants of the 
same age (-1.14 and -2.40, boys and girls respectively; p < 0.005). 
The mean %TBF SD-score in infants with BPD was not significantly below zero at 6 weeks 
post-term age. However, at 12 months post-term age, the mean %TBF in girls with BPD was 
-2.05 and significantly lower than in healthy term infants of the same age (p < 0.0001).
Nutritional intake
The relation between nutritional intake at the start of a period (from 6 weeks to 3 months, 
from 3 to 6 months, and from 6 to 9 months post-term age) and the increase in absolute 
weight, length, FFM, and TBF at the end of that period was evaluated. No correlation was 
found between the energy and protein intake at 6 weeks, 3 and 6 months post-term age 
and the absolute gain in weight, length, FFM, and TBF. The relation between nutritional 
intake at the start of a period and the change in SD-score during that period was evaluated. 
No correlation was found between energy and protein intake at 6 weeks, 3 and 6 months 
post-term age and the change in SD-score for weight, length, FFM, and TBF.
Table 4 Body composition in preterm infants with BPD during the first year of life. 
6 weeks 3 months 6 months 9 months 12 months
Boys
FFM (kg) 3.300 (0.070) ** 4.127 (0.069) ** 5.393 (0.078)** 6.297 (0.089)** 6.838 (0.105)**
TBF (kg) 0.560 (0.070) 1.033 (0.069) 1.647 (0.078)* 1.913 (0.089)** 1.831 (0.105)**
%TBF 15.3   (1.6) 19.0   (1.5) 23.2   (1.5) 24.0   (1.6) 21.3   (1.7)
Girls
FFM (kg) 2.637 (0.078) 3.387 (0.076) 4.506 (0.079) 5.266 (0.089) 5.665 (0.110)
TBF (kg) 0.493 (0.078) 0.893 (0.075) 1.364 (0.079) 1.493 (0.089) 1.274 (0.110)
%TBF 17.0   (1.7) 20.0   (1.6) 22.8   (1.5) 22.2   (1.5) 18.2   (1.7)
Results are given as estimated mean (SE) at given post-term ages. 
FFM: Fat Free Mass, TBF: Total Body Fat, %TBF: percentage Total Body Fat.
* p < 0.01, ** p < 0.001, significantly different from girls with BPD.
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We calculated dietary intake by recording a 48 hour feeding
history during each visit at the neonatal follow up clinic. All
infants received formula feeding according to the policy on the
unit, and were exclusively formula fed until at least 3 months
post-term age. Solid food was introduced at a time determined
by the paediatrician (current Dutch recommendations for
term infants are to introduce solids at 4–6 months of age).
Anthropometric measurements
Anthropometric measurements were carried out by one
observer (MH) at each visit. Recumbent crown-heel length
was measured to the nearest millimetre on a length board.
Weight was measured on an electronic baby scale (TEC, Tokyo
Electronic Co, Tokyo, Japan) to the nearest gram. Head
circumference (fronto-occipital) was measured using a stand-
ard plastic measuring tape (1 cm wide) to the nearest
millimetre. All anthropometric measurements were per-
formed three times, and the mean was used for analysis. Birth
weight was expressed as SD scores for gestational age accord-
ing to the standards of Usher andMcLean.17 The anthropomet-
ric measurements after discharge were expressed as SD scores
for post-term age, according to the Dutch reference.18
Measurement of body composition
The TOBEC measurements (Body Composition Analyser,
model HP-2; EM-Scan Inc, Springfield, Illinois, USA) were
performed by GH and MH. The principle underlying the
TOBEC technique is that lean tissue or FFM is far more elec-
trically conductive than fat, because of its greater content of
electrolytes.When a conductive mass passes through the elec-
tromagnetic field, a small amount of energy is produced
within the conductive mass. This energy is distracted from the
magnetic field, detected as a phase change in coil impedance,
and serves as an index of the amount of conductive
mass—that is, the infant’s FFM. The amount of TBF is calcu-
lated by subtracting FFM from body weight.
The TOBEC procedure was carried out as described by De
Bruin et al.14 Before each measurement, background noise and
a cylindrical reference phantom were measured. All measure-
ments were performed in the peak mode. The infants were
undressed and carefully swaddled in a fully extended position
in a large blanket. Care was taken that the limbs did not touch
each other or the trunk. The infants were not fed for two hours
before the measurement and they did not have a fever. When
the infant had urinated, it was swaddled again in a dry blan-
ket and measured again.
One TOBEC reading took about 10 seconds, and a complete
TOBEC measurement consisted of 8–10 of these readings. The
mean of the readings was taken for further body composition
calculations. FFM, TBF, and TBF as a percentage of weight
(%TBF) were calculated. The SD scores for FFM, TBF, and
%TBF were expressed for post-term age using the reference
centiles for body composition constructed by De Bruin et al.15
Hydration is known to influence the conductance of the FFM,
and is a potential measurement error in non-stable infants. As
all our infants were stable with supplemental oxygen without
a need for additional diuretic treatment, we believe that the
calculation of the FFM was not influenced by their hydration.
Statistical analysis
Statistical analysis was performed using SPSS 9.0 for
Windows 95 (SPSS Software, Chicago, Illinois, USA) and SAS
version 8.0 for Windows (SAS Institute Inc, Cary, North Caro-
lina, USA). Differences in baseline data between boys and girls
were tested with Student’s t test. All statistical analysis
requiring repeated measurement analyses were carried out
using SAS Proc mixed. Repeated measurement analyses were
performed because of incomplete data for some of the infants.
We used a model for repeated measurements with a random
intercept and a random slope (age) for the subjects. The mod-
els for anthropometric data included age and sex as fixed
effects, and the interaction between age and sex if significant.
The models for body composition data also included weight, to
correct for the fact that infants weighing less than 3 kg could
not be measured by TOBEC. Using these models, we tested the
differences in absolute values between boys and girls with
BPD, the differences between infants with BPD and the refer-
ence population by measuring the difference from zero for the
Table 1 Neonatal data for 29 infants with
bronchopulmonary dysplasia
Mean SD No
Gestational age (weeks) 27.1 1.6
Birth weight (g) 852 173
Birth weight SD score −1.11 1.17
Head circumference −0.21 1.10
Apgar 1 min 5.0 2.5
Apgar 5 min 7.8 1.7
Dexamethasone treatment (days) 32.5 34.9
Ventilation (days) 29.1 15.8
Extra O2 requirement (days) 201 221
Antenatal steroids 25
HELLP 12
PROM 5
RDS treated with surfactant 23
Ductus treated with indocid and/or ligation 22
Sepsis 19
Intraventricular haemorrhage > grade 2 6
HELLP, haemolysis elevated liver enzymes-low platelet syndrome;
PROM, premature rupture of the membranes; RDS respiratory distress
syndrome.
Table 2 Daily nutritional intake in preterm infants
with bronchopulmonary dysplasia during the first half
year of life
6 weeks 3 months 6 months
Volume intake
(ml/kg/day)
138 (28) 142 (30) 115 (17)
Energy intake
(kcal/kg/day)
119 (32) 109 (26) 100 (21)
Protein intake
(g/kg/day)
2.7 (0.7) 2.4 (0.5) 2.2 (0.4)
Fat intake (g/kg/day) 6.7 (2.5) 5.7 (1.5) 4.1 (1.0)
Values are mean (SD) at given post-term age.
Figure 1 Weight SD scores (SDS) in infants with
bronchopulmonary dysplasia plotted against post-term age in the first
year of life. The mean and the 25th and 75th centiles are shown.
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mean SD scores, and we measured the differences in mean SD
scores at different ages in the infants with BPD.
To compare data at different ages, the means given in the
Results section were calculated (estimated) means from the
repeated measurement models. p < 0.05 was considered
significant. Pearson correlation was used to evaluate the rela-
tion between nutritional intake and growth.
RESULTS
Twenty nine patients with BPD (15 boys) were prospectively
followed up. Table 1 shows the baseline characteristics and
neonatal morbidity of these infants. The mean (SD)
gestational age was 27.1 (1.6) weeks. The boys with BPD had
a significantly higher mean birth weight 955 (165) g and
mean birth weight SD score −0.56 (1.0) than the girls with
BPD (743 (102) g and −1.69 (1.0) respectively; p < 0.001 and
p < 0.01 respectively). The mean head circumference SD score
in the boys was significantly higher than in the girls
(p < 0.01). The boys and girls with BPD were not significantly
different with regard to their perinatal morbidity, particularly
the number of days receiving dexamethasone, artificial venti-
lation, or supplemental oxygen. All infants developed BPD as
defined by Northway et al,16 and 21 infants progressed to
chronic lung disease, defined as a requirement for supplemen-
tal oxygen at 36 weeks postconceptional age. Twenty six
infants were treated with dexamethasone in order to be
weaned from the ventilator. Feeding history could be
accurately collected until 6 months post-term age. Weaning
was started at 3 months post-term age in some of the i fants,
but ost were predominantly for ula fed until 6 months
post-term age. Table 2 shows the calculated energy, protein,
and fat intake during the first half year after term.
Anthropometric measurements
Table 3 gives the mean weight, length, and head circumference
during the first year of life. As in healthy infants, a clear sex
difference was seen. The boys w h BPD had a significantly
higher mean w ight, length, and head circumference at all
ages than the girls with BPD ( < 0.001).
In boys and girls with BPD, a sim lar growth pattern for
weight and length was seen. Infants with BPD had
significantly lower mean weight SD scores at 6 weeks post-
term age than althy term infants of the same age (−1.44 and
−2.68, boys and girls respectively; p < 0.0001). The mean
weight SD score improved significantly from 6 weeks to 6
months post-term age (p < 0.0001), but worsened again from
6 months to 12 months post-term age (p < 0.0001). At 12
months after term, the mean weight SD score in infants with
BPD was not significantly improved compared with the mean
weight SD score at 6 weeks after term and remained
significantly lower than in healthy term infants of the same
age ( p < 0.0001) (fig 1).
Infants with BPD had significantly lower mean length SD
scores at 6 weeks post-term age than healthy infants of the
s me age (−2.31 and −2.99, boys an girls respectively;
p < 0.0001). The mean length SD scores improved signifi-
cantly from 6 weeks to 12months post-term age (p < 0.0001).
In girls with BPD, the mean length SD score was significantly
lower than in healthy term infants at 12 months post-term
age (p < 0.001) (fig 2).
M asurements of body composition
Total FFM increased gradually duri g th first year of life in
infants with BPD (table 4). TBF increas d during the first 9
months after term, but decreas d between 9 and 12 months
after t rm.
FFM and TBF i the infants with BPD were compared with
sex specific body composi ion data for healthy t rm Dutch
in ants of the sam post-term age and expre sed in SD s ores
(fig 3). Although variability s seen between patients, the pat-
tern for eac individual patient is quite cons ant. In infants
wi h BPD, the mean FFM SD scores were significantly b low 0
at 6 weeks post-term age (−2.39 and −3.11, boys and girls
respectively; p < 0.0001). They increased slightly uring the
first year, but were significantly lower than in healthy term
infants at 12months post-term age (−1.01 and −2.56, boys and
girls respectively; p < 0.001).
The mean TBF SD scores in infants with BPD were signifi-
cantly below 0 at 6 weeks post-term age (−0.91 and −0.73 for
boys and girls respectively; p < 0.05). The mean TBF SD scores
at 12 months post-term age were significantly lower than in
healthy infants of the same age (−1.14 and −2.40, boys and
girls respectively; p < 0.005).
The mean %TBF SD score in infants with BPD was not sig-
nificantly below 0 at 6 weeks post-term age. However, at 12
Table 3 Anthropometric measurements in preterm infants with bronchopulmonary
dysplasia during the first year of life
6 weeks 3 months 6 months 9 months 12 months
Boys
Weight (kg) 3.863 (0.128) 5.156 (0.127) 7.038 (0.178) 8.209 (0.259) 8.670 (0.364)
Length (cm) 51.4 (0.6) 56.7 (0.6) 64.8 (0.6) 70.5 (0.7) 73.9 (0.9)
Head ci cumference (cm) 37.9 (0.3) 40.2 (0.3) 43.5 (0.3) 45.4 (0.4) 46.0 (0.4)
Girls
Weight (kg) 3.134 (0.134) 4.276 (0.132) 5.874 (0.176) 6.761 (0.246) 6.938 (0.337)
Length (cm) 48.8 (0.6) 54.1 (0.6) 62.3 (0.7) 67.9 (0.7) 71.3 (0.9)
Head circumference (cm) 36.0 (0.4) 38.3 (0.4) 41.6 (0.4) 43.5 (0.4) 44.1 (0.4)
Results are expressed as estimated mean (SE) at given post-term ages. At all ages, weight, length, and head
circumference were significantly greater for boys than for girls (p<0.001).
Figure 2 Length SD scores (SDS) in infants with bronchopulmonary
dysplasia plotted against post-term age in the first year of life. The
mean and the 25th and 75th centiles are shown.
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Figure 1 Wei ht SD-scores in infants with br nchopulmonary dysplasia in the first year of life.
Weight SD-scores (SDS) plotted against post-term age in the first year of life. The ean and the 25th and 75th centiles are shown.
Figure 2 Len th SD-scores in infants with bronchopulmonary dyspla ia in the first year of life. 
Length SD-scores (SDS) plotted against post-term age in the first year of life. The mean and the 25th and 75th centiles are shown.
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The fact that FFM and TBF in our preterm infants with BPD
were lower than healthy term reference values, measured by
the same method, may have different explanations. It may
well be that BPD itself causes less deposition of FFM and TBF
because of inadequate absorption of nutrients during the
acute phase of lung disease, the medical treatment of the
infants (with fluid restriction, steroids, and diuretics),
elevated metabolic rate, and the increased work of breathing.
The data of Rawlings et al31 suggest that prematurity itself may
also explain at least some of our results. As we did not have a
control group of healthy preterm infants, it is not possible to
conclude whether the effect on FFM and TBF is due to BPD or
prematurity itself. Finally, growth retardation at birth or dur-
ing the first few weeks of life in preterm infants, especially
those with major morbidities as observed by Ehrenkranz et
al,6 may have caused a persisting abnormal body composition.
Dietarymanipulation of growth rates and body composition
in preterm infants seems reasonable.32–37 Increases in weight,
TBF, and FFM have been obtained in preterm boys, but not
girls, who were fed a preterm formula (higher in energy, pro-
tein, calcium, and phosphorus) from discharge for 6 months.
The authors attributed the changes in growth and body com-
position to the higher protein intake.34 Recent intervention
studies have shown a positive effect on weight, length, and
head circumference, especially in boys.36–38 So far, only one
study, by Brunton et al,32 has described the effect of nutritional
intervention in infants with BPD. Feeding an enriched
formula (2.5 g protein/kg/day compared with 2.0 g protein/kg/
day) resulted in a significantly greater gain in length and
FFM, but not in weight, in infants with BPD fed the enriched
formula at 3 months of age. From this study, it seems to be
possible to increase FFM and linear growth by giving a high
protein/high mineral formula. Interestingly, the intake for our
infants was comparable to the enriched formula, but both
weight and FFMwere lower in our children than in the infants
studied by Brunton et al.
Interpretation of body composition data depends on
whether post-term age or body weight is regarded as the
appropriate reference. The weights of our preterm infants with
BPD at 6 weeks post-term age are comparable to the weights
of healthy newborn infants, and the %TBF is comparable to
the %TBF found by TOBEC and dual energy x ray absorptiom-
etry in healthy term neonates.39–41 Also, the FFM in infants
with BPD is comparable to that of infants of equal weight.
These data, together with the anthropometric data, indicate
that preterm infants with BPD are growth retarded, with less
body fat and lean mass than healthy infants of the same post-
term age, and they have body proportions regarding fat free
mass and fat according to their weight. As this growth restric-
tion may have permanent effects, interventions are needed to
improve growth in these preterm infants. Long lasting nutri-
tional intervention studies with both increased protein and
energy are needed to determine whether this will improve
growth and body composition at a later age. As growth distur-
bance in the perinatal period may result in disturbance of the
endocrine control of growth, these studies should include
hormonal evaluations.Measurements of body composition are
essential in these studies to evaluate the FFM and TBF and to
prevent overnutrition in some infants.
. . . . . . . . . . . . . . . . . . . . .
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Figure 3 Fat free mass - , total body fat - , and % total body fat SD-scores in infants with bronchopulmonary dysplasia in the first year of life.
A: Fat free mass SD-score, 
B: Total body fat SD-score, 
C: % total body fat SD-score, plotted against post-term age in the first year of life. The mean and the 25th and 75th centiles are shown.
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Discussion
This study was designed primarily to measure the length, weight, and body composition 
of preterm infants with BPD during their first year of life and to compare these with data 
obtained for healthy term infants. 
The first result of interest is that weight, length, FFM, and TBF in infants with BPD 
were already low at the first measurement at 6 weeks post-term age, indicating that the 
growth pattern was already abnormal in early life and that a deficit in FFM and TBF had 
built up in the first months of life. Interestingly, both FFM and TBF were low, resulting in 
a proportionately normal body composition. Several other studies already showed early 
postnatal growth retardation in preterm infants especially in those with major morbidities 
such as BPD.5,6 We report for the first time that this growth retardation has an effect on 
both TBF and FFM. Prenatal growth retardation has a similar effect on body composition, 
resulting in lower FFM and TBF.19 
The second result of interest is that growth during the first year in infants with BPD was 
not sufficient to catch up. Infants with BPD have a significantly lower weight, length, FFM, 
and TBF than healthy term infants at 12 months post-term age. This was despite the fact 
that the energy and protein intake during the first six months after term were at, or even 
above, the recommendations for healthy term infants.20,21
There are several possible explanations for the reduced growth in preterm infants with 
BPD. In the early neonatal period, major morbidities resulting in a delay in starting and 
achieving full enteral feeding may be a major cause.6 Subsequently, when enteral feeding is 
established, difficulties in sucking and swallowing or gastro-oesophageal reflux may lead to 
a lower intake of energy and protein than calculated.22-24 Furthermore, frequent pulmonary 
infections may lead to episodes of decreased intake with consequently lower growth rates. 
It has also been argued that the energy and protein requirements of infants with BPD are 
higher because of an elevated resting metabolic rate, caused by a high respiratory rate due 
to lower lung compliance.23,25,26 Recurrent episodes of hypoxemia during feeding and sleep 
may result in inadequate oxygenation for metabolic demands, with subsequent insufficient 
use of dietary substrates.27,28 However, we can extract from our data that the nutritional 
intake of the preterm infants with BPD in this study was insufficient to achieve catch up 
growth. This may indicate that preterm infants with BPD need a higher intake of energy 
and protein after discharge than recommended for healthy term infants. Another possible 
explanation is that the growth disturbance in the perinatal period resulted in disturbance of 
the endocrine control of growth with long term effects on the growth pattern. 
It is important to emphasise three aspects of the study. Firstly, the number of subjects 
is relatively small because we decided to include cases encountered over a period of two 
years only. We did not want to prolong the inclusion period, because the changes in medical 
and nutritional treatments that are likely to occur over a long period may have influenced 
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the outcome. Secondly, the food intake of the infants was not controlled, so as to collect 
growth and body composition data in the situation present in most paediatric departments. 
Thirdly, we were only able to compare our patients with healthy term infants and not with 
a healthy preterm control group. The results obtained can be explained by the presence of 
BPD in these preterm infants, but may also be explained by prematurity itself.
TOBEC is a reliable and validated method for measuring body composition. We were 
therefore able to compare the data in preterm infants with BPD with data from healthy term 
Dutch infants. At the end of the first year, TBF and FFM in these preterm infants with BPD 
were still low compared with that in controls.15 Also, when compared with the reference 
infants described by Fomon et al. the infants with BPD have lower FFM and TBF at the end 
of the first year.29 
Other data on body composition in (pre) term infants during the first year of life have 
recently been published. Butte et al. combining several techniques to measure body 
composition, showed that FFM was slightly higher in healthy term infants and TBF was 
much higher than in our children with BPD.30 Rawlings et al. found a similar pattern of 
accretion of FFM and TBF in preterm infants to that in our study, with an increase in FFM 
during the first year, while TBF increased from birth till 6 months, but not between 6 and 
12 months.31 Both in the study of Rawlings et al. and in our study, FFM was significantly 
lower than the reference data. Interestingly, the absolute amount of TBF was higher in 
their study, and not different between boys and girls. This may partly be explained by the 
method used, as Rawlings et al. used the dual energy x ray absorptiometry method, which 
may have overestimated TBF, or it may be due to differences between the groups of infants 
studied. The number of girls included in our study who were small for gestational age may 
have influenced our results.
The fact that FFM and TBF in our preterm infants with BPD were lower than healthy 
term reference values, measured by the same method, may have different explanations. It 
may well be that BPD itself causes less deposition of FFM and TBF because of inadequate 
absorption of nutrients during the acute phase of lung disease, the medical treatment of 
the infants (with fluid restriction, steroids, and diuretics), elevated metabolic rate, and the 
increased work of breathing. The data of Rawlings et al. suggest that prematurity itself may 
also explain at least some of our results.31 As we did not have a control group of healthy 
preterm infants, it is not possible to conclude whether the effect on FFM and TBF is due 
to BPD or prematurity itself. Finally, growth retardation at birth or during the first few 
weeks of life in preterm infants, especially those with major morbidities as observed by 
Ehrenkranz et al. may have caused a persisting abnormal body composition.6 
Dietary manipulation of growth rates and body composition in preterm infants seems 
reasonable.32-37 Increases in weight, TBF, and FFM have been obtained in preterm boys, 
but not girls, who were fed a preterm formula (higher in energy, protein, calcium, and 
phosphorus) from discharge for 6 months. The authors attributed the changes in growth 
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and body composition to the higher protein intake.34 Recent intervention studies have 
shown a positive effect on weight, length, and head circumference, especially in boys.36-38 
So far, only one study, by Brunton et al. has described the effect of nutritional intervention 
in infants with BPD.32 Feeding an enriched formula (2.5 g protein/kg/day compared with 
2.0 g protein/kg/day) resulted in a significantly greater gain in length and FFM, but not in 
weight, in infants with BPD fed the enriched formula at 3 months of age. From this study, 
it seems to be possible to increase FFM and linear growth by giving a high protein/high 
mineral formula. Interestingly, the intake for our infants was comparable to the enriched 
formula, but both weight and FFM were lower in our children than in the infants studied 
by Brunton et al.
Interpretation of body composition data depends on whether post-term age or body 
weight is regarded as the appropriate reference. The weights of our preterm infants 
with BPD at 6 weeks post-term age are comparable to the weights of healthy newborn 
infants, and the %TBF is comparable to the %TBF found by TOBEC and dual energy x 
ray absorptiometry in healthy term neonates.39-41 Also, the FFM in infants with BPD is 
comparable to that of infants of equal weight. 
These data, together with the anthropometric data, indicate that preterm infants with BPD 
are growth retarded, with less body fat and lean mass than healthy infants of the same post-
term age, and they have body proportions regarding fat free mass and fat according to their 
weight. As this growth restriction may have permanent effects, interventions are needed 
to improve growth in these preterm infants. Long lasting nutritional intervention studies 
with both increased protein and energy are needed to determine whether this will improve 
growth and body composition at a later age. As growth disturbance in the perinatal period 
may result in disturbance of the endocrine control of growth, these studies should include 
hormonal evaluations. Measurements of body composition are essential in these studies to 
evaluate the FFM and TBF and to prevent over-nutrition in some infants.
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Worsening of V’MAXFRC in infants with 
bronchopulmonary dysplasia in the 
first year of life: a more favorable 
outcome after High-Frequency 
Oscillation ventilation
Ward Hofhuis, Marianne W.A. Huijsman, Els C. van der Wiel, 
Wim P. J. Holland, Wim C. J. Hop, Govert Brinkhorst, 
Johan C. de Jongste, Peter J.F.M.Merkus
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Abstract
Little is known about the development of maximal flow at functional residual capacity, a 
measure of airway patency, in infants with bronchopulmonary dysplasia (BPD). In a follow-
up study, we evaluated V’
MAXFRC 
in very low birth weight infants with BPD, treated with high-
frequency oscillation ventilation (HFO) or conventional mechanical ventilation. 
In 36 infants with BPD, V’
MAXFRC
 was evaluated at 6 and/or 12 months post-term age, and 
the relationship between perinatal factors and lung function was studied. Mean (SD) birth 
weight and gestational age were 837 (152) g and 26.8 (1.7) weeks, respectively. At 6 and 12 
months, mean V’
MAXFRC
 was significantly below normal. Between 6 and 12 months, there was 
a mean (95% confidence interval) reduction in V’
MAXFRC
 (SD-score) of 0.5 (0.2–0.7) (p < 0.001). 
At 12 months, the mean V’
MAXFRC
 (SD-score) was higher for children initially treated with HFO 
(n = 15), as compared with children treated with conventional mechanical ventilation (n = 
16): mean (95% confidence interval) difference was 0.6 (0.2–1.0) (p = 0.008). 
Conclusion: We conclude that very low birth weight infants with BPD have decreased 
V’
MAXFRC
 that worsens during the first year of life. Initial treatment with HFO was associated 
with a more favourable outcome of V’
MAXFRC
 at 12 months post-term age.
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Introduction
Bronchopulmonary dysplasia (BPD) is a common sequel of mechanical ventilation and 
oxygen therapy in prematurely born infants.1 Despite advances in prenatal and neonatal 
care, including antenatal and postnatal steroids, surfactant treatment, and high-frequency 
oscillation ventilation (HFO), BPD is still one of the major complications in mechanically 
ventilated premature infants.2 The overall incidence of BPD has remained high as a 
result of the increased survival of extremely premature infants, who are most likely to 
develop BPD.2 Long-term studies show that survivors of BPD have abnormal pulmonary 
function tests at school age, whereas infants who received initial HFO showed normal 
lung function at school age.3,4,5 Only a few studies evaluated lung function during the first 
years of life in children with BPD. In young children with BPD, lung function parameters, 
such as functional residual capacity (FRCp), compliance, resistance, and conductance, 
show a gradual improvement toward the normal range during the first 3 years of life.6–8 
Nevertheless, maximal flow at FRC (V’
MAXFRC
 ), used as a measure of airway patency, is 
known to be decreased during the first 2 years of life.6,8,9 Due to advances in prenatal and 
neonatal care, results obtained in the past may not be valid for infants who develop BPD 
nowadays. There are no recent studies that evaluated V’
MAXFRC
 during the first year of life 
in very low birth weight (VLBW) infants with BPD, in the era of surfactant therapy and 
HFO.
Therefore, we aimed at evaluating V’
MAXFRC
 at 6 and 12 months post-term age, in a group 
of VLBW infants with BPD. Furthermore, we studied the relationship between lung function 
and perinatal patient characteristics.
Methods
Patients
A follow-up study was conducted in neonates who developed BPD, born between January 
1998 and September 1999. All infants were born in or transferred immediately after birth to 
the Neonatal Intensive Care Unit of the Sophia Children’s Hospital. The inclusion criteria 
were birth weight of 1250 g or less, need for mechanical ventilation from day 1 for at least 
7 days, need for continuous supplemental oxygen for at least 28 days and/or at 36 weeks 
gestational age, and chest radiogram at 1 month of age typical for BPD. The exclusion 
criteria were major congenital anomalies, meconium aspiration, or suspected hypoplasia 
of the lungs. Artificial ventilation in the Neonatal Intensive Care Unit was administered 
by conventional mechanical ventilation (CMV) or HFO. Initial ventilation strategy was not 
randomized in our study. Preferably, initial HFO was started in the youngest and smallest 
infants. This was not always feasible due to the limited availability of HFO equipment, and 
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hence, initial ventilation strategy was partly determined by chance. When infants developed 
hyaline membrane disease, surfactant (Survanta, 100 mg/kg/dose) was administered.
Neonates with severe hyaline membrane disease received additional doses. When 
infants developed a persistent need for artificial ventilation, treatment also included fluid 
restriction and diuretics. To wean them off the ventilator, most infants were treated with 
dexamethasone, administered in a 3-week course starting with a dose of 0.5 mg/kg/day that 
was gradually tapered. All infants were age-corrected to a gestational age of 40 weeks. The 
study was approved by the Medical Ethics Committee of the Erasmus University Medical 
Center. All parents gave informed consent.
Lung Function
Lung function measurements were performed at 6 and 12 months post-term age, when the 
infants were free from acute respiratory symptoms. To prevent the infants from waking up 
during the measurements, they were sedated with choral hydrate (50–75 mg/kg). FRCp 
was measured by means of a modified whole body plethysmograph (Jaeger, Wurzburg, 
Germany). Equipment and procedures were in accordance with recently published 
guidelines, in which the FRCp measurement is described in detail.10 The mean FRCp of 
three to five technically acceptable measurements was expressed as SD-score. V’
MAXFRC
 
was assessed using the end-tidal rapid thoracoabdominal compression technique (RTC) 
(Custom-made equipment; Department for Experimental Medical Instrumentation, Erasmus 
University Medical Center, Rotterdam, The Netherlands). Equipment and procedures were 
in accordance with recently published guidelines, in which the rapid thoracoabdominal 
compression technique is described in detail.11 The mean V’
MAXFRC
 of three to five technically 
acceptable measurements was expressed as SD-score according to Sly et al. and Tepper 
and Reister.11,12
Statistical analysis
Lung function at the first and second measurements was compared using mixed-model 
analysis of variance (SAS, PROC MIXED). Between the groups initially treated with HFO or 
CMV, lung function and anthropometric data were compared using independent-samples 
t tests. Comparison of percentages was done using Fisher’s exact test. Where applicable, 
the difference in lung function was evaluated using paired Student’s t test. The influence 
of various perinatal variables on the level of lung function was evaluated by multiple 
regression analyses. The significance level was set at a p value of less than 0.05.
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Results
A cohort of 36 white infants was enrolled. Lung function was measured in 28 infants 
at 6 months and in 31 infants at 12 months post-term age. In 23 infants, lung function 
was measured both at 6 and 12 months post-term age. Reasons for not completing both 
measurements were failure to sleep during the procedure (n = 6), airway infections (n = 5), 
and loss to follow-up (n = 2). Anthropometric data of the total cohort of 36 infants and of 
the subgroups of 28 infants measured at 6 months and 31 infants measured at 12 months 
are shown in Table 1. 
The first and second lung function measurements were performed at mean (SD) post-
term ages of 6.2 (0.9) months and 12.6 (1.1) months, respectively. The results of the FRCp 
and the V’
MAXFRC
 measurements are shown in Table 2. Mean (SEM) FRCp values in SD-score 
at the first and second measurements were -1.2 (0.3) and -0.6 (0.2), respectively. Mean 
(SEM) V’
MAXFRC
 in SD-score was significantly below zero (normal value) at the first and 
second measurements: -1.7 (0.1) and -2.2 (0.1), respectively (Table 2, Figure 1). Between 
Table 1 Anthropometric data.
Total group
N = 36
6 months
N = 28
12 months
N = 31
Gestational age (wk) 26.8 (1.7) 26.9 (1.7) 26.9 (1.7)
Birth weight (g) 837 (152) 826 (156) 852 (156)
Birth weight  SD scorea -1.2 (1.3) -1.4 (1.1) -1.2 (1.4)
Males 22 18 19
Antenatal steroids 28 22 24
Tocolyses 24 19 21
PROM 7 7 5
PDA 27 19 24
Surfactant treated newborns 29 23 24
Dexamethasone treated newborns 32 25 27
Dexamethasone treatment (days) 23 (15) 21 (10) 25 (16)
Initial HFO ventilation 18 15 15
Ventilation (days) 27 (13) 25 (10) 27 (14)
Extra Oxygen requirement (days) 151 (161) 150 (174) 166 (169)
Oxygen dependence at 28 days 35 27 30
Oxygen dependence at GA 36 weeks 30 22 26
Results are given as mean (SD) or number of infants. Shown are the total group and the subgroups of infants measured at 6 months and at 12 
months post-term age. Twenty-three infants completed both measurements. 
PROM: premature rupture of membranes. PDA: persistent ductus arteriosus. HFO ventilation: high-frequency oscillatory ventilation. GA: 
gestational age.
a: Reference values by Usher and McLean 20. 
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the two measurements, there was a mean (95% confidence interval) change of V’
MAXFRC
 in 
SD-score of -0.5 (-0.7 to -0.2) (p < 0.001). When V’
MAXFRC
 in SD-score was calculated using 
normative data by Tepper and Reister 12, similar results were seen: the mean (SEM) V’
MAXFRC
 
SD-scores at the first and second measurements were -1.6 (0.1) and -2.0 (0.1), respectively. 
The mean (95% CI) change of V’
MAXFRC
 in SD-score was -0.4 (-0.7 to -0.1) (p = 0.006).
At 12 months, the mean (SEM) V’
MAXFRC
 in SD-score was better in the group that received 
initial HFO (n = 15) as compared with the group that initially received CMV (n = 16): -1.9 
(0.2) and -2.5 (0.1), respectively. Mean (95% CI) of the difference between the groups 
was: 0.6 (0.2 - 1.0), (p = 0.008) (Table 3). The distributions of perinatal factors did not 
differ between these two groups, except for birth weight (in grams) and requirement 
of surfactant therapy (Table 4). After allowing for the potential confounders (days on 
ventilation, gestational age, and birth weight) using multiple regression analyses, this 
difference remained significant (p = 0.038). However, when both ventilation groups were 
Table 2 Lung function during first year of life in infants with BPD.
Measurement 1 
N = 28
Measurement 2 
N = 31
Mean difference
 (95% CI)
FRCp (ml/kg) 23.6 ± 1.3 25.5 ± 1.0 1.9 (-1.3 to 5.0)
FRCp (SD - score)
 a -1.2 ± 0.3 -0.6 ± 0.2 0.6 (-0.2 to 1.4)
V’maxFRC (ml/s) 70.3 ± 9.4 119.0 ± 9.0 48.7 (26.9 to 72.4)
 **
V’maxFRC (SD-score)
 b -1.7 ± 0.1 -2.2 ± 0.1 -0.5 (-0.7 to –0.2) **
Results are given as mean ± SEM.
FRCp: functional residual capacity, V’maxFRC: forced expiratory flow at FRC
At measurement 1 and 2, the mean (SD) corrected age was 6.2 ± 0.9 and 12.6 ± 1.1 months, respectively.
a: Reference equation by Stocks et al.10. 
b: Reference equation by Sly et al.11.
**: p<0.001.
Table 3 Lung function measurements at 12 months post-term age in infants with BPD, after initial high-frequency oscillation or conventional 
mechanical ventilation.
HFO
N = 15
CMV
N = 16
Mean difference
(95% CI)
FRCp (ml/kg) 25.5 ± 1.3 25.5 ± 1.4 n.s.
FRCp (SD-score)
 a -0.6 ± 0.3 -0.6 ± 0.4 n.s.
V’maxFRC (ml/s) 148.1 ± 11.9 89.7 ± 11.3 58.5 (24.9 to 92.0)
‡
V’maxFRC (SD-score)
 b -1.9 ± 0.2 -2.5 ± 0.1 0.6 (0.2 to 1.0)§
Results are given as mean ± SEM or mean (95% confidence interval). 
FRCp: functional residual capacity. V’maxFRC: forced expiratory flow at FRC. 
a: Reference equation by Stocks et al.10. 
b: Reference equation by Sly et al.11.
‡: p=0.001. §: p=0.008
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compared with adjustment for number of surfactant dosages, the difference in mean V’
MAXFRC
 
(SD- score) at 12 months lost significance (p = 0.085).
Similar results were seen within the subgroup of 23 infants who completed both 
measurements. To study the difference between 6 and 12 months precisely, individual 
mean V’
MAXFRC
 values were inter- or extrapolated linearly to values at exactly 6 and 12 
months post-term age. At 6 and 12 months, the mean (SEM) of these adjusted V’
MAXFRC 
SD-
scores were -1.7 (0.1) and -2.1 (0.1), respectively (mean [95% CI] change: -0.4 [-0.7 to -0.1], 
p = 0.006). At 12 months, the mean (SEM) of the adjusted V’
MAXFRC
 in SD-score was better 
in the group that received initial HFO (n = 12) as compared with the group that received 
CMV (n = 11): -1.9 (0.2) and -2.4 (0.1), respectively (mean [95% CI] difference: 0.6 [0.1–1.0], 
p = 0.014) (Figure 2). 
Table 4 Anthropometric data of 31 infants with BPD measured at 12 months post-term age, subgrouped by initial ventilation treatment.
Initial HFO
N = 15
CMV
N = 16
Gestational age (wk) 26.5 (1.7) 27.2 (1.8)
Birth weight (g) 778 (135) † 921 (146) †
Birth weight SD-score a -1.5 (1.6) -0.9 (1.1)
Males 12 7
Maternal steroids 14 10
Tocolyses 12 9
PROM 3 2
PDA 10 14
Surfactant treated newborns 9 15
Number of times of surfactant therapy 1 (0-2) ‡ 2 (0-4)‡
Dexamethasone treated newborns 14 13
Duration dexamethasone treatment (days) 24 (11) 25 (20)
Duration of ventilation (days) 28 (10) 26 (17)
Duration of oxygen dependence (days) 127 (128) 202 (197)
Oxygen dependence at 28 days 14 16
Oxygen dependence at GA 36 weeks 13 13
Results are given as mean (SD), or median (range), or number of infants.
HFO ventilation: high-frequency oscillatory ventilation, CMV: conventional mechanical ventilation, PROM: premature rupture of membranes, PDA: 
persistent ductus arteriosus, GA: gestational age. 
 a: Reference values by Usher and McLean 20. 
†: p=0.009. 
‡: p=0.002.
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Figure 2 Effect of first intention HFO on V’MAXFRC  in 23 infants with BPD during the first year. 
Mean V’MAXFRC in SD-score
11 in the subgroup of 23 infants who completed both lung function measurements at 6 and 12 months. Error bars 
represent SEM. Individual mean V’MAXFRC values were inter- or extrapolated to values at exactly 6 and 12 months post-term age. 
 = infants treated with first intention HFO (n=12) 
● = infants treated with CMV (n=11).
Figure 1 Lung function data of 36 infants with BPD in the first year. 
Mean V’MAXFRC is expressed in SD-score according to Sly et al.
11 The first (n=28) and second (n=31) measurements were done at mean (SD) post-
term ages of 6.2 (0.9) months and 12.6 (1.1) months, respectively. Twenty-three infants completed both measurements (connected data points).
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Discussion
In a follow-up study, we evaluated lung function in a cohort of 36 VLBW infants with BPD, 
during the first year of life. Furthermore, we studied the relationship between lung function 
and perinatal patient characteristics. During the first year of life, mean V’
MAXFRC
 was below 
reference values and showed a significant worsening between 6 and 12 months post-term 
age. At 12 months, mean V’
MAXFRC
 was significantly better in the initial HFO-treated group, 
as compared with the group treated with CMV.
To our knowledge, this is the first study on growth of airway function during the first 
year of life in VLBW infants with BPD, which also addresses a possible relationship with 
HFO. Tepper et al. and Iles and Edmunds also found decreased V’
MAXFRC
 during the first 
year of life.6,9. However, due to the survival of younger and smaller infants and differences 
in treatment modalities, our study population cannot be compared with the population 
studied by Tepper et al.6 Iles and Edmunds studied a population more comparable to our 
population, but no information about treatment modalities was provided.9 The decreasing 
V’
MAXFRC
 may reflect abnormal functional or anatomic development of the airways, which 
is consistent with pathologic findings.6,13 This could explain the abnormal pulmonary 
function tests in preterm-born children with BPD at school age.3,4 Alternatively, worsening 
of airway patency may be due to airway damage and dysfunction of peripheral airways, 
and central airway damage and collapse during dynamic compression.14,15 Factors such as 
thickened airway walls, increased smooth muscle layer, disturbed development of airway 
size and/or airway compliance, or altered alveolar architecture may also play a role here.16,17 
Furthermore, the relative decline of V’
MAXFRC
 during the first year of life was irrespective of 
the reference equation used.11,12 The FRCp was within the normal range at 6 months and 
demonstrated a trend to normalization at 12 months of age. This is consistent with previous 
reports.6–8,18 With no apparent decline of the mean FRCp between 6 and 12 months, the 
change in FRCp cannot explain the reduction in V’
MAXFRC.
19 
First intention HFO is associated with a shorter time of ventilator dependency and 
oxygen dependency in VLBW infants with respiratory distress syndrome.20 Furthermore, 
it is speculated that early HFO used with a lung recruitment strategy in combination with 
surfactant therapy ameliorates acute neonatal lung injury that predisposes some preterm 
infants to develop BPD.5 The HIFI study group found that the use of HFO, in comparison 
with CMV, did not improve V’
MAXFRC
 at 9 months post-term age.21 In our study, the V’
MAXFRC
 at 
12 months was significantly better in the group initially treated with HFO, compared with the 
group initially managed with CMV. This discrepancy could be explained by the difference 
in timing of measurement or by the fact that in our study, HFO was used as initial therapy. 
Our data suggest that, in VLBW infants, initial treatment with HFO is associated with a 
more favourable development of V’
MAXFRC
 at 12 months post-term age. This finding provides 
further suggestive evidence that initial HFO combined with surfactant therapy reduces 
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acute neonatal lung injury.5 Initial ventilation treatment was not intentionally randomized 
in our study, and therefore this association cannot be considered causal. Nevertheless, the 
HFO and CMV groups were not different by any perinatal patient characteristic, except for 
small difference in birth weight in grams, but not in SD-score, and number of surfactant 
doses. The difference in birth weight does not explain our finding, as the lower birth weight 
of the HFO group would unfavourably affect lung function, whereas we found better 
results after HFO. Fewer doses of surfactant were given to the infants who were initially 
ventilated with HFO, as compared with CMV. This may reflect reduced respiratory distress 
after HFO. We regard the number of surfactant doses not as a confounder but as a possible 
first positive outcome of HFO. 
In summary, VLBW infants with BPD, born in the era of surfactant therapy and HFO, 
show a worsening of decreased V’
MAXFRC
 during the first year of life. Initial treatment with 
HFO was associated with a more favourable development of V’
MAXFRC
 at 12 months post-
term age. This finding supports the hypothesis that initial treatment with HFO in premature 
neonates prone to develop BPD leads to less airway damage and better medium term 
outcome.
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Infants who develop BPD often show retarded growth in the first years of life. It is unknown 
if this growth retardation is due to their prematurity, the lung disease they have developed 
or is induced by drugs like glucocorticoids, or due to other factors or a combination. 
Glucocorticoids are used frequently in preterm infants. They are given antenatally 
to mothers who are at risk to deliver prematurely in order to induce lung maturation. 
Glucocorticoids are also given postnatally to preterm infants with persisting respiratory 
problems to improve lung function and promote weaning from the ventilator. 
Adrenal function
Glucocorticoids in preterm infants are frequently given either in the first postnatal week 
because of circulatory problems not reacting on volume expansion and cardiotonic drugs, 
or later because of persisting respiratory problems in order to wean the infants off the 
ventilator. In the latter case the dose is much higher and the duration of glucocorticoid 
treatment much longer. In the past no evidence for adrenal insufficiency was found in 
preterm infants with gestational age of 34 - 37 weeks when the infants were tested with high 
doses of ACTH.1 However, recent studies show that serum cortisol levels in preterm infants 
are not correlated with clinical illness.2 These observations seemed to be contradictory, 
questioning the adrenal function in very preterm infants, as they are treated nowadays.
Therefore we investigated the adrenal function in very preterm infants with and without 
severe illness on day 4. We have shown by performing a low dose ACTH test in very 
preterm infants with a gestational age of less than 30 weeks that baseline serum cortisol 
levels and cortisol levels after ACTH administration were significantly lower in ventilated 
infants, while baseline 17-OHprogesterone levels were significantly higher. Interestingly, 
the infants who developed BPD had lower cortisol levels after ACTH administration. These 
data show an impaired adrenal response to stress in sick ventilated very preterm infants 
born after gestational ages less than 30 weeks. Other studies, by measuring either cortisol 
levels or performing an ACTH test also suggested a relative adrenal insufficiency in sick 
preterm infants, especially in the very young infants, suggesting a gestational age and 
thereby maturational effect.3,4
Although, it is not quite clear whether the adrenals in sick ventilated very preterm infants 
are down-regulated by high interleukin levels or have a decreased activity of the enzymes 
CYP21A2 or CYP11B, the fact remains that these infants have relative low cortisol levels 
when submitted to additional stress such as an ACTH test. This impaired adrenal function is 
related to adverse outcome like BPD, major cerebral morbidity and mortality. 
Glucocorticoids effect many aspects of lung development including growth and 
differentiation and have anti-inflammatory characteristics. As the development of BPD 
is associated with chorioamnionitis, high interleukin levels, and ongoing inflammation it 
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may be worthwhile to dampen this response by the use of physiologic or stress doses of 
hydrocortisone to compensate for the relative adrenal insufficiency in order to prevent 
BPD and major morbidity.5 Double-blind, placebo-controlled trials starting with physiologic 
doses of glucocorticoids within the first week might give an answer to the question if it is 
possible with a physiological dose of glucocorticoids to reduce the incidence of BPD and, 
may be of even greater importance, the need for later glucocorticoid treatment. A recent 
study suggests a beneficial effect of prophylactic use of hydrocortisone on the incidence 
of BPD in very preterm infants.6 More trials are needed to confirm this observation and to 
evaluate potential adverse effects. 
Growth
Disturbance of growth in preterm infants with BPD can be due to their prematurity, the 
lung disease they have developed or induced by drugs like glucocorticoids given to the 
infants, or due to endocrine changes in the growth hormone- insulin-like growth factor-I 
(GH-IGF-I axis) or to other factors or a combination. 
Glucocorticoids are known to have a number of adverse effects in preterm infants, 
reduced growth being one of them. How glucocorticoids effect growth is not very clear. 
Studies have shown a higher protein breakdown in infants receiving glucocorticoids. Other 
studies indicate that the impaired growth in infants with BPD might be due to an increased 
metabolic rate, which is still debated. Another aspect regarding growth is the nutritional 
intake. Infants treated for BPD often have a restricted fluid and thereby restricted energy 
and protein intake. So far no study has clearly shown that the growth retardation in infants 
with BPD can be overcome by increasing the nutritional intake, which can be expected 
when the reduced growth is due to either higher energy requirements or a less than optimal 
intake. Studies on growth and body composition of preterm infants with BPD might help 
to answer this question.
The potential contribution of GH, IGF-I and the IGFBP’s to the impairment of growth in 
sick very preterm infants at risk for BPD is unknown. Also the effect of glucocorticoids on 
the GH-IGF-I axis in these very preterm infants is not known. In this study we therefore 
measured levels of GH, IGF and IGF-binding proteins before and during the administration 
of glucocorticoids, which were given to facilitate weaning from the ventilator. Secondly, 
we investigated if the administration of recombinant human growth hormone rhGH during 
glucocorticoid treatment in very preterm infants might improve growth.
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GH-IGF-I axis
In our study in ventilated very preterm infants we have found serum GH and IGF-I levels 
comparable to those found in non-ventilated preterm infants.7,8 Serum GH and IGF-I levels 
were not correlated with severity of respiratory failure. Serum GH levels were related with 
IGF-I levels suggesting that GH exerts some effect through IGF-I production. Based on 
these results no evidence was found for GH deficiency in sick ventilated very preterm 
infants. Therefore we conclude that the reduced growth found in sick very preterm infants 
cannot be explained by GH deficiency.
Effect of glucocorticoids
We have shown that the use of DEXA results in low levels of serum GH after two days, 
without an acute decline in serum immunoreactive IGF-I levels. Therefore the question 
remained whether these low GH levels observed after start of DEXA were responsible for 
the decline in growth in these infants. 
In the randomised-placebo-controlled trial with rhGH in ventilated preterm infants 
being treated with DEXA, two major observations were obtained. Concerning the effect of 
recombinant human growth hormone, no beneficial effect was observed of simultaneous 
administration of rhGH during and three weeks after discontinuation of DEXA treatment 
on growth. The stagnation in increase of length, weight, knee-heel length and head 
circumference occurred in the group receiving DEXA/placebo as well as in the group 
receiving rhGH next to DEXA, and was limited to the first week of DEXA treatment. 
Simultaneous treatment with rhGH and DEXA did not result in an improvement in growth 
in the rGH treated group. Therefore the use of rhGH in order to prevent the adverse-effects 
of high dose DEXA in preterm infants cannot be recommended.
Concerning the effect of glucocorticoids on growth (weight, length, knee-heel length 
and head-circumference), we observed that the impairment in growth was confined to 
the first week of DEXA treatment suggesting a dose-related growth inhibiting effect of 
DEXA. In most NICU’s (and also in our study) DEXA treatment is given in a tapering dose 
with the highest doses of 0.5, 0.3 and 0.25 mg/kg, respectively in the first week. Several 
other studies, by comparing growth during and after discontinuation of DEXA, reported a 
decline in growth during DEXA treatment in preterm infants.9 One, small, study suggested 
a possible dose- effect of DEXA on growth.10
The use of glucocorticoids is associated with an extensive list of adverse effects. Evidence 
for its beneficial effects as the decreased incidence of mortality and incidence of BPD justify 
the use of glucocortocoids in very selected cases only. Because of the described serious 
adverse effects, future research might be directed at:
a. finding alternative treatments in order to avoid the use of systemic glucocorticoids
b. restriction of the indication for systemic glucocorticoids to infants developing signs of BPD 
in whom all other treatment options aimed at weaning them from the ventilator have failed
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c. finding the lowest safe dose, optimal time and duration of administration of glucocorticoids 
for those infants where systemic glucocorticoids seem to be the only option to wean 
them from the ventilator. 
The fact, we did not see stunting of growth after the first week of DEXA, suggests that 
dosages of DEXA less than 0.25 mg/kg/day may have less side effects as far as growth of 
weight, length and head-circumference is concerned. A dose of 0.25 mg/kg/day DEXA is 
approximately six times the basal cortisol production in a preterm infant. 
Several treatment options instead of high dose DEXA are currently and will be in the 
coming years under investigation. Lower dose of DEXA as suggested in our study results 
in less impairment of growth. A recently published trial with low dose DEXA treatment 
shows promising results with a similar beneficial effect on dynamic pulmonary mechanics 
and subsequent oxygen requirement in infants either treated with high or low dose 
DEXA during one week.11 Pulse treatment with glucocorticoids in one study produced 
less side effects but was found to be less effective in preventing BPD.9 The use of other 
glucocorticoids such as solumedrol or hydrocortisone might, according to recent studies, 
also be an alternative, although the latter study was retrospectively performed in different 
NICU’s.12,13 
Outcome of infants with BPD
Growth and body composition.
We have shown that most of the infants with BPD are growth retarded at 6 weeks post-term 
age implicating that the infants were discharged from the neonatal intensive care unit with 
retarded growth. Secondly, our study shows that with a nutritional intake equal to or even 
above current recommendations we are not able to achieve a catch-up growth in infants 
with BPD and the infants remain proportionately low in total body fat and fat free mass.
Many infants with major morbidities develop growth retardation during their stay on the 
NICU possibly because it takes longer to begin with and convert to full enteral feeding.14 
Dietary strategies should focus on achieving early sufficient protein and energy intake 
in order to prevent the severity of this growth retardation. This might be achieved by 
introduction of early enteral feeding with the intention to achieve an adequate nutritional 
intake earlier. This strategy could also affect the incidence of BPD in another way as sepsis 
often occurs in patient with parenteral nutrition. By decreasing the incidence of catheter-
related sepsis it might be possible to influence the incidence of BPD positively.15,16 
Our study indicates that growth retarded infants with BPD might have a need for a 
higher caloric and protein intake after discharge in order to achieve catch-up growth. 
Intervention studies with postdischarge feeding in preterm infants without BPD show 
an increase in length, weight and fat free mass.17-19 Therefore, it might be worthwhile to 
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perform a postdischarge intervention study in infants with BPD who have developed a 
deficit in protein and energy during their stay on the NICU. Remarkably, the greatest effect 
of a postdischarge feeding in otherwise healthy preterm infants was observed in infants 
with a birth weight below 1250 g and in boys.18,19 No good explanation has been found for 
these results. 
Studies aimed at both the prevention of diminished growth in infants developing BPD 
in the neonatal period as well as studies on achieving catch-up growth thereafter are 
needed.
Lung function.
We have shown an abnormal development or function of the airways in infants with 
BPD during the first year. The lung function even worsened, in spite of the fact that 
the pulmonary complaints of the infants clinically improved during the first year. Infants 
initially treated with HFO showed a less impaired lung function compared to the infants 
initially treated with conventional ventilation. If this can be confirmed in other trials, then 
HFO might be the initial choice for infants with RDS who need ventilation. Recently a 
beneficial effect of HFO on pulmonary outcome was published.20
Longterm follow-up studies are needed to evaluate the development of lung function in 
infants who develop BPD these days. 
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General introduction
In the last decades important advances in neonatal intensive care have been made leading 
to an increased survival of especially very preterm infants. Associated with the decline in 
mortality there is an increase in morbidity partly because of an increase in chronic lung 
disease (CLD) defined as oxygen need at 36 weeks postmenstrual age. The incidence of 
CLD is 56% in infants born with a weight between 500-750 g. The terms bronchopulmonary 
dysplasia (BPD) and CLD are both used in the literature describing persisting lung disease 
in preterm infants. Within the framework of this thesis the term BPD is used according to 
the classification of the NICHD/NHLBI/ORD. By this definition infants have BPD when 
they received supplemental oxygen for at least 28 days after birth because of persistence of 
clinical features of respiratory failure such as tachypnea, retraction and rales. 
Many infants who develop BPD show retarded growth during infancy and childhood. It is 
unknown if this growth retardation is due to prematurity, the lung disease the infants have 
developed or is induced by drugs like glucocorticoids, or due to endocrine disturbances 
or other factors. As retarded growth in general might also reflect disturbances in growth of 
organs such as lungs, kidneys and the brain, the implications of such a persistent growth 
disturbance might have long-term effects on the development, functioning and survival 
of many organs. In addition, glucocorticoids have a number of adverse effects, reduced 
growth being one of them.
In Chapter 1 an introduction to the epidemiology and pathofysiology of BPD is given. 
Nowadays, many infants who might develop BPD are being treated with glucocorticoids 
either antenatally, postnatally or both. The benefits and the potential adverse effects of 
treatment with glucocorticoids in human and animal studies are described. Glucocorticoids 
influence lung development, disturb growth and endocrine function. Therefore we 
performed studies in infants with BPD investigating the adrenal function, the GH-IGF-I 
axis, growth and lung function.
In Chapter 2 the adrenal function in very preterm infants born after a gestational age of 
less than 30 weeks is described. The aim of the study was to investigate whether there was 
a difference in adrenal function in very preterm infants with and without severe illness and 
if there was a relation between adrenal function and outcome. 
In 21 infants a low dose ACTH test with a standard dose of 0.5 µg iv. (corresponding to 5 
µg/m2 in these small infants) was performed on day 4 of life. Baseline cortisol and 17 OH-
progesterone levels, and cortisol levels 30 and 60 minutes after ACTH administration were 
determined. Illness severity was measured using the SNAP score. 
In ventilated infants baseline serum cortisol levels and cortisol/17OH-progesterone 
ratios were low while at the same moment baseline serum 17OH-progesterone levels 
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were high compared to non-ventilated infants. The increase in serum cortisol after ACTH 
administration was significantly lower in ventilated than in non-ventilated infants. Infants 
who developed BPD showed lower baseline cortisol/17OH-progesterone ratio’s and 60 
minutes cortisol levels after ACTH administration.
These data suggest an impaired adrenal response to stress in sick ventilated very preterm 
infants with gestational ages younger than 30 weeks, which is associated with a more 
adverse outcome as BPD. The high levels of the precursor 17OH-progesterone suggest 
a diminished activity of the enzyme CYP21A2 or a lower conversion of 11-deoxycortisol 
to cortisol by CYP11B. Further studies are required to investigate if supplementation with 
physiological doses of hydrocortisone in the first week of life might reduce the incidence 
of BPD.
In Chapter 3 the GH-IGF-I axis is described in sick ventilated very preterm infants. The 
aim of the study was to evaluate the potential contribution of GH, IGF-I and the IGFBP’s to 
the growth retardation of preterm infants with respiratory failure at risk for BPD. In 24 very 
preterm ventilated infants 6- hour GH profiles were performed and serum levels of IGF-I, 
IGFBP-1 and -3, nutritional intake and severity of respiratory failure were determined. The 
6-hour GH profiles were analysed using the Pulsar program resulting in mean, baseline and 
maximal GH values and the number of GH peaks. 
A wide variation was found in serum mean GH levels ranging from 6.0 to 55.8 µg/l. 
Serum IGF-I levels varied from 20.7 to 117.8 ng/ml and were correlated with serum GH 
levels. Unexpectedly, serum GH levels did not correlate with birth weight, gestational and 
postnatal age, weight gain and severity of respiratory failure. Serum GH and IGF-I levels 
in these ventilated very preterm infants were comparable to those found in non-ventilated 
preterm infants and thus not correlated with severity of respiratory failure. GH levels were 
related with IGF-I suggesting GH exerts some effect through IGF-I production. 
Based on these results no evidence for GH deficiency in sick ventilated very preterm 
infants was found. Therefore we conclude that the reduced growth found in sick very 
preterm infants cannot be explained by GH deficiency. 
In Chapter 4 the effect of dexamethasone (DEXA) administration is described on the GH-
IGF-I axis in ventilated very preterm infants developing BPD. The aim of the study was 
to evaluate the short-term effect of DEXA on the GH-IGF axis in ventilated very preterm 
infants at risk for developing BPD. In 10 very preterm ventilated infants 6-hours GH profiles 
were performed and serum IGF-I, IGFBP-1 and -3 levels were measured immediately 
before and two days after start of dexamethasone treatment.
Serum GH levels declined significantly during DEXA treatment, however without a 
decline in serum IGF-I and IGFBP-3 levels. A concomitant decline in serum IGFBP-1 was 
found. Serum GH levels during DEXA correlated neither with the time interval between the 
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administration of DEXA and the second GH profile nor with the cumulative DEXA dose 
administered.
In conclusion, two days of DEXA treatment in very preterm ventilated infants has a 
suppressive effect on serum GH levels, without an acute decline in serum immunoreactive 
IGF-I levels. Therefore, the question remains whether the low GH levels observed after start 
of DEXA are responsible for the decline in growth rate in these infants.
In Chapter 5 a randomised-placebo-controlled trial with recombinant human GH (rhGH) 
in ventilated preterm infants being treated with DEXA is described. The aim of this study 
was to investigate if treatment with rhGH is able to overcome the growth inhibiting effect 
of DEXA treatment in very preterm infants. Ventilated very preterm infants (n = 30) were 
included in the study after the attending neonatologist had decided to initiate DEXA 
treatment to facilitate weaning from the ventilator. The infants were randomly assigned to 
receive either DEXA/ placebo or DEXA/ GH treatment. DEXA was administered during a 
24 days period, in a tapering scheme. Simultaneously rhGH or placebo was administered 
during 42 days. Fifteen infants were treated with DEXA/GH. Weight, length, knee-heel 
length and head-circumference were measured. Serum GH, IGF-I and IGFBP-1 and -3 
levels were determined. 
The growth in weight, length, knee-heel length and head-circumference was not 
significantly different between the two treatment groups over a period of 42 days. In the 
first week on DEXA no growth in weight, length, knee-heel length and head-circumference 
occurred in both treatment groups. In the second and third week of DEXA treatment as 
well as in the 3- week period after discontinuation of DEXA, growth was not significantly 
different between the GH and the placebo group. Interestingly growth during week two 
and three of DEXA was not different from the growth after discontinuation of DEXA.
Serum IGF-I levels did not increase during the 42-days study period, while serum IGFBP-
3 increased during DEXA, in both groups. 
We conclude that treatment with rhGH is not able to overcome the DEXA-induced 
growth failure in this 6-week period in very preterm infants at risk for BPD. However, long-
term follow-up is needed to evaluate the effect on growth, neurodevelopment and lung 
function. Secondly, the negative effects on growth by DEXA are limited to the first week of 
DEXA administration with high doses of DEXA, thereby suggesting a dose-related growth 
inhibiting effect of DEXA. We therefore suggest that future research should be directed at 
the use of lower doses of glucocorticoids, aiming at both, maintenance of the beneficial 
effect of DEXA of weaning from the ventilator, and prevention of adverse effects.
In Chapter 6 the growth and body composition in preterm infants with BPD during the 
first year is described. The aim of the study was to evaluate the pattern of growth and body 
composition in infants who had developed BPD, in their first year of life. Preterm infants 
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with BPD were prospectively followed at the neonatal follow-up clinic at 6 weeks, 3, 6, 9 
and 12 months post-term age. Anthropometry and body composition determined by total 
body electric conductivity (TOBEC) were measured and compared with those of healthy 
infants at the same post-term age. Nutritional intake was calculated. 
The infants with BPD had a significantly lower weight and length at 6 weeks post-
term age compared to healthy term infants. A transient catch-up growth in weight, but an 
insufficient catch-up growth in length occurred during the first year. At 12 months post-term 
age the weight in infants with BPD was significantly lower than in healthy infants, as was 
the length in girls with BPD. The amount of fat free mass was significantly lower at 6 weeks 
post-term age, increased, but remained lower than in healthy term infants at the end of the 
first year, while the amount of total body fat remained lower during the whole first year 
compared to healthy controls.
Thus, although the nutritional intake during the first 6 months was normal and the 
protein intake even above recommendations made by the WHO for healthy infants, an 
insufficient catch-up in length and fat free mass and no catch-up in weight and total body 
fat occurred. 
This study indicates that infants with BPD have a retarded growth already at 6 weeks 
post-term age, while their body composition at 12 months shows lower amounts of fat free 
mass and fat compared to healthy controls. Despite an adequate nutritional intake for these 
infants, levels of protein and fat remain lower than normal during the first year. Nutritional 
intervention studies are needed to evaluate if nutrition is the major determinant of growth 
and body composition in these preterm infants and to find out whether enriched formulas 
will improve growth and body composition at later age.
In Chapter 7 the development of airway function in preterm infants with BPD is described 
either treated with conventional ventilation or with high frequency oscillation (HFO). The 
aim of the study was to evaluate the V’ 
MAXFRC
 (measure of airway patency) in preterm infants 
after they had developed BPD, during their first year. In 36 preterm infants with BPD lung 
function measurements were performed at 6 and/ or 12 months post-term age. Functional 
residual capacity (FRC
p
) and maximal flow at FRC (V’
MAXFRC
) was determined and related 
with perinatal factors. 
The FRC
p
 was within the normal range at 6 and 12 months post-term age. In infants 
with BPD the V’
MAXFRC 
at 6 and 12 months was significantly lower than in reference infants 
and even worsened between 6 and 12 months post-term age. In infants initially treated 
with HFO the mean V’
MAXFRC
 at 12 months was better than in infants initially treated with 
conventional ventilation. 
This study shows that infants with BPD have decreased V’
MAXFRC 
that worsens during the 
first year of life. Initial treatment with HFO was associated with a more favourable outcome 
at 12 months post-term age. 
Groei bij zuigelingen met bronchopulmonale dysplasie, 
hormonale en pulmonale aspecten
klinische en follow-up studies
    
Inleiding
In de afgelopen decennia hebben belangrijke ontwikkelingen in de behandeling van 
pasgeboren zuigelingen (neonatologie) plaats gevonden. Hierdoor is de kans op 
overleving voor met name de zeer veel te vroeg geboren (premature) pasgeborene 
duidelijk toegenomen. Deze daling in sterfte gaat echter gepaard met een grotere kans 
op restverschijnselen, zoals chronische longziekte (CLD). CLD wordt gedefinieerd als de 
noodzaak tot extra zuurstoftoediening bij premature pasgeborenen op de leeftijd van 
36 weken na de laatste menstruatie. Bij ongeveer 56% van de pasgeborenen met een 
geboortegewicht van 500-750 gram onstaat CLD. Naast de term CLD wordt ook de term 
BPD (bronchopulmonale dysplasie) gehanteerd om de chronische longbeschadiging bij 
premature pasgeborenen te beschrijven. In dit proefschrift wordt de term BPD gehanteerd 
volgens de laatste classificatie van de NICHD/NHLBI/ORD. In deze classificatie is er 
sprake van BPD als pasgeborenen vanaf de geboorte gedurende minstens 28 dagen 
zuurstofbehoefte hebben en daarbij klachten van de luchtwegen zoals een versnelde 
ademhaling, intrekkingen van de borstkas en abnormaal ademgeruis bij het beluisteren 
van de longen. 
Veel zuigelingen met BPD vertonen een verminderde groei, zowel op de zuigelingen- 
als op de kinderleeftijd. Het is onduidelijk waardoor deze groeiachterstand wordt 
veroorzaakt: door de vroeggeboorte, de longbeschadiging, medicatie zoals het gebruik van 
glucocorticoiden, door veranderingen in de hormoon-assen of door andere factoren. Een 
verminderde groei kan een uiting zijn van veranderingen in de groei van organen zoals de 
longen, de nieren en de hersenen, waardoor deze groeiachterstand mogelijk langdurige 
effecten heeft op de ontwikkeling, functie en overleving van diverse organen. Veel 
premature pasgeborenen krijgen, voor of na de geboorte, glucocorticoiden toegediend. 
Enerzijds, om voor de geboorte de longrijping te bevorderen, anderzijds om bij beademde 
pasgeborenen de ernst van BPD te verminderen. Het gebruik van glucocorticoiden is 
geassocieerd met verminderde groei.
In hoofdstuk 1 wordt een inleiding gegeven over de epidemiologie en pathofysiologie van 
BPD. De pasgeborenen die in de huidige tijd BPD ontwikkelen zijn veelal behandeld met 
glucocorticoiden. De voor- en nadelen van behandeling met glucocorticoiden gevonden 
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bij studies in mensen en dieren worden besproken. Glucocorticoiden beinvloeden de 
longontwikkeling, de groei en de functie van de hormoon-assen. Bij zuigelingen met 
BPD hebben wij dan ook de bijnier- en de groeihormoonas, de groei en longfunctie 
onderzocht.
In hoofdstuk 2 wordt de functie van de bijnier van premature zuigelingen geboren na 
een zwangerschapsduur van minder dan 30 weken beschreven. Het doel van de studie 
was om te onderzoeken of er een verschil was in bijnierfunctie van zeer jonge premature 
pasgeborenen die wel of niet ernstig ziek waren na de geboorte. Tevens onderzochten wij 
of er een relatie bestond tussen de bijnierfunctie en de outcome van deze kinderen. 
Bij 21 pasgeborenen werd op de 4e levensdag een bijnierstimulatietest met een 
standaarddosis van 0.5 µg ACTH (lage dosis) verrricht. Uitgangswaarden van cortisol, en de 
voorloper 17OH-progesteron werden bepaald evenals cortisol spiegels 30 en 60 minuten na 
toediening van ACTH. De ernst van ziekte werd bepaald met behulp van de SNAP-score.
Bij beademde pasgeborenen bleken de basale waarden van cortisol en de ratio 
cortisol/10OH-progesteron laag en de 17OH-progesteron waarden hoog in vergelijking 
met niet beademde pasgeborenen. De stijging in cortisol na toediening van ACTH was 
significant lager in de beademde groep. Bij pasgeborenen die later BPD onwikkelden, was 
op dag 4 de basale cortisol/17OH-progesteron ratio lager evenals de cortisol waarde 60 
minuten na toediening van ACTH vergeleken met beademde pasgeborenen die geen BPD 
ontwikkelden.
Deze data suggereren een veminderde bijnierfunctie in reactie op stress bij ernstig zieke 
beademde pasgeborenen geboren na een zwangerschapsduur van minder dan 30 weken. 
Deze verminderde functie is geassocieerd met een slechtere prognose zoals het krijgen van 
BPD. 
De hoge waarden van de voorloper van cortisol, 7OH-progesteron suggereert een 
verminderde activiteit van het enzym CYP21A2 of een verminderde omzetting van 11-
deoxycortisol naar cortisol door CYP11B. Nieuwe studies zijn nodig om aan te tonen of 
suppletie met fysiologische doseringen hydrocortison in de 1e levensweek zinvol is om de 
incidentie van BPD te verminderen. 
In hoofdstuk 3 wordt de activiteit van de groeihormoon- IGF as beschreven bij ernstig 
zieke beademde premature pasgeborenen. Het doel van de studie was om na te gaan 
wat de activiteit van de GH-IGF-I as bijdraagt aan de groeiachterstand die ontstaat bij 
pasgeborenen die BPD ontwikkelen. In totaal werd bij 24 kinderen een GH profiel verricht, 
waarbij gedurende 6 uur GH spiegels en eenmalig IGF-I, IGFBP-1 en IGFBP-3 spiegels 
werden bepaald. De gemeten GH waarden werden geanalyseerd met het Pulsar programma 
waardoor de gemiddelde, de baseline en de maximale GH waarden werden berekend. 
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De gemiddelde GH waarden varieerden van 6.0 tot 55.8 µg/l. De IGF-I waarden 
varieerden van 20.7 tot 117.8 ng/ml en correleerden met de GH waarden. Er bleek geen 
relatie te bestaan tussen de serum GH waarden en zwangerschapsduur, geboortegewicht, 
postnatale leeftijd, gewichtstoename en ernst van ziekte. De gemeten GH en IGF-I waarden 
bij zieke beademde premature pasgeborenen bleken overeen te komen met serum GH 
waarden gevonden bij gezonde premature pasgeborenen. De gevonden correlatie tussen 
serum GH en IGF-I suggereert dat er mogelijk sprake is van enige invloed van GH op de 
IGF-I produktie.
Op basis van deze gegevens concludeerden wij dat er geen sprake is van GH deficientie 
bij beademde premature pasgeborenen. De groei-achterstand die ontstaat bij zieke 
premature pasgeborenen kan dan ook niet door GH deficientie verklaard worden. 
In hoofdstuk 4 wordt het effect van dexamethason (DEXA) op de GH-IGF-I as beschreven 
bij zeer premature beademde pasgeborenen die BPD onwikkelen. Het doel van de studie 
was om het korte-termijn effect van DEXA op de GH-IGF-I as bij beademde premature 
pasgeborenen die BPD onwikkelen te onderzoeken. 
Bij 10 beademde premature pasgeborenen werd een 6-uur GH profiel verricht en serum 
IGF-I, IGFBP-1 en -3 waarden bepaald, direct voor start van de dexamethason behandeling 
en 2 dagen daarna. Tijdens DEXA behandeling daalden de GH waarden, echter zonder een 
gelijktijdige daling van IGF-I en IGFBP-3. Zowel het tijdsinterval tussen de toediening van 
DEXA en het 2e GH profiel als de cumulatieve dosis DEXA die was toegediend, waren niet 
gecorreleerd met de gemeten GH waarden tijdens DEXA behandeling.
Concluderend, 2 dagen behandeling met DEXA bij zeer premature pasgeborenen 
veroorzaakt een daling van de serum GH waarden, zonder gelijktijdige daling van de 
serum IGF-I waarden. Het blijft dan ook de vraag of de lage GH waarden gemeten na 
toediening van DEXA verantwoordelijk zijn voor de afname in groei tijdens behandeling 
met dexamethason bij deze pasgeborenen. 
In hoofdstuk 5 wordt een gerandomiseerde-placebo-gecontroleerde studie beschreven 
met recombinant humaan GH (rhGH) in beademde premature pasgeborenen die 
behandeld worden met dexamethason. Het doel van de studie was te onderzoeken 
of gelijktijdige behandeling met rhGH het groeiremmende effect veroorzaakt door 
behandeling met dexamethason kan voorkomen. In deze studie werden 30 zeer premature 
beademde pasgeborenen geïncludeerd, nadat de behandelend neonatoloog had besloten 
om dexamethason behandeling te starten om de kinderen van de beademing te krijgen. 
De kinderen werden gerandomiseerd en behandeld met de combinatie DEXA en placebo 
of met DEXA en rhGH. DEXA werd gedurende 24 dagen, in een afbouwschema gegeven. 
Tegelijkertijd werd gedurende 42 dagen rhGH of placebo behandeling gegeven. Vijftien 
kinderen werden behandeld met DEXA en GH, 15 kinderen met DEXA en placebo. 
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Gewicht, lengte, knie-hiel lengte en schedelomvang werden gemeten. Serum GH, IGF-I en 
IGFBP-1 en -3 waarden werden bepaald.
De groei van zowel gewicht, lengte, knie-hiel lengte en schedelomvang was niet 
verschillend tussen beide behandelingsgroepen in deze periode van 6 weken. In de 1e 
week van de DEXA behandeling vond geen groei plaats, niet in de GH en niet in de 
placebogroep. Opmerkelijk was het feit dat de groei in de 2e en 3e week van de DEXA 
behandeling gelijk was aan de groei in de eerste 3 weken na staken van DEXA. Serum IGF-
I waarden veranderden niet in deze 42 dagen, terwijl serum IGFBP-3 waarden toenamen 
tijdens DEXA behandeling. 
Wij concluderen dat behandeling met rhGH, in een periode van 6 weken, de negatieve 
effecten van DEXA op de groei bij zeer premature pasgeborenen die BPD ontwikkelen, 
niet kan compenseren. Lange termijn vervolgstudies zijn nodig om eventuele latere effecten 
op groei, longfunctie en ontwikkeling te evalueren. Als tweede wordt geconcludeerd dat 
de negatieve effecten van DEXA op de groei beperkt zijn tot de 1e week van de DEXA 
behandeling, tijdens de hoge doseringen. Dit suggereert een dosis-afhankelijk, groei-
remmend effect van DEXA. Wij suggereren dat toekomstige studies vooral het gebruik 
van DEXA in een lagere dosis dan thans gebruikelijk evalueren. Hierdoor kunnen wellicht 
andere ernstige bijwerkingen voorkomen worden.
In hoofdstuk 6 wordt de groei en de lichaamssamenstelling van zuigelingen met BPD 
beschreven. Het doel van deze studie was de groei en verandering in lichaamssamenstelling 
van zuigelingen met BPD gedurende het eerste levensjaar te beschrijven. In dit onderzoek 
werden 29 zuigelingen met BPD op de neonatale follow-up polikliniek op de leeftijden 
van 6 weken, 3, 6, 9 en 12 maanden na de uitgerekende datum vervolgd. Tijdens deze 
follow-up periode werden lengte, gewicht en lichaamssamenstelling met behulp van de 
TOBEC methode gemeten en de voedingsintake van de kinderen berekend. Alle kinderen 
werden in de neonatale periode langdurig beademd (gemiddeld 29 dagen) en behandeld 
met dexamethason.
In vergelijking met gezonde Nederlandse kinderen hadden de kinderen met BPD een 
achterstand in lengte en gewicht op de leeftijd van 6 weken na de uitgerekende datum. 
Gedurende het eerste jaar is er sprake van enige inhaalgroei van lengte, maar vindt geen 
inhaalgroei van het gewicht plaats. Aan het eind van het eerste jaar zijn de kinderen met 
BPD lichter en de meisjes met BPD ook kleiner in vergelijking met hun leeftijdsgenoten.
Met behulp van de TOBEC metingen kon de hoeveelheid vetweefsel en vetvrije massa 
van de kinderen berekend worden. De zuigelingen met BPD hadden op 6 weken na de 
uitgerekende datum een duidelijk verminderde hoeveelheid vetweefsel en vetvrije massa in 
vergelijking met gezonde Nederlandse kinderen. In het eerste levensjaar vindt zowel bij de 
jongens als bij de meisjes enige inhaalgroei van de hoeveelheid vetvrije massa plaats, maar 
deze blijft te laag in vergelijking met gezonde kinderen. De hoeveelheid vetweefsel blijft 
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lager gedurende het eerste levensjaar en bij meisjes is er tevens een duidelijke afname van 
de procentuele hoeveelheid vetweefsel.
De voedingsintake werd gedurende de eerste 6 maanden berekend. Ondanks een 
normale energie intake en een eiwitintake hoger dan geadviseerd door de WHO voor 
gezonde zuigelingen, vond een onvolledige inhaalgroei van lengte en vetvrije massa plaats 
en geen inhaalgroei van gewicht en hoeveelheid vetweefsel. 
Deze resultaten suggereren dat premature pasgeborenen met BPD waarschijnlijk een 
hogere energie- en eiwitbehoefte hebben dan gezonde pasgeborenen om een goede 
inhaalgroei te kunnen bewerkstelligen. Interventie studies met eiwit- en energieverrijkte 
voeding zullen in de toekomst laten zien of het mogelijk is bij deze kinderen een normale 
groei en lichaamssamenstelling te bewerkstelligen.
In hoofdstuk 7 wordt de ontwikkeling van de luchtwegen beschreven bij premature 
zuigelingen met BPD, die in de neonatale periode beademd werden met conventionele 
beademing of hoog-frequente beademing (HFO). Het doel van de studie was de lucht
wegdoorgankelijkheid (V’
maxFRC 
) bij zuigelingen met BPD gedurende het 1e levensjaar te 
onderzoeken.
Bij 36 ex-premature zuigelingen met BPD werd op 6 en /of 12 maanden na de uitgerekende 
datum longfunctie onderzoek verricht. De functionele residuale capaciteit en de V’
maxFRC 
werden bepaald. Bij de zuigelingen met BPD was de V’
maxFRC
 op 6 en 12 maanden duidelijk 
lager en verslechterde in deze periode ten opzichte van gezonde kinderen. De zuigelingen 
met BPD, initieel behandeld met HFO hadden een betere luchtwegdoorgankelijkheid op 12 
maanden dan de zuigelingen initieel behandeld met conventionele beademing.
De resultaten van deze studie tonen een verminderde en verdere verslechtering van de 
luchtweg-doorgankelijkheid bij zuigelingen met BPD gedurende het 1e levensjaar. Initiele 
behandeling met hoog-frequente beademing resulteerde in een betere longfunctie op 12 
maanden.
In conclusie: Zuigelingen met BPD tonen een verminderde groei in het eerste levensjaar 
met te weinig vetweefsel en vetvrije massa. De luchtwegdoorgankelijk van zuigelingen met 
BPD is verminderd in vergelijking met gezonde zuigelingen van dezelfde leeftijd en lengte. 
De groei van de luchtwegen is vertraagd. 
De achterstand in de groei bij premature pasgeborenen die BPD ontwikkelen ontstaat 
reeds tijdens het verblijf op de NICU, maar wordt niet veroorzaakt door groeihormoon 
deficientie. Dexamethason veroorzaakt een daling van de serum GH waarden, zonder 
daling van IGF-I. GH behandeling tijdens gebruik van dexamethason heeft geen positieve 
invloed op de groei. Het groeiremmend effect van DEXA lijkt beperkt tot de 1e week 
tijdens de hoge doseringen DEXA. Zieke premature pasgeborenen hebben een relatieve 
bijnierinsufficientie in de eerste levensweek. Pasgeborenen die later BPD ontwikkelen 
152
Ch
ap
te
r 9
waren minder goed in staat hun cortisol productie te vergroten dan pasgeborenen die 
geen BPD ontwikkelden. Mogelijk leidt behandeling van deze bijnierinsufficientie tot 
voorkoming van BPD en is daarmee samenhangend ook de groeiachterstand te voorkomen. 
Tevens zal blijken of verbeterde groei eveneens resulteert in een verbeterde groei van de 
luchtwegen. 
&
Dankwoord
Curriculum vitae
List of abbreviations

Samenvatting 155
Dankwoord
Dit onderzoek was niet mogelijk geweest zonder de medewerking van de ouders van 
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wetenschappelijk onderzoek op het moment dat uw kind ernstig ziek was en de prognose 
in vele gevallen nog onduidelijk. Met behulp van onderzoek is het veelal mogelijk de 
behandeling van kinderen te verbeteren en daarom wil ik u allen bedanken voor uw 
bijdrage en het in mij gestelde vertrouwen 
Prof.dr. P.J.J. Sauer, beste Pieter, ooit ben ik als kinderarts bij jou in opleiding gekomen 
tot neonatoloog. In die periode heb ik je leren kennen en waarderen als een hardwerkend 
persoon die altijd voor iedereen klaar stond en betrokken was bij zijn afdeling en 
medewerkers. 
‘Idealiter?’ startte mijn onderzoek vlak voor je vertrek naar Groningen. Je niet aflatende 
interesse en steun, de uitvinding van e-mail en het feit dat de reisafstand Groningen-
Rotterdam korter is dan andersom, hebben er sterk toe bijgedragen dat dit onderzoek heeft 
plaatsgevonden en is afgerond. Je kritische opmerkingen en heldere blik hebben menig 
artikel verbeterd. Dank je wel!
Prof.dr. H.A Büller, beste Hans ik wil je graag bedanken voor het feit dat je mij als 
promovendus hebt begeleid. Je snelle correcties en goede adviezen in de eindfase hebben 
er voor gezorgd dat we deze deadline hebben gehaald. De aandacht die er komt voor 
follow-up onderzoek van de neonatologie klinkt mij als muziek in de oren.
Dr. A.C.S. Hokken – Koelega, beste Anita, hartelijk dank voor onze goede samenwerking, 
waarbij wij ondanks het feit dat we beiden druk bezet zijn, kunnen terugblikken op 
productieve jaren. Deze samenwerking tussen neonatologie en endocrinologie geeft 
een verruimende dimensie. Ik weet niet wie de lat hoger legt, jij of ik, maar je kritische 
opmerkingen heb ik gewaardeerd.
Dankzij de inzet van velen heeft de multidisciplinaire BPD poli, gestart in 1997, gestalte 
gekregen. 
Prof.dr. J.C. de Jongste en dr. PJ.F.M. Merkus, beste Johan en Peter, de gecombineerde 
BPD follow-up dateert van 1997. Onze gemeenschappelijke interesse naar de morbiditeit 
en luchtwegproblematiek van deze groep kinderen heeft inmiddels geresulteerd in een 
vervolgonderzoek bij kinderen met BPD. Jullie rustige en plezierige manier van werken 
heeft veel bijgedragen aan dit resultaat.
Els van der Wiel, we hebben samen de nodige poliafspraken gecombineerd met 
longfunctieonderzoeken en jij hebt vervolgens alles weer opnieuw ingepland, bijvoorbeeld 
wanneer door ziekte van de BPD- kinderen alle afspraken verzet moesten worden. De 
eerste keer aan ouders uitleggen wat het longfunctieonderzoek betekende , kostte mij wel 
enige tijd en energie. Hoe succesvol het longfunctieonderzoek was, bleek uit de bereidheid 
van ouders tot participatie aan de vervolgmetingen.
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Ward, ik ben erg blij dat je de pulmo groep kwam versterken. Je hebt voor mij het 
onderzoek aanmerkelijk verlicht.
Dr. A.H. Cromme, beste Adri je enthousiasme voor het vak en het verrichten van 
onderzoek door het nauwkeurig vervolgen van geselecteerde patientengroepen heeft 
geresulteerd in een fraaie follow-up. Zowel op de afdeling neonatologie als poliklinisch 
is het gelukt de kinderen met behulp van echocardiografie te vervolgen, wat volgens 
mij alleen bij een ‘bepaalde gedrevenheid’ lukt. Ik wil je hartelijk danken voor onze 
samenwerking. 
Prof.dr. S.L.S Drop, Prof.dr. G.J. Bruining, Dr. S.M.P.F de Muinck-Keizer, beste Sten, Mu 
en Sabine, ik wil jullie hartelijk danken voor de ondersteuning bij het onderzoek en het 
feit dat ik als ‘niet-endo’ bij de besprekingen aanwezig mocht zijn. Het waren voor mij 
leerzame momenten. 
Alle personen betrokken bij de reguliere BPD follow-up hebben in belangrijke mate 
bijgedragen aan het onderzoek. Het is mij niet gelukt alle resultaten in het proefschrift 
te verwerken, wat niet betekent dat de nog niet gepubliceerde data minder belangrijk 
zouden zijn. Ik wil met name Margriet Bruning, kinderfysiotherapeute bedanken voor de 
nauwgezette wijze waarop zij alle kinderen heeft vervolgd. Petra Mazer, psychologe, naast 
je andere werkzaamheden ben je in staat geweest ontwikkelingsonderzoek bij de kinderen 
met BPD te verrichten . Margriet en Petra hartelijk dank voor jullie kundige en plezierige 
inbreng. 
Lena hartelijk dank voor je poliklinische ondersteuning van de spreekuren en je 
betrokkenheid bij de patienten.
De verpleegkundigen van de dagverpleging wil ik bedanken voor de mogelijkheid de 
jonge zuigelingen met BPD na het ondergaan van diverse onderzoeken gedurende enige 
tijd te kunnen observeren.
Dit onderzoek was niet gelukt zonder de steun van researchverpleegkundigen. Ineke 
van Vliet, je ommezwaai van I.C. naar researchverpleegkundige bij de start van deze studie 
heeft mij veel geholpen. Anneke Saarloos, hartelijk dank voor de datacollectie. Jelly en 
Francis van Emmen, dit onderzoek is bijna een familie produktie geworden.
Mijn huidige en vroegere collega’s van de afdeling neonatologie Luc, John, Anne, 
Anton, Martin, Erik, Ans, Nynke, Paul, Monique, Daniëlla, Renate, Rene, Hans, Jacqueline, 
Angelique, Andre, Anne, Kathleen en Cynthia, jullie hebben allen verschillende fasen van 
het onderzoek meegemaakt. Hartelijk dank voor de geboden hulp, kameraadschap en de 
ruimte die ik heb gekregen om dit proefschrift af te ronden.
De verpleegkundigen en oud-verpleegkundigen van de afdeling neonatologie wil ik 
hartelijk bedanken voor de plezierige samenwerking, waarbij wij allen (maar jullie nog 
ietsje meer) keken naar de delicate balans tussen het verrichten van onderzoek en de 
belasting voor het kind. Juist bij zieke kinderen zoals de kinderen die BPD ontwikkelen 
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is dit extra belangrijk. De hulp bij het verzamelen van urine- en plasmamonsters, naast de 
gezelligheid op zaal, heb ik erg gewaardeerd. 
Ingrid Luijendijk en Darcos Wattimena, wel een proefschrift maar geen eiwit turnover! 
Maar wees gerust: ”die doen we hierna!” 
Wim Rietveld, ik denk met veel plezier terug aan de momenten dat wij gezamenlijk 
voor de couveuses stonden en discussieerden over het ontwerp, de grootte en de 
materiaalkeuze van de benodigde schuifmaten. De precisie waarmee jij de knemometer en 
de neonatometer hebt gemaakt, vinden hun effect in het onderzoek.
Ir. W.C.J. Hop, beste Wim, ik heb talloze uren bij je doorgebracht totdat alle data ook 
echt in detail geanalyseerd waren. Op de een of andere manier wist je altijd wel een gaatje 
voor mij vrij te maken, en dat terwijl ik toch een van de velen was die bij je aanklopte. 
Dank je wel.
Dr. J. de Rijke, beste Jolanda, hartelijk dank voor je hulp bij de analyse van de 
laboratorium bepalingen. 
Bijna als laatste, maar zeker niet onbelangrijk de secretaresses. Magda, hartelijk dank 
voor je hulp en vriendschap. Han, secretaresse van Pieter, op alle mogelijke manieren wist 
jij te bereiken dat de afstand G-R en vice versa sterk gereduceerd werd. Hartelijk dank voor 
al je administratieve ondersteuning. Ook de andere secretaresses Conne, Dini en Irma heb 
ik regelmatig geraadpleegd. Dank voor jullie steun en handige tips.
Mijn paranimfen Dieck Huijsman en Henriëtte Moll,  Dieck en Henriëtte dank voor al 
deze jaren, jullie zijn er ‘gewoon’ altijd!
Lieve mams, en paps, ik kan jullie niet genoeg bedanken voor de mogelijkheden die 
jullie mij in mijn jeugd geboden hebben. Mams, jouw inzet, ondersteuning en bereidheid 
tot oppassen, logeerpartijen als dat voor mij beter uitkwam, kan ik natuurlijk niet in een 
regel uitdrukken. Je bent van onschatbare waarde, dank je wel!
Lieve Wouter en Nicoline, jullie leven erg mee met de afronding van ‘het boekje’. Nicoline, 
op je vraag: ’Mama wat gebeurt er als je doctor wordt. Kom je dan in een hogere level, of 
zo?’ Eigenlijk weet ik het ook niet. Wouter, je bent mijn schrijverij ook wel beu getuige je 
bemoedigende opmerking: ’Mam is dat boekje nu nog niet af! Zal ik het vanmiddag even af 
schrijven?’. Ik ben blij dat jullie er zo over kunnen praten en dat we ons in elkaars wereld 
kunnen verplaatsen. Binnenkort ben ik ook weer van de partij!
Hugo, je relativerende opmerkingen en je distantie tot de medische wereld hebben er 
voor gezorgd dat onze kinderen ondanks mijn uithuizige baan toch een goede periode 
hebben doorgemaakt. Je weet soms beter dan ik wat er op school en thuis speelt en 
leidt dit alles weer in goede banen. Je eindeloos geduld als ik weer eens opbelde met de 
mededeling dat ik nog even bleef werken of in het weekend besloot nog even naar het 
Sophie te gaan. Zonder jouw hulp had ik dit niet kunnen volbrengen. Vanaf nu ben ik weer 
een volledig lid van ‘the family’!
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Curriculum vitae
De auteur van dit proefschrift werd in 1958 te Benthuizen geboren. In 1976 behaalde 
zij het VWO diploma aan het Erasmus College te Zoetermeer. In datzelfde jaar werd de 
studie geneeskunde aangevangen. Zij behaalde in 1983 het artsexamen. In 1983 werd zij 
aangesteld als arts-assistent in de kinderkliniek te Leiden en vanaf 1984 was zij werkzaam 
op de afdeling kinderchirurgie van het Erasmus MC, locatie Sophia. In 1986 werd 
aangevangen met de opleiding tot kinderarts op de afdeling kindergeneeskunde van het 
Erasmus MC (opleider prof.dr. H.K.A. Visser). De niet-academische stage vond plaats in het 
Medisch Centrum Rijnmond Zuid, locatie Zuider (opleider dr. R.N. Sukhai). Registratie tot 
kinderarts volgde in april 1990.
Vanaf januari 1990 was zij werkzaam als chef de clinique van de medium care van 
het Erasmus MC, locatie Sophia. Tevens was zij werkzaam bij de subafdeling nefrologie 
(subhoofd dr. E.D. Wolff). In augustus 1992 werd gestart met de opleiding neonatologie 
(opleider prof.dr. P.J.J.Sauer). Sedertdien is zij werkzaam als staflid op de afdeling 
neonatologie (afdelingshoofd dr. L.J.I. Zimmermann). 
Sedert 1992 is zij betrokken bij de neonatale follow-up en vanaf 1996 met name bij de 
follow-up van kinderen met bronchopulmonale dysplasie (BPD). In 2001 is zij gestart met 
follow-up onderzoek naar de morbiditeit en hospitalisatie van kinderen met BPD (subsidie: 
ZonMW en NAF)
De auteur is lid van de sectie neonatologie van de Nederlandse Vereniging voor 
Kindergeneeskunde en van de werkgroep Landelijke Neonatale Follow-up. Binnen deze 
werkgroep is zij betrokken bij de opzet van een uniforme landelijke neonatale follow-up 
registratie. Tevens is zij lid van de Medisch Ethische Commissie, patientenzorg van het 
Erasmus MC, locatie Sophia.
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List of abbreviations
ACTH adrenocorticotropic hormone
AGA  appropriate for gestational age
BPD  bronchopulmonary dysplasia
BW  birth weight
CHL  crown-heel length
CI confidence interval
CLD  chronic lung disease
CMV   conventional mechanical ventilation
C/ 17OHP  cortisol/ 17-hydroxyprogesterone ratio
CPAP  continuous positive airway pressure
CRH corticotrophin-releasing hormone
CYP11B  11ß-hydroxylase
CYP21A2  21-hydroxylase
DEXA  dexamethasone 
DHEA  dehydroepiandrostenedione
FEV1  forced expiratory volume 1 sec
FFM  fat free mass
FRC
p 
  functional residual capacity
FVC  forced vital capacity
GA  gestational age
GH  growth hormone
HFO  high frequency oscillation
HPA-axis  hypothalamic-pituitary- adrenal axis
IGF-I  insulin-like growth factor-I
IGFBP-1   IGF-binding protein-1
IGFBP-3   IGF-binding protein-3
IVH  intraventricular hemorrhage
KHL  knee-heel length
MAP  mean airway pressure
NCPAP  nasal continuous positive airway pressure
NEC  necrotising enterocolitis
NICU  neonatal intensive care unit
O
2 
  oxygen
OFC  occipito-frontal headcircumference
17 OHP  17-hydroxyprogesterone
PDA  patent ductus arteriosus
PEEP  positive end expiratory pressure
160
PMA  postmentrual age
PPV  positive pressure ventilation
PROM  premature rupture of membranes
RDS  respiratory distress syndrome
rhGH  recombinant human growth hormone
ROP  retinopathy of prematurity
SDS standard deviation score
SGA  small for gestational age
SNAP  Score for Neonatal Acute Physiology
TBF  total body fat
TOBEC  total body electric conductivity
VLBW  very low birth weight
V’
MAXFRC    
maximal flow at FRC


